SCHEDULE 14A

(RULE 14A-101)

INFORMATION REQUIRED IN PROXY STATEMENT

SCHEDULE 14A INFORMATION

PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES

EXCHANGE ACT OF 1934

Filed by the Registrant    x

Filed by a Party other than the Registrant    ¨

Check the appropriate box:

 

¨    Preliminary Proxy  Statement

 

¨    Confidential, for Use of  the Commission Only (as permitted by Rule 14a-6(e)(2))

x    Definitive   Proxy Statement

 

¨    Definitive Additional Materials

 

¨    Soliciting Material Under Rule 14a-12

 

THE COOPER COMPANIES, INC.

 

(Name of Registrant as Specified in Its Charter)

 

 

(Name of Person(s) Filing Proxy Statement, if Other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

x    No fee required.

¨    Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

 

 (1) Title of each class of securities to which transaction applies:

                                                                                                                                                                                                                              

 (2) Aggregate number of securities to which transaction applies:

                                                                                                                                                                                                                              

 

 (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

                                                                                                                                                                                                                              

 

 (4) Proposed maximum aggregate value of transaction:

                                                                                                                                                                                                                              

 

 (5) Total fee paid:

                                                                                                                                                                                                                              

 

 ¨ 

Fee paid previously with preliminary materials:

 

 ¨ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.

 

 (1) Amount previously paid:

                                                                                                                                                                                                                              

 

 (2) Form, Schedule or Registration Statement No.:

                                                                                                                                                                                                                              

 

 (3) Filing Party:

                                                                                                                                                                                                                              

 

 (4) Date Filed:

                                                                                                                                                                                                                              


LOGO

January 29, 2016February 1, 2019

Dear Stockholder:

You are cordially invited to join us at the 20162019 Annual Meeting of Stockholders (the “Annual Meeting”) of The Cooper Companies, Inc., which will be held at 8:00 a.m. (PDT) on March 14, 201618, 2019 at the offices of The Cooper Companies, Inc., 6140 Stoneridge Mall Road, Suite 145,590, Pleasanton, California 94588.

California. At the Annual Meeting we will ask our stockholders to vote on the proposals detailed in our Proxy Statement and related materials.

We will be providing access to electour proxy materials electronically under the U.S. Securities and Exchange Commission’s “notice and access” rules. As a Boardresult, beginning on or about February 6, 2019, we are mailing a Notice of Directors, ratify the Audit Committee’s appointmentInternet Availability of Proxy Materials to many of our independent registered public accounting firm forstockholders instead of a paper copy of this Proxy Statement and our 2018 Annual Report on Form10-K (the “Annual Report”). This approach conserves natural resources and reduces our printing and distribution costs, while providing a timely and convenient method of accessing the current fiscal yearmaterials and approvevoting.

The Notice contains instructions on how to access our materials through the amendmentinternet and also contains instructions on how to receive a paper copy of our long-term incentive plan governing equity awards forproxy materials, including this Proxy Statement, our employees. We2018 Annual Report, and a form of proxy card or voting instruction card. All stockholders who do not receive a Notice, including stockholders who have previously requested to receive paper copies of proxy materials, will also ask our stockholders to take an advisory vote onreceive a paper copy of the compensation of our Named Executive Officers.proxy materials by mail.

Your vote is important to us and we hope that you will take this opportunity to participate in the affairsimportant. Regardless of the Company. Whether or notwhether you plan to attend the Annual Meeting, we urgehope you to readwill vote as soon as possible. You may vote by proxy by following the accompanying materials regarding matters to be votedinstructions on and use either the proxy card or voting instruction form provided tocard. Voting may be done over the internet, by telephone, or by mail (if you to submitreceived paper copies of the proxy materials). Voting by proxy will ensure your vote by proxy. Additional information about voting your shares is included inrepresentation at the Proxy Statement.Annual Meeting regardless of whether you attend.

We look forward to seeing you at the Annual Meeting.

Sincerely,

LOGO

A. Thomas Bender

Chairman of the Board of Directors

Sincerely,
LOGO
A. Thomas Bender
Chairman of the Board of Directors


THE COOPER COMPANIES, INC.

6140 Stoneridge Mall Road, Suite 590

Pleasanton, CA 94588

 

 

NOTICE OF ANNUAL MEETING OF STOCKHOLDERS

 

 

Meeting Date:

  Monday, March 14, 2016                                                      18, 2019
Meeting Time:         Time:8:00 a.m. (PDT)

Location:

  

The Cooper Companies, Inc.

6140 Stoneridge Mall Road, Suite 145590

Pleasanton, California 94588

Admission:

  All stockholders are cordially invited to attend the meetingAnnual Meeting in person.

Agenda:

  

1.  Elect the sevennine directors named in the Proxy Statement;

2.  Ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending October 31, 2016;

2019;

3.  Approve the amendment and restatement of the 2007 Long-Term Incentive Plan to add 1,700,000 shares to the total reserved for grant and extend the expiration date of the plan through December 31, 2026;

2019 Employee Stock Purchase Plan;

4.  Hold an advisory vote on the compensation of our Named Executive Officers; and

5.  Transact any other business that may properly come before the meeting.

Stockholders of record at the close of business on Tuesday, January 19, 2016,22, 2019, or their legal proxy holders, will be entitled to vote at the Annual Meeting.

On or about February 2, 2016,6, 2019, we will mail either (1) a Notice of Internet Availability of Proxy Materials (the “Notice”) containing instructions on how to access an electronic copy of our proxy materials and vote your shares or (2) a copy of this Proxy Statement and our Annual Report on Form 10-K for the fiscal year ended October 31, 2015.2018. The Notice will also contain instructions on how to request a paper copy of our proxy materials.

You may vote by following the instructions on the Notice or by using the proxy card accompanying the paper copy of materials. If phone or internet voting is available to you, instructions will be included on your proxy card.

Your vote is important to usYOUR VOTE IS IMPORTANT TO US.. Regardless of whether you plan to attend the meeting,Annual Meeting, we encourage you to vote your shares as soon as possible to ensure that your vote is recorded. We look forward to your participation.

By Order of the Board of Directors

 

LOGO

Carol R. KaufmanLOGO

Randal L. Golden, Esq.

Secretary

Dated: January 29, 2016February 1, 2019


Table of ContentsTABLE OF CONTENTS

 

 

 

NOTICE OFPROPOSALS TO BE PRESENTED AT THE ANNUAL MEETING OF STOCKHOLDERS

 1

STOCKHOLDER PROPOSALS AND NOMINATIONS FOR DIRECTORProposals

1

Other Company Information

1

Voting Information

1

Other Q&A

3

Stockholder Proposals and Nominations for Director

  5 

OWNERSHIP OF THE COMPANY

  6 

Principal Securityholders

6

Securities Held by Insiders

7

CORPORATE GOVERNANCE

  9 

The Board of Directors

9

Corporate Governance Policies

12

REPORT OF THE AUDIT COMMITTEE

  16 

EXECUTIVE OFFICERS OF THE COMPANY

  18 

REPORT OF THE ORGANIZATION AND COMPENSATION COMMITTEE

  20 

COMPENSATION DISCUSSION AND ANALYSIS

  2120 

EXECUTIVE COMPENSATION TABLES

  37 

Summary Compensation Table

  37 

Grants of Plan Based Awards Table

  39 

Outstanding Equity Awards at Fiscal Year End Table

  4142 

Option Exercises and Stock Vested Table

  45 

Non-Qualified Deferred Compensation Table

45

Pension Benefits Table

  46 

CEO Pay Ratio

47

POTENTIAL PAYMENTS UPON TERMINATION OR CHANGE IN CONTROL

  48 

DIRECTOR COMPENSATION

  5450 

PROPOSAL 1 — ELECTION OF DIRECTORS

  5853 

PROPOSAL 2 — RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC

ACCOUNTING FIRM

  6359 

PROPOSAL 3 — APPROVAL OF THE AMENDMENT AND RESTATEMENT OF THE 2007 LONG-

TERM INCENTIVE2019 EMPLOYEE STOCK PURCHASE PLAN

  6460 

PROPOSAL 4 — ADVISORY VOTE ON EXECUTIVE COMPENSATION

  7465 

OTHER MATTERS

  7566 

RECOMMENDATIONS

  7566 

EXHIBIT A - THIRD AMENDED AND RESTATED 2007 LONG-TERM INCENTIVE PLAN– 2019 Employee Stock Purchase Plan

  A-1 


PROPOSALS TO BE PRESENTED AT THE COOPER COMPANIES, INC.ANNUAL MEETING

Our 2019 Annual Meeting will be held at 8:00 a.m. (PDT) on March 18, 2019 at the offices of The Cooper Companies, Inc., 6140 Stoneridge Mall Road, Suite 590,

Pleasanton, CA 94588California.

 

 

We will hold our Annual Meeting of Stockholders, or the Annual Meeting, on Monday, March 14, 2016 at 6140 Stoneridge Mall Road, Suite 145, Pleasanton, California. The meeting will start at 8:00 a.m. (PDT).LOGO

This Proxy Statement was provided to all stockholders of record at Tuesday, January 19, 201622, 2019 and is presented on our behalf by order of the Board of Directors. It contains information regarding theabout our Company and the proposals which willto be presented at the Annual Meeting. We have also furnished our 20152018 Annual Report on Form 10-K to all stockholders of record. The 2015 Annual Report on Form 10-K contains our financial statements for the fiscal year ended October 31, 20152018 and other useful information, but it is not part of the materials for the solicitation of proxies.

Proposals

No.

     Board Recommendation     Page
  1  ELECTION OF NINE DIRECTORS IDENTIFIED BELOW  LOGO     FOR each director     53
  2  RATIFICATION OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM  LOGO     FOR     59
  3  APPROVAL OF THE 2019 EMPLOYEE STOCK PURCHASE PLAN  LOGO     FOR     60
  4  ADVISORY VOTE ON EXECUTIVE COMPENSATION  LOGO     FOR     65

We are not aware of any other business to be brought before the meeting. If any additional business is properly brought before the meeting, the designated officers serving as proxies will vote in accordance with their best judgment.

Other Company Information

Corporate Governance – page 9

Compensation Discussion & Analysis – page 20

Executive Compensation Tables – page 37

Director Compensation – page 50

You may also find useful information about the Company on our website athttp://www.coopercos.com. Information contained on our website is not, and should not be considered, a part of this Proxy Statement or any other filing or report filed with or furnished to with the Securities and Exchange Commission (the “SEC”).

Proposals to be Presented

At the Annual Meeting, stockholders will be asked to consider and act on the following proposals:

Our Board     

Recommends

You Vote:      

Proposal 1 — Election of Directors (p. 58)Voting Information

FOR

The Board recommends the re-election of the seven nominees presented in this Proxy Statement to our Board of Directors. This proposal requires a favorable majority of the votes cast at the Annual Meeting to pass.

Proposal 2 — Ratification of Appointment of Independent Registered Public Accounting Firm (p. 63)

FOR

The Board recommends the ratification of its appointment of KPMG LLP as our independent registered public accounting firm for the 2016 fiscal year. This proposal requires the favorable majority of shares entitled to vote and present in person, or represented by proxy, to pass.

Proposal 3 – Amendment of the Amended & Restated 2007 Long-Term Incentive Plan (p. 64)

FOR

The Board recommends the approval of the amended and restated 2007 Long-Term Incentive Plan as presented in this Proxy Statement. This proposal requires a favorable majority of the votes cast at the Annual Meeting to pass.

Proposal 4 — Advisory Vote on Executive Compensation (p. 74)

FOR

The Board recommends approval, on an advisory basis, of the compensation of our executive officers as presented in this Proxy Statement. This proposal requires the favorable majority of shares entitled to vote and present in person, or represented by proxy, to pass.

Detailed information regarding each of these proposals is presented in this Proxy Statement starting on page 58. Additional information about us, our Board and its committees, equity ownership, compensation of officers and directors, and other matters can be found starting on page 6.

 

1


We are not aware of any other business to be brought before the meeting. If any additional business is properly brought before the meeting, the designated officers serving as proxies will vote in accordance with their best judgment.

Voting Information

We strongly encourage you to vote.

Your vote is important to us. Regardless of whether you plan to attend the meeting, we encourage you to read this Proxy Statement and the accompanying materials and to vote your shares as soon as possible to ensure that your vote is recorded. We look forward to your participation.

1 | Page   


Who is entitled to vote at the Annual Meeting?

Our Record Date for this year’sthe Annual Meeting is January 19, 2016.22, 2019. All stockholders who owned our stock at the close of business on the Record Date are entitled to receive proxy materials and to vote at the Annual Meeting and any continuations, adjournments or postponements thereof.

As of the Record Date, there were 48,390,17649,339,170 shares of our common stock outstanding and entitled to vote at the Annual Meeting.

How many votes do I have?

Each outstanding share of our common stock is entitled to one vote at the Annual Meeting. You have one vote per share that you owned at the close of business on the Record Date.

How do I vote my shares?

You can vote your shares in person at the Annual Meeting or vote by proxy. The method of voting by proxy differs for shares held as a record holder and shares held in “street name.” If you hold your shares of common stock as a record holder you may vote your shares by following the instructions on the Notice, or by completing, dating, and signing the proxy card included with this Proxy Statement and promptly returning it in thepre-addressed, postage paid envelope provided to you. If phone or internet voting is available to you, instructions are included in the Notice or on your proxy card.

If you hold your shares of common stock in “street name,” which means your shares are held of record by a broker, bank, or other nominee, you will receive the proxy materials from your broker, bank, or other nominee with instructions on how to vote your shares. Your broker, bank, or other nominee may allow you to deliver your voting instructions by phone or through the Internet.internet. If you wish to vote your shares in person you may do so by attending the Annual Meeting and requesting a ballot.

What happens if I vote my shares by proxy?

When you return a completed proxy card, or vote your shares by telephone or internet, you authorize our officers listed on the proxy card to vote your shares on your behalf as you direct.

If you sign and return a proxy card, but do not provide instructions on how to vote your shares, the designated officers will vote on your behalf as recommended by the Board:

 

Shares will be votedFOR each of the individuals nominated to serve as directors;

Shares will be voted FOR each of the individuals nominated to serve as directors;

Shares will be voted FOR ratification of the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending October 31, 2019;

Shares will be voted FOR the approval of the 2019 Employee Stock Purchase Plan; and

Shares will be voted FOR the compensation of our Named Executive Officers as described in this Proxy Statement.

 

Shares will be votedFOR ratification of the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending October 31, 2016;2 | Page   

Shares will be votedFOR the amendment of the Amended & Restated 2007 Long-Term Incentive Plan; and


 

2


Shares will be votedFOR the compensation of our Named Executive Officers as described in this Proxy Statement.

Can I change or revoke my vote after I return my proxy card or voting instructions?

If you choose to vote your shares by proxy, you may revoke or change your vote at any time prior to the casting of votes at the Annual Meeting. To revoke or change your vote, you may take any of the following actions:

 

 1.

Execute and submit a new proxy card;

 2.

Submit new voting instructions through telephonic or internet voting, if available to you;

 3.

Notify Carol R. Kaufman,Randal L. Golden, Secretary of the Company, in writing that you wish to revoke your proxy; or

 4.

Vote your shares in person at the Annual Meeting.

Attending the Annual Meeting in person will not automatically revoke your proxy.

How many votes must be present to hold the Annual Meeting?

In order to conduct business and have a valid vote at the Annual Meeting a quorum must be present in person or represented by proxies. A quorum is defined as a majority of the shares outstanding on the Record Date and entitled to vote. In accordance with Delaware law and our Bylaws, broker “non-votes”“non-votes” and proxies reflecting abstentions will be considered present and entitled to vote for purposes of determining whether a quorum is present.

What are broker “non-votes”“non-votes”?

Broker “non-votes”“non-votes” occur when a broker is not permitted to vote on behalf of shares it holds for a beneficial owner and the beneficial owner does not provide voting instructions. Shares held in a broker’s name may be voted by the broker, but only in accordance with the rules of the New York Stock Exchange. Under those rules, the broker must follow the instructions of the beneficial owner. If instructions are not provided, NYSE rules determine whether the broker may vote the shares based on its own judgment or if it is required to withhold its vote, and thevote. This determination depends on the proposal being voted on. For the proposals to be presented at the Annual Meeting, broker discretionary voting is only permitted for the ratification of our independent registered public accounting firm.

Other Q&A

Why did I receive aone-page notice in the mail regarding the Internetinternet availability of proxy materials instead of a full set of proxy materials?

The SEC permits us to provide our proxy materials electronically to stockholders if theyyou have not previously requested to receive only printed materials on an ongoing basis. Accordingly, on or about February 2, 2016,6, 2019, we mailed a Notice of Internet Availability of Proxy Materials (“the Notice”). The Notice includes instructions on how to access the proxy materials over the Internetinternet or to request a printed copy.

The Notice was sent to our stockholders of record at January 19, 2016.22, 2019. All stockholders receiving the Notice have the ability to access the proxy materials electronically through the website referred to in the Notice, and they also have the option to request a printed set of the proxy materials. We encourage stockholders to take advantage of the availability of proxy materials on the Internet.

internet.

 

3 | Page   


Can I vote my shares by filling out and returning the Notice of Internet Availability of Proxy Materials?

No. The Notice only identifies the items to be voted on at the Annual Meeting. You cannot vote by marking the Notice and returning it. The Notice provides instructions on how to cast your vote.

Who pays for the proxy solicitation and how will the Company solicit votes?

We pay all costs associated with the solicitation of proxies, including any costs incurred by brokers and other fiduciaries to forward proxy solicitation materials to beneficial owners.

We may solicit proxies in person or by mail, telephone, facsimile, ore-mail. Proxies may be solicited on our behalf by any of our directors, officers, or employees. Additionally, we have retained the firm of D.F. King & Co., Inc. to assist with the solicitation of proxies and will pay a fee of $16,500 for this service, plus reasonable costs and expenses.

How can stockholders present proposals for consideration at the 2017 Annual Meeting?

Proposals to be presented under Rule 14a-8 must be submitted no later than October 5, 2016 to be included in our next Proxy Statement and considered at the 2017 Annual Meeting of Stockholders. Detailed information for stockholders regarding how to present proposals under our Bylaws to be considered at the 2017 Annual Meeting is presented on page 5. Proposals should be sent to Carol R. Kaufman, Secretary, The Cooper Companies, Inc., 6140 Stoneridge Mall Road, Suite 590, Pleasanton, CA 94588.

How can I communicate with the Board of Directors?

Any interested party can contact our Board to provide comments, to report concerns, or to ask a question, at the following address:

CorporateRandal L. Golden

Vice President, Secretary & General Counsel

The Cooper Companies, Inc.

6140 Stoneridge Mall Road, Suite 590

Pleasanton, CA 94588

Communications are distributed to the Board, or to any individual directors as appropriate, depending on the facts and circumstances outlined in the communication. You may also communicate online with our Board of Directors as a group through our website. Please refer to our website athttp://www.coopercos.com for any changes in this process.

 

4 | Page   


STOCKHOLDER PROPOSALS AND NOMINATIONS FOR DIRECTORStockholder Proposals and Nominations for Director

 

Our

SEC rules and our Bylaws allowpermit stockholders to nominate directors for election and to propose other business to be considered by stockholders at the Annual Meeting. Under the Bylaw provisions, stockholders wishing to submit proposals must notify the Company Secretary in writing. Notice must be sent no earlier than the close of business on the 120th day prior to the anniversary date of the prior year’s annual meeting and no later than the close of business on the 90th day prior to the anniversary date of the prior year’s annual meeting.Meeting under various mechanisms.

To be considered at the 20172020 Annual Meeting, director nominations andor other proposals for consideration under these provisions must be submitted no earlier than November 14, 2016 and no later than December 14, 2016. in writing to:

Randal L. Golden, Secretary

The Cooper Companies, Inc.

6140 Stoneridge Mall Road, Suite 590

Pleasanton, CA 94588

Proposals to be Presented Under Rule14a-8 and Director Nominations under Bylaw Article II, Section 16 (“Proxy Access”):

No later than October 9, 2019.

Proposals and Director Nominations Submitted Under Other Bylaw Provisions:

No earlier than November 18, 2019 and no later than December 18, 2019.

In the event that we set the date for the 20172020 Annual Meeting more than 30 days before or more than 70 days after March 14, 2017, director nominations and other proposals must18, 2020, submissions may be submittedmade no earlier than the close of business on the 120th day prior to the announced meeting date and no later than the close of business on the later of the 90th day prior to the announced meeting date and the 10th day following our first public disclosure of the date of the meeting.

Also,The Corporate Governance and Nominating Committee will consider director nominees suggested by stockholders on the same terms as nominees selected by the Committee. See page 9 for information about the Committee’s criteria for director nominations.

The person recommending the nominee must be a stockholder entitled to vote at the 2020 Annual Meeting. To be considered, recommendations must include:

(1)

the nominee’s written consent to being named in the Proxy Statement and to serve as a director if elected;

(2)

the name and address of the stockholder submitting the recommendation or the beneficial owner on whose behalf the proposed candidate is being suggested for nomination;

(3)

a statement of the proposed nominee’s qualifications to serve as director; and

(4)

the class and number of our shares owned by the stockholder or beneficial owner submitting the recommendation.

If we increase the number of directors to be elected at the 20172020 Annual Meeting and we do not make a public announcement at leastwith less than 100 daysdays’ notice prior to March 14, 201718, 2020, stating the size of the increase and naming all the nominees for director, then stockholder nominations for directors will be considered if the proposal is delivered to our Secretary at our principal offices no later than 10 days after we make a public announcement of the increased board size. This only applies to nominations for positions created by the increase and does not apply to nominations for current positions. This also does not apply to proposals other than the nomination of director candidates. Nominations or proposals should be submitted, in writing, to Carol R. Kaufman, Secretary, The Cooper Companies, Inc., 6140 Stoneridge Mall Road, Suite 590, Pleasanton, CA 94588. A stockholder’s notice to nominate a director or bring any other business before the 2017 Annual Meeting must set forth certain information specified in our Bylaws.

Our Corporate Governance and Nominating Committee of the Board of Directors will also directly consider suggestions from stockholders for potential Board nominees for election as directors to be presented at the 2017 Annual Meeting. The person recommending the nominee must be a stockholder entitled to vote at the 2017 Annual Meeting, and the recommendation must be received in writing between November 14, 2016 and December 14, 2016. To be considered, recommendations should include: (i) the nominee’s written consent to being named in the Proxy Statement as a nominee and to serve as a director if elected, (ii) the name and address of the stockholder submitting the recommendation or beneficial owner on whose behalf the proposed candidate is being suggested for nomination, and (iii) the class and number of our shares owned beneficially and of record by the stockholder or beneficial owner submitting the recommendation. The Corporate Governance and Nominating Committee will consider nominees suggested by stockholders on the same terms as nominees selected by the Committee.

 

5 | Page   


OWNERSHIP OF THE COMPANY

Principal Securityholders

The following table contains information regarding all individuals or groups who have advised us that they own more than five percent (5%) of the outstanding shares of our common stock. Information is presented is as of January 15, 2016.22, 2019.

 

Name & Address of Beneficial Owner             Aggregate Number
  of Shares Beneficially Held  
  

 Percentage 

      of Shares      

Massachusetts Financial Services Company(1)

111 Huntington Avenue

Boston, MA 02199

   5,402,120     11.20%

FMR LLC(2)

245 Summer St.

Boston, MA 02210

   5,316,735     11.04%

T. Rowe Price Associates, Inc.(3)

100 E. Pratt Street

Baltimore, MD 21202

   4,307,591     8.90%

BlackRock, Inc. (4)

55 East 52nd Street

New York, NY 10022

   3,720,060     7.70%

Vanguard Group, Inc.(5)

100 Vanguard Blvd.

Malvern, PA 19355

   3,041,874     6.31%

  Name & Address of Beneficial Owner

 

  

Aggregate Number
of Shares Beneficially Held

 

  

Percentage

of Shares

 

  T. Rowe Price Associates, Inc. (1)

  100 E. Pratt Street

  Baltimore, MD 21202

 

  5,636,279  11.5%

  Vanguard Group, Inc. (2)

  100 Vanguard Blvd.

  Malvern, PA 19355

 

  5,122,120  10.48%

  BlackRock, Inc. (3)

  55 East 52nd Street

  New York, NY 10022

 

  3,616,339  7.4%

  Massachusetts Financial Services Company (4)

  111 Huntington Avenue

  Boston, MA 02199

 

  2,662,207  5.4%

  Generation Investment Management LLP (5)

  20 Air Street, 7th Floor

  London, United Kingdom W1B 5AN

 

  2,535,141  5.2%

  State Street Corporation (6)

  One Lincoln Street

  Boston, Massachusetts 02111

  2,507,949  5.12%

 

(1)Based on information disclosed in a Schedule 13G filed by Massachusetts Financial Services Company (“MFS”) on January 8, 2016. MFS beneficially owns and has the sole power to dispose of or direct the disposition of all 5,402,120 shares and the sole power to vote or direct the vote of 4,951,584 of these shares.

(2)Based on information disclosed in a Schedule 13G/A filed by FMR LLC, Abigail P. Johnson and Edward C. Johnson 3d on August 24, 2015. FMR LLC, Abigail P. Johnson and Edward C. Johnson 3d, through their control of the subsidiaries of FMR LLC, have the sole power to dispose of or direct the disposition of all 5,316,735 shares and the sole power to vote or direct the voting of 603,843 of these shares. According to this Schedule 13G/A, Fidelity Management & Research Company, Pyramis Global Advisors Trust Company and Pyramis Global Advisors (Canada) ULC, each a subsidiary of FMR LLC, beneficially owns a portion of these 5,316,735 shares.

(3)Based on information disclosed in a Schedule 13G/A filed by T. Rowe Price Associates, Inc. on February 13, 2015.January 10, 2018. According to this Schedule 13G/A, T. Rowe Price Associates beneficially owns and has the sole power to dispose of or direct the disposition of all 5,636,279 of these 4,307,591 shares and has the sole power to vote or to direct the vote of 984,6241,689,033 of these shares.

(4)(2)

Based on information disclosed in a Schedule 13G/A filed by The Vanguard Group, Inc. on February 9, 2018. According to this Schedule 13G/A, The Vanguard Group beneficially owns and has the sole power to dispose of or direct the disposition of 5,044,983 of these shares and has the shared power to dispose of or direct the disposition of 77,137 of these shares; and has the sole power to vote or to direct the vote of 69,724 of these shares and has shared power to vote 10,530 of these shares.

(3)

Based on information disclosed in a Schedule 13G/A filed by BlackRock, Inc. on January 26, 2015.February 8, 2018. According to this Schedule 13G/A, BlackRock, Inc., directly and through its subsidiaries, beneficially owns, and has the sole power to dispose of or direct the disposition of all 3,616,339 of these 3,720,060 shares and has the sole power to vote or direct the vote of 3,512,9693,177,089 of these shares.

(5)(4)

Based on information disclosed in a Schedule 13G13G/A filed by The Vanguard Group, Inc.Massachusetts Financial Services Company (“MFS”) on February 11, 2015. According to this Schedule 13G, The Vanguard Group9, 2018. MFS beneficially owns and has the sole power to dispose of or direct the disposition of 3,004,791all 2,662,207 of these shares and the sole power to vote or direct the vote of 2,459,886 of these shares.

(5)

Based on information disclosed in a Schedule 13G filed by Generation Investment Management LLP (“GIM”) on April 16, 2018. Generation Investment Management LLP beneficially owns and has the sharedsole power to dispose of or direct the disposition of 37,08319,433 of these shares and has the shared

6 | Page   


power to dispose of or direct the disposition of 2,515,708 of these shares; and has the sole power to vote or to direct the vote of 42,38319,433 of these shares and has shared power to vote 2,515,708 of these shares. According to this Schedule 13G, Vanguard Fiduciary Trust Company,Generation Investment Management US LLP, a wholly owned subsidiary of The Vanguard Group, beneficially owns 28,383GIM, has the shared power to dispose of or direct the disposition of and the shared power to vote or direct the vote of 1,190,689 of these shares and Vanguard Investments Australia Ltd.,shares; Generation IM Fund PLC, a wholly owned subsidiary of GIM, has the Vanguard Group beneficially owns 22,700shared power to dispose of or direct the disposition of and the shared power to vote or direct the vote of 750,249 of these shares; and Generation IM Global Equity Fund, LLC a wholly owned subsidiary of GIM, has the shared power to dispose of or direct the disposition of and the shared power to vote or direct the vote of 624,317 of these shares.
(6)

Based on information disclosed in a Schedule 13G filed by State Street Corporation on February 14, 2018. State Street Corporation has the shared power to dispose of or direct the disposition of and to vote or direct the voting of all 2,507,949 of these shares.

 

6


 

Securities Held by Insiders

The following table contains information regarding ownership of our common stock by each of our directors, the executives named in the Summary Compensation Table, and all of the current directors and executive officers as a group. The figures in this table represent sole voting and investment power except where otherwise indicated.

 

                                                                                                                      Common Stock Beneficially
Owned as of January 15, 2016
 
  

Name of Beneficial Owner                                                                          

  Number
of Shares
   

 

   Percentage 
of Shares
 
 

A. Thomas Bender

   64,154     (1      *  
 

Michael H. Kalkstein

   48,768     (2      *  
 

Carol R. Kaufman

   154,652     (3      *  
 

Jody S. Lindell

   65,035     (4      *  
 

Greg W. Matz

   39,292     (5      *  
 

Daniel G. McBride

   74,551     (6      *  
 

Gary S. Petersmeyer

   11,818     (7      *  
 

Steven Rosenberg

   73,368     (8      *  
 

Allan E. Rubenstein, M.D.

   26,749     (9      *  
 

Robert S. Weiss

   375,357     (10      *  
 

Albert G. White III

   64,058     (11      *  
 

Stanley Zinberg, M.D.

   55,132     (12      *  
 

All current directors and executive officers as a group (15 persons)

   1,080,218      2.2%  
   Common Stock Beneficially
Owned as of January 22, 2019
 
Name of Beneficial Owner Number
of Shares
      Percentage
of Shares
 

Brian G. Andrews

 

  

 

11,686

 

 

 

  

 

(1

 

 

  * 

Robert D. Auerbach, M.D.

 

  

 

9,125

 

 

 

  

 

(2

 

 

  * 

A. Thomas Bender

 

  

 

33,087

 

 

 

  

 

(3

 

 

  * 

Colleen E. Jay

 

  

 

4,987

 

 

 

  

 

(4

 

 

  * 

Michael H. Kalkstein

 

  

 

36,062

 

 

 

  

 

(5

 

 

  * 

Carol R. Kaufman

 

  

 

90,875

 

 

 

  

 

(6

 

 

  * 

William A. Kozy

 

  

 

5,257

 

 

 

  

 

(7

 

 

  * 

Jody S. Lindell

 

  

 

55,838

 

 

 

  

 

(8

 

 

  * 

Daniel G. McBride

 

  

 

97,871

 

 

 

  

 

(9

 

 

  * 

Gary S. Petersmeyer

 

  

 

8,169

 

 

 

  

 

(10

 

 

  * 

Allan E. Rubenstein, M.D.

 

  

 

4,584

 

 

 

      

 

*

 

 

 

Holly R. Sheffield

 

  

 

-

 

 

 

      * 

Robert S. Weiss

 

  

 

312,491

 

 

 

  

 

(11

 

 

  * 

Albert G. White III

 

  

 

            102,906

 

 

 

  

 

(12

 

 

  * 

Stanley Zinberg, M.D.

 

  

 

30,619

 

 

 

  

 

(13

 

 

  * 

All current directors and executive officers as a group (17 persons)

  833,833       1.7
*

Less than 1% ownership.

(1)

Includes 8,379 shares which Mr. Andrews could acquire upon the exercise of currently exercisable stock options.

 (1)(2)

Includes 989 restricted5,326 shares granted to Mr. Bender pursuant towhich Dr. Auerbach could acquire upon the termsexercise of the Second Amended and Restated 2006 Long-Term Incentive Plan for Non-Employee Directors (the “2006 Directors’ Plan”). Mr. Bender has sole voting power with respect to these shares; however, disposition is restricted pursuant to the terms of the 2006 Directors’ Plan. Also includes 45,510currently exercisable stock options.

(3)

Includes 14,950 shares which Mr. Bender could acquire upon the exercise of currently exercisable stock options.

 (2)(4)

Includes 8991,766 shares granted to Mr. Kalkstein pursuant towhich Ms. Jay could acquire upon the termsexercise of the 2006 Directors’ Plan. Mr. Kalkstein has sole voting power with respect to these shares; however, disposition is restricted pursuant to the terms of the 2006 Directors’ Plan. Also includes 33,509currently exercisable stock options.

(5)

Includes 26,591 shares which Mr. Kalkstein could acquire upon the exercise of currently exercisable stock options; 30,727all of these exercisable options are held by an estate planning trust in which Mr. Kalkstein maintains 50% or greater control.

 

7 | Page   


 (3)(6)

Includes 112,97244,977 shares which Ms. Kaufman could acquire upon the exercise of currently exercisable stock options.

 (4)(7)

Includes 8991,766 shares granted to Ms. Lindell pursuant towhich Mr. Kozy could acquire upon the termsexercise of the 2006 Directors’ Plan. Ms. Lindell has sole voting power with respect to these shares; however, disposition is restricted pursuant to the terms of the 2006 Directors’ Plan. Also includes 46,009currently exercisable stock options.

(8)

Includes 34,091 shares which Ms. Lindell could acquire upon the exercise of currently available stock options; all of Ms. Lindell’s exercisable options are held by estate planning trusts in which Ms. Lindell maintains 50% or greater control.

 (5)(9)

Includes 24,723 shares which Mr. Matz could acquire upon the exercise of currently exercisable stock options.

(6)Includes 49,34166,627 shares which Mr. McBride could acquire upon the exercise of currently exercisable stock options.

 (7)(10)

Includes 899 shares granted to Mr. Petersmeyer pursuant to the terms of the 2006 Directors’ Plan. Mr. Petersmeyer has sole voting power with respect to these shares; however, disposition is restricted pursuant to the terms of the 2006 Directors’ Plan. Also includes 9,7595,864 shares which Mr. Petersmeyer could acquire upon the

7


exercise of currently available stock options; 6,977all of these exercisable options are held by an estate planning trust in which Mr. Petersmeyer maintains 50% or greater control.

 (8)(11)

Includes 899 shares granted to Mr. Rosenberg pursuant to the terms of the 2006 Directors’ Plan. Mr. Rosenberg has sole voting power with respect to these shares; however, disposition is restricted pursuant to the terms of the 2006 Directors’ Plan. Also includes 61,009 shares which Mr. Rosenberg could acquire upon the exercise of currently exercisable stock options.

(9)Includes 899 shares granted to Dr. Rubenstein pursuant to the terms of the 2006 Directors’ Plan. Dr. Rubenstein has sole voting power with respect to these shares; however, disposition is restricted pursuant to the terms of the 2006 Directors’ Plan. Also includes 18,710 shares which Dr. Rubenstein could acquire upon the exercise of currently exercisable stock options.

(10)Includes 226,650166,871 shares which Mr. Weiss could acquire upon the exercise of currently exercisable stock options.

 (11)(12)

Includes 30,97365,467 shares which Mr. White could acquire upon the exercise of currently exercisable stock options.

 (12)(13)

Includes 899 shares granted to Dr. Zinberg pursuant to the terms of the 2006 Directors’ Plan. Dr. Zinberg has sole voting power with respect to these shares; however, disposition is restricted pursuant to the terms of the 2006 Directors’ Plan. Also includes 43,50920,091 shares which Dr. Zinberg could acquire upon the exercise of currently exercisable stock options; all of Dr. Zinberg’s exercisable options are held by estate planning trusts in which Dr. Zinberg maintains 50% or greater control.

 

8 | Page   


CORPORATE GOVERNANCE

TheAbout Our Board of Directors

Board Facts:

 Board size: 9 directors

 All directors are elected annually

•   7 independent directors

 Majority vote required for election

•   2 women

•   Separate Lead Director & Chairman

Our Board of Directors is elected annually andhas nine members, each of our directorswhom stands for election every year. Presently the Board is comprised of eight directors, however, the Board has chosen to reduce the size of the Board to seven and Mr. Rosenberg will not be standing for re-election at the Annual Meeting.annually. All of our directors, except Mr.Messrs. Weiss and White, have been determined by the Board to be independent. Mr. Weiss serves as our Chief Executive Officer and is compensated for his position as an executive. He receives no additional compensation for his service on the Board.

In making this determination, the Board has affirmed that each of the independent directors meets the objective requirements for independence set forth by the NYSE and the SEC, and that each has no relationship to the Company, either directly or indirectly, through an organization that has a relationship with the Company, other than as a stockholder of the Company or through his or hertheir service on the Board. The Board and its active committees conduct regular self-evaluations and review director independence and committee composition to ensure continued compliance with regulations.

Directors who are not also employees, orNon-Employee Directors, are compensated for their services as described in the section headedDirector Compensation”Compensation on page 54.50. Mr. White serves as our Chief Executive Officer and receives no additional compensation for his service on the Board. Mr. Weiss was compensated as an employee through December 2018 and is considered aNon-Employee Director as of January 1, 2019. Compensation for both Messrs. Weiss and White is discussed in more detail in ourCompensation Discussion & Analysis and executive compensation disclosures starting on page 37.

Under our Corporate Governance Principles, directors are not permitted to serve on the boards of more than two other public companies while they serve on our Board. We do not limit service on private company boards of directors or withnon-profit organizations.

Identification of Candidates

The Corporate Governance and Nominating Committee is responsible for identification and selection of qualified candidates for nomination to the Board. The Committee believes that nominees for election to the Board must possess certain minimum qualifications and attributes.

To be nominated for election, an individual must: (i) meet the objective independence requirements set forth by the SEC and NYSE (other than executive nominees), (ii) exhibit strong personal integrity, character, and ethics and a commitment to ethical business and accounting practices, (iii) not serve on more than two other public company boards, (iv) not be involved in on-going litigation with us or be employed by an entity which is engaged in such litigation, and (v) not be the subject of any on-going criminal investigations, including investigations for fraud or financial misconduct.

(i)

meet the objective independence requirements set forth by the SEC and NYSE (other than executive nominees);

(ii)

exhibit strong personal integrity, character, and ethics and a commitment to ethical business and accounting practices;

(iii)

not serve on more than two other public company boards;

(iv)

not be involved inon-going litigation with us or be employed by an entity which is engaged in such litigation; and

(v)

not be the subject of anyon-going criminal investigations, including investigations for fraud or financial misconduct.

The Corporate Governance and Nominating Committee does not currently maintain a separate diversity policy.policy regarding nominees for director. Instead the Committee relies on diversity as one of many factors in the consideration of director nominees who meet these stated criteria.

The Corporate Governance and Nominating

9 | Page   


Committee will consider suggestions from stockholders for nominees for election as directors at our Annual Stockholder Meetings on the same terms as nominees selected by the Committee. Stockholder suggestions must be received on a timely basis and meet the criteria set forth in the information onStockholder Proposals Andand Nominations Forfor Director on page 5.

As of the date of this Proxy Statement, no stockholder suggestions for director nominees have been received by the Corporate Governance and Nominating Committee. Except as set forth above, the Corporate Governance and Nominating Committee does not currently have a formal process for identifying and evaluating nominees for directors, including nominees recommended by stockholders.

9


Board Leadership Structure

We maintain separate positions for the Chairman and Chief Executive Officer (CEO). We also maintain an independent Lead Director position, which is currently held by Dr. Allan E. Rubenstein.

We feel this division provides a balance between the independence of our directors and the experience of our officers. Our current Chairman has significant business experience with the Company, but has also been affirmatively determined to be independent by our Board. We feel that maintaining an independent Chair provides for strong, knowledgeable leadership of the Board separate from the CEO position’s immediate,day-to-day involvement with the Company.

Board Committees

 

Board Committees

The Board currently maintains fourthree standing committees whose functions areas described below. Committee membership is determined by the Board and reviewed regularly.

As required by the SEC and NYSE, all members of theour Audit Committee, Corporate Governance and Nominating Committee, the Audit Committee, and the Organization and Compensation Committee are independent directors. At the Board’s discretion, other committees may include directors who have not been determined to be independent. Currently the Board maintains one committee, the Science and Technology Committee, which has non-independent director membership.

Audit

Corporate Governance &
Nominating

Organization &
Compensation

A. Thomas Bender (Chairman)

Allan E. Rubenstein, M.D. (Lead Director)

Colleen E. Jay

Michael H. Kalkstein

William A. Kozy

Jody S. Lindell

Gary S. Petersmeyer

Robert S. Weiss

Albert G. White III

Stanley Zinberg, M.D.

- Committee Chair

Each committee maintains a written charter detailing its authority and responsibilities. These charters are updated periodically as legislative and regulatory developments and business circumstances warrant. The committee charters are available in their entirety on our website athttp://www.coopercos.com.www.coopercos.com.

LOGO

(1)Mr. Rosenberg serves on the noted committees at the time of this Proxy Statement. He will not be standing for re-election at the Annual Meeting and will resign his place on these committees at that time.

 

 

The Audit Committee provides advice with respect to our financial matters and assists the Board in fulfilling its oversight responsibilities regarding: (i) the quality and integrity of our financial statements, (ii) our compliance

10 | Page   


with legal and regulatory requirements, (iii) review of our potential risk factors, (iv) the qualifications, independence, and performance of the independent registered public accounting firm serving as auditors of the Company, (v) retention and engagement of the

10


independent registered public accounting firm, and (vi) the performance of the Company’s Internal Audit function and internal controls. The Audit Committee advises and makes recommendations to the Board regarding our financial, investment, and accounting procedures and practices.

 

 

The Organization and Compensation Committee, or the Compensation Committee, reviews and approves all aspects of the compensation paid to our Chief Executive Officer and all executives identified by the Organization and Compensation Committee as officers under Section 16(a) of the Exchange Act. The Organization and Compensation Committee also approves all compensation for employees whose total combined annual base salary plus targetnon-equity incentive bonus is $500,000$750,000 or greater, regardless of whether they have been designated as officers under Section 16(a). Members of the Organization and Compensation Committee are not eligible to participate in any of our executive compensation programs.

The Organization and Compensation Committee also approves the composition of our designated comparative peer group for comparative compensation review, approves all awards under our equity andnon-equity incentive bonus plans, and has approval authority for all agreements providing for the payment of benefits following a change in control of the Company, severance following a termination of employment, or any other special arrangement with the executive officers or employees which would affect their compensation. The Organization and Compensation Committee also oversees succession planning, diversity & inclusion, and management development programs designed to strengthen our internal pool of candidates for executive level positions and promote mentoring of senior level employees.

 

 

The Corporate Governance and Nominating Committee develops, implements, and maintains the corporate governance standards by which we conduct business, and advises and makes recommendations to the Board concerning our primary governance policies. The Corporate Governance and Nominating Committee meets with the Chief Executive Officer and senior corporate staff as it deems appropriate to fulfill its obligations with regard to our corporate governance standards. The Corporate Governance and Nominating Committee also performs the functions described underIdentification of Candidates on page 9.

 

 

The Science and Technology Committee evaluates new and existing technologies. The Science and Technology Committee’s primary functions are to: (i) discuss technology that falls outside the usual scope of current business, (ii) periodically review our research and development projects and portfolio, (iii) annually review our key technologies and assess the position of these technologies versus third party products and processes, and (iv) provide information and guidance to the Board on matters relating to science and technology. The Science and Technology Committee functions on an ad hoc basis.Meetings

 

 

Meetings

The Board and its committees met as follows during our most recent fiscal year ended October 31, 2015:year:

 

   Number of Meetings

Board of Directors

 1012

Audit Committee

 78

Organization and& Compensation Committee

 68

Corporate Governance and& Nominating Committee

 1

Science and Technology Committee

53

11


TheNon-Employee Directors also meet routinely inhold executive sessionsessions in connection with regular meetings of the Board and more often as they deem appropriate. Either Mr. Bender, as Chair, or Dr. Rubenstein, as Lead Director, presides over executive sessions.

During the 20152018 fiscal year, each director attended at least 90% of the aggregate of board meetings and meetings of committees on which the director served. Currently we do not maintain a formal policy regarding director attendance at the Annual Meeting.

 

11 | Page   


Corporate Governance Policies

We have an ongoing commitment to good governance and business practices. In furtherance of this commitment, we regularly monitor developments in the area of corporate governance and review our policies and procedures in light of such developments. We seek to comply with the rules and regulations promulgated by the SEC and the NYSE and implement other corporate governance practices we believe are in the best interest of the Company and its stockholders. In keeping with this commitment, our corporate Bylaws include a majority voting standard for the election of our directors and we maintain various corporate policies that reflect our dedication to good governance. Additionally, we allowed our stockholder rights plan to expire by its terms at the end of the 2017 fiscal year and we have recently adopted amendments to our Bylaws to include proxy access provisions. We believe that the policies currently in place enhance our stockholders’ interests.

Corporate Governance Principles

The Board has approved a set of Corporate Governance Principles for the Company. The Principles are available in their entirety on our website athttp://www.coopercos.com. The Principles set out our standards for director qualifications, director responsibilities, Board committees, director access to officers and employees, director orientation and continuing education, and performance evaluations of the Chief Executive Officer and of the Board and its committees.

The Principles also address compensation and stock ownership requirements for ourNon-Employee Directors. These topics are discussed in more detail in the section onDirector Compensationstarting on page 54.50.

Ethics and Business Conduct Policy

We have adopted an Ethics and Business Conduct Policy, or Code of Ethics Policy, which is available in its entirety on our website athttp://www.coopercos.com. All our employees, officers, and directors, including the Chief Executive Officer and Chief Financial Officer, are required to adhere to the Code of Ethics Policy in discharging their work-related responsibilities. Employees are encouraged to report any conduct that they believe in good faith to be an actual or apparent violation of the Code of Ethics.Ethics Policy.

The Code of Ethics Policy includes provisions relating to: (i) conflicts of interest;interest, (ii) the protection and proper use of Company assets;assets, (iii) relationships with customers, suppliers, competitors and associates;associates, (iv) government relations and anti-corruption regulations;regulations, and (v) and compliance with laws and regulations, including laws and regulations relating to insider trading, equal employment opportunity, harassment, health and safety. We most recently updated the Code of Ethics in July 2014 with revisions to enhance readability and to provide additional detail regarding the Company’s expectations regarding the conduct of our employees, officers and directors and reporting of violations.

The Code of Ethics Policy is translated into multiple languages to facilitate readability for our employees and all employees receive a copy of the Code of Ethics Policy both at their date of hire and annually. The Code of Ethics Policy is also posted on our internal web pages for ease of access.

12


Amendments to the Code of Ethics Policy and any waivers from the Code of Ethics Policy granted to directors or executive officers will be made available through our website. As of the date of this proxy statement, no waivers or requests have been requested or granted.

Stock Trading Policy: Hedging & Pledging

We have implemented a Stock Trading Policy that applies to our senior executives, including our Named Executive Officers, and all members of the Board of Directors. Under this Policy, trading in Company securities is prohibited except during specifically designated windows. Additionally, executives and members of the Board are prohibited from engaging in various trading practices which would suggest speculation in our securities, including short sales, puts, calls, forward sales, equity swaps, or other hedging transactions. Our policy does permit executives and members of the Board to pledge securities as collateral, but only upon prior notice to, and approval from, the Company.

12 | Page   


Procedures for Handling Accounting Complaints

The Audit Committee has established procedures for receipt and handling of potential complaints we may receive regarding accounting, internal accounting controls, or auditing matters, and to allow for the confidential, anonymous submission by our employees of concerns regarding accounting or auditing matters. In furtherance of this goal, we have established a confidential reporting system managed by an independent third-party vendor through which employees may report concerns about our business practices. The reporting system provides both a telephone hotline and online reporting options in multiple languages.

Board of Directors’ Role in Risk Oversight

Our Board of Directors recognizes the importance of appropriate oversight of potential business risks in running a successful operation and meeting its fiduciary obligations to our business and our stockholders. While our management team has responsibility for theday-to-day assessment and management of potential business risks, the Board maintains responsibility for creating an appropriate culture of risk management and setting the proper “tone at the top.”

In this function, the Board, directly and through its committees, takes an active role in overseeing our aggregate risk potential and in assisting management with addressing specific risks, including competitive, legal, regulatory, operational, and financial risks. Each committee of the Board regularly reviews risks related to its area of focus as follows:

 

The Audit Committee reviews potential risks within our financial operations, information technology systems, and internal controls;

The Corporate Governance and Nominating Committee reviews potential risks in relation to general governance and compliance matters; and

The Organization and Compensation Committee reviews risks associated with retention of key executives, how our compensation practices influence executive risk taking, and matters of succession planning; and

planning.

The Science and Technology Committee reviews potential risks in connection with current technology and potential technology investments.

Each committee reports regularly to the Board on these topics and contributes to the overall Board review of potential business risks. Management also addresses risks and risk management in regular reports to the Board and its committees.

13


The Board believes that its current leadership structure and majority independent membership all facilitate risk oversight by combining experienced leadership with independent direction from the Board and committees. Both our Chairman and our CEO have in-depth understanding of our history and specific challenges we face as a business. Our CEO’s experienceday to day involvement with operations allows him to promptly identify and raise key business risks to the Board and our Chairman’s history with the Company provides the Board with an independent voice who can also provide insight into management decisions and market dynamics based on our specific business operations. The Board believes that the balance between our Chairman, CEO, Lead Director, and the independent committees of the Board enhances our risk oversight process and appropriately limits levels of risk within our enterprise.

Additionally, we maintain both a Chiefan internal Risk Officer and a Chief Governance Officer position withinCommittee, composed of members of senior management. Our Chief Risk Officer maintains responsibilitymanagement, which is responsible for direct risk oversight andthe review of our potential and identified business risks,risks. The Risk Committee provides reports to the Board of Directors, and heads our management risk committee. The Chief Governance Officer holds responsibility for ensuring compliance training and communication of key policies to our employees. Thethe Board feels that the appointment of executive officers that aremaking senior management directly responsible for monitoring risk and compliance issues ensures active positions dedicatedmanagement dedication to the identification of potential business risks andrisks. It also enhances the “tone at the top” message of the importance of risk oversight, governance, and compliance.compliance within the Company.

Risk and Executive Compensation

Our Organization and Compensation Committee reviews and assesses the possible risks related to our executive compensation programs. Based on this assessment, the Organization and Compensation Committee has

13 | Page   


concluded that the structure of our compensation program structure does not create unreasonable risk or the likelihood of a material adverse impact on the Company. In making this determination, the Organization and Compensation Committee considered possible compensation-based risks and means by which potential risks may be mitigated, including through the operation of our internal control structure and the Committee’s oversight. The Organization and Compensation Committee also considered the structure of our compensation plans, including the use of a combination of short- and long-term compensation programs, equity ownership guidelines for our senior executives, capped bonus targets under short-term incentive plans, and clawback provisions for short-term bonus awards.

Management Succession Planning

At least annually, and more often as deemed appropriate, the Organization and Compensation Committee meets with management to discuss plans for CEO succession as well as possible succession plans for senior management.our executive management, including our CEO. Succession plans are designed to allow for an orderly transition of the top executive posts either in the ordinary course of business or in response to emergency situations. Management develops and presents plans for identification, mentoring, and continuing development of appropriate leadership skills forpotential internal candidates for CEO and otherexecutive leadership positions. The Committee provides oversight, input, and recommendations with regard to the criteria to be used for identification of potential candidates for succession to leadership positions. The Committee also meets with individual members of management occasionally throughout the year to assess leadership development within the executive team.

Related Party Transactions

We review all relationships and transactions in which the Company and our directors and executive officers or their immediate family members are participants. The Company’s legal and governance staff is primarily responsible for monitoring and obtaining information from the directors and

14


executive officers with respect to related personparty transactions and for then determining, based on the facts and circumstances, whether the Company or a related personparty has a direct or indirect material interest in the transaction.

KPMG LLP, as our independent registered public accounting firm, reviews our controls around the identification and reporting of related party transactions as required by current accounting standards.

The Corporate Governance and Nominating Committee of our Board reviews and approves or ratifies all transactions between the Company and related personsparties that are required to be disclosed under SEC rules, and we disclose such transactions in our Proxy Statement.

We have determined that there were no material related party transactions during the 20152018 fiscal year.

Compensation Committee Interlocks and Insider Participation

During the 2018 fiscal year, 2015, all of the members of the Organization and Compensation Committee were independent directors, and no member was an employee or former employee of the Company. NoCompany, and no Committee member had any relationship requiring disclosure as a related party transaction. During the 2015 fiscal year,Also, none of our executive officers served on the compensation committee (or its equivalent) or board of directors of another entity whose executive officer served on the Organization and Compensation Committee.

 

14 | Page   


Section 16(a) Beneficial Ownership Reporting Compliance

Section 16(a) of the Exchange Act requires our executive officers, directors, and anyone owning more than ten percent of a registered class of our equity securities to file reports with the SEC detailing their ownership and any changes in ownership. SEC regulations also require these persons to provide us with a copy of all reports filed.

Based solely on our review of the copies of reports and related amendments we have received, we believe that during and with respect to the 20152018 fiscal year, all Section 16(a) filing requirements applicable to our officers, directors andgreater-than-ten-percent owners were met.

 

15 | Page   


REPORT OF THE AUDIT COMMITTEE

 

At the date of this Proxy Statement, theOur Audit Committee is comprised ofcurrently has four independent directors:members: Jody S. Lindell (Chair), Michael H. Kalkstein, William A. Kozy, and Gary S. Petersmeyer and Steven Rosenberg. ThePetersmeyer. Our Board has determined that all members of the Audit Committee are independent directors and are financially literate as required by the NYSE andNYSE. Our Board has also determined that Ms. Lindell meets the qualifications of an audit committee financial expert as defined by the SEC.

The Audit Committee operates under a written charter adopted by the Board in December 2003 and most recently amended in October 2011.March 2017. The Audit Committee’s charter is available in its entirety on our website athttp://www.coopercos.com.www.coopercos.com.

The Audit Committee’s primary duties and responsibilities relate to:

 

Management’s maintenance of the

The reliability and integrity of our accounting policies and financial reporting and financial disclosure practices;

Management’s establishmentEstablishment and maintenance of processes by management to assure that an adequate and effective system of internal controls is functioning effectivelyexists within the Company; and

Engagement, retention, and termination of our independent registered public accounting firm.

The Audit Committee provides advice with respect to our financial matters and assists the Board in fulfilling its oversight responsibilities regarding: (i) the quality and integrity of our financial statements, (ii) our compliance with legal and regulatory requirements, (iii) review of our potential risk factors, (iv) the qualifications, independence and performance of KPMG LLP (“KPMG”), in its role as our independent registered public accounting firm, (v) retention and engagement of KPMG, and (vi) the performance of our internal audit function and review of our internal controls.

Management is responsible for the Company’s internal controls and the financial reporting process. The Committee has engaged Ernst & Young LLP (“EY”), to assist in the assessment of the Company’s internal controls over financial reporting and to provide internal audit services. Such services provided by EY are jointly directed by management and the Audit Committee.

KPMG, as the Company’s independent registered public accounting firm, is responsible for performing an independent audit of the Company’s consolidated financial statements in accordance with the standards of the Public Company Accounting Oversight Board (United States) and to issue a report on the audit process. The Audit Committee’s responsibility is to monitor and oversee these processes. In this context, the Audit Committee has met and held discussions with management and KPMG regarding the fair and complete presentation of the Company’s financial results.

The Audit Committee held 78 meetings during the 20152018 fiscal year, including regular meetings in conjunction with the close of each fiscal quarter, during which the Audit Committee reviewed and discussed the Company’s financial statements with management and KPMG. These Audit Committee meetings routinely include executive sessions of the committee, as well as private sessions with each of KPMG, Internal Audit, EY, and management.

The Audit Committee reviewed and discussed the audited consolidated financial statements of the Company for the fiscal year ended October 31, 20152018 with management and KPMG, and management represented to the Audit Committee that the Company’s consolidated financial statements were prepared in accordance with United States generally accepted accounting principles (GAAP). The Audit Committee discussed with KPMG the matters required to be discussed by the Public Company Accounting Oversight Board Auditing Standard No. 16 “Communication with Audit Committees.

 

16 | Page   


The Audit Committee also reviewed and discussed with KPMG, Internal Audit, EY, and management the processes and procedures associated with our assessment of internal controls over financial reporting, including management’s assessment of such controls.

The Audit Committee maintains policies and procedures for thepre-approval of work performed by KPMG. Under its charter, the Audit Committee must approve all engagements in advance. All engagements with estimated fees above $150,000 require consideration and approval by the full Audit Committee. The Chair of the Audit Committee has the authority to approve on behalf of the full Audit Committee all engagements with fees estimated to be below $150,000. Management recommendations are considered in connection with such engagements, but management has no authority to approve engagements.

In the 20152018 fiscal year, the Audit Committee received both the written disclosures and the letter from KPMG that are mandated by applicable requirements regarding the independent registered public accounting firm’s communications with the Audit Committee concerning independence and the Audit Committee discussed KPMG’s independence from the Company with the lead engagement partner. The Audit Committee or its Chair approved all audit services provided by KPMG for the fiscal year ended October 31, 2015.2018. The total fees paid or payable to KPMG for the last two fiscal years are as follows:

 

 

  Fiscal Year Ended

 

      October 31, 2015          October 31, 2014    

Audit Fees

  $4,105,000  $4,384,000

Audit Related Fees

  $-0-  $-0-

Tax Fees

  $-0-  $-0-

All Other Fees

  $-0-  $144,000

Audit fees for the 2014 fiscal year included work performed in connection with the acquisition of Sauflon Pharmaceuticals Ltd. (“Sauflon”). Other fees represent work performed to assist with the conversion of Sauflon accounting from International Financial Reporting Standards (IFRS) to United States GAAP.

    Fiscal Year Ended
    October 31, 2018  October 31, 2017

Audit Fees

  $5,304,315  $4,539,800

Audit Related Fees

  $-0-    $-0-  

Tax Fees

  $-0-    $-0-  

All Other Fees

  $-0-    $-0-  

Based on the Audit Committee’s discussions with KPMG, Internal Audit, EY, and management, the Audit Committee’s review of the representations of management, the certifications of the Chief Executive Officer and Chief Financial Officer, and the written disclosures and the letter from KPMG to the Audit Committee, the Audit Committee recommended to the Board that our audited consolidated financial statements be included in our Annual Report on Form10-K for the fiscal year ended October 31, 20152018 for filing with the SEC.

THE AUDIT COMMITTEE

Jody S. Lindell (Chair)

Michael H. Kalkstein

William A. Kozy

Gary S. Petersmeyer

Steven Rosenberg

17 | Page   


EXECUTIVE OFFICERS OF THE COMPANY

 

Set forth below is information regarding our current executive officers and other senior employees named in this Proxy Statement who are not also directors. The individuals listed below served in the positions set forth as of the date the Notice was mailed.

 

DANIEL G. MCBRIDE

 AGE: 51            

Age: 54

EXECUTIVE VICE PRESIDENTExecutive Vice President & CHIEF OPERATING OFFICERChief Operating Officer / PRESIDENT OF COOPERVISION, INC.

President, CooperVision, Inc.

Mr. McBride has served as Executive Vice President and Chief Operating Officer since November 2013 and as the President of CooperVision, our contact lens subsidiary since February 2014. He previously served as our Chief Risk Officer from July 2011 through October 2013, as our General Counsel from November 2007 through January 2013,2014, and as Vice President from July 2006 through October 2013. He also served as Senior Counsel from February 2005 through November 2007. Prior to joining Cooper, Mr. McBride was an attorney with Latham & Watkins LLP from October 1998 to February 2005, concentrating on mergers and acquisitions and corporate finance matters. He holds a B.S. in Finance from Santa Clara University and a J.D. from Stanford Law School.

 

ABLBERTRIAN G. WAHITE III

EXECUTIVE VICE PRESIDENT & CHIEF STRATEGY OFFICERNDREWS

 

Age: 40

AGE: 46            
Senior Vice President, Chief Financial Officer & Treasurer

Mr. WhiteAndrews has served as ExecutiveSenior Vice President, Chief Financial Officer & Treasurer since May 2018. He has served as our Treasurer since January 2013 and Vice President since December 2015 and as Chief Strategy Officer since July 2011. He previously served as Vice President, Investor Relations from November 2007 through March 2013.2014. He also served as Vice President, &Global Logistics and Service for CooperSurgical, a position he held from June 2017 to May 2018. Mr. Andrews previously served as Assistant Treasurer for the Company from April 2006 throughto December 2012. Prior to joining the Company,Cooper, he served as a Director withheld various corporate and investment banking positions at KeyBanc Capital Markets for three yearsfrom 2002 to 2006 and at ING Barings from 2000 to 2001. He holds a B.A. in a number of leadership positions within KeyBank National Association over the prior eight years.Economics from Columbia University.

 

CHAROLOLLY R. KSAUFMANHEFFIELD

 

Age: 48

AGE: 66            
EXECUTIVE VICE PRESIDENT, SECRETARY, CHIEF ADMINISTRATIVE  OFFICERExecutive Vice President & CHIEF GOVERNANCE OFFICERChief Strategy Officer

Ms. Kaufman has servedSheffield joined Cooper as Executive Vice President since July 2012& Chief Strategy Officer in June 2018. Prior to joining Cooper, Ms. Sheffield had over 20 years of experience in investment banking. She joined Cooper from UBS Securities LLC, where she was a Managing Director, Global Head of Medical Technology from 2009 to May 2018. From 2000 to 2009, Ms. Sheffield was at Credit Suisse and Chief Governance Officer since March 2013. She previously served as Senior Vice President of Legal Affairs from December 2004 to July 2012. She has also served as Vice President1997-2000, Ms. Sheffield was at Donaldson, Lufkin & Jenrette until it was acquired by Credit Suisse. Ms. Sheffield received a B.S. from Cornell University and Chief Administrative Officer since October 1995 and as Vice President of Legal Affairs and Secretary since March 1996. From January 1989 through September 1995, she served as Vice President, Secretary and Chief Administrative Officer of Cooper Development Company, a healthcare and consumer products company. She previously held a variety of financial positions with Cooper Laboratories, Inc. (our former parent) since joining that company in 1971. Ms. Kaufman currently serves as a director for Insperity, Inc. (NYSE: NSP), a publicly traded provider of human resources outsourcing options, and is the chair of its nominating and corporate governance committee and a member of its finance, risk management and audit committee.an M.B.A. from Columbia Business School.

 

GREG W. MATZ

AGE: 56            

SENIOR VICE PRESIDENT, CHIEF FINANCIAL OFFICER & CHIEF RISK OFFICER

Mr. Matz has served as our Senior Vice President since November 2014, as Chief Risk Officer since November 2013 and as our Chief Financial Officer since December 2011. He previously served as Vice President from December 2011 to November 2013 and as Vice President, Finance from July 2011 to December 2011. He joined CooperVision, Inc. in May 2010 as Vice President and Chief Financial Officer and served in that position until October 2011. Prior to joining CooperVision, he spent 25 years in the Electronic Measurement, Chemical Analysis and Life Science markets. He served in a

18


variety of senior management roles in Agilent Technologies Inc. from 1999-2010, including Vice President and Controller of the Wireless Business Unit, Vice President and Director of Internal Audit and Assistant Corporate Controller. Prior to Agilent, Mr. Matz worked at Hewlett Packard from 1984-1999 in a variety of financial and marketing roles. Mr. Matz started his career at KPMG in San Francisco from 1981-1984. Mr.��Matz is a Certified Public Accountant.

RANDAL L. GOLDEN, ESQ.

VICE PRESIDENT & GENERAL COUNSEL

Age: 57

 
Vice President, General Counsel & SecretaryAGE: 54            

Mr. Golden has served as Corporate Secretary since May 2018 and has also served as Vice President since November 2014 and as our General Counsel from February 2014. He previously served as our Assistant General Counsel from May 2013 through January 2014. He also served as senior counselSenior Counsel from March 2010, when he joined the Company, until May 2013. Prior to joining Cooper, he served as Senior Director & Legal Counsel at Align Technology, Inc. from 2005 through 2010 and as Director of Legal Affairs & Senior Counsel with Nokia, Inc. from 2000 to 2005. Mr. Golden also held various associate and senior legal positions prior to 2000, focusing on litigation and commercial and business law. He holds a B.S. in Finance from the University of Illinois and a J.D. from the U.C.L.A. School of Law.

 

18 | Page   


TAINAGOSTINO F. MRALONEYICUPATI

VICE PRESIDENT & CORPORATE CONTROLLER

 Age: 52AGE: 53            
Senior Vice President, Finance & Tax And Chief Accounting Officer

Ms. MaloneyMr. Ricupati has served as our Chief Accounting Officer since October 2017 and as Senior Vice President, Finance & Tax since July 2017. Mr. Ricupati previously served as Vice President, since November 2014 and as our Corporate Controller since January 2014. She previously served as Senior Director of Finance and Assistant Corporate Controller prior to her appointment. She also served as Director of Internal AuditTax for the Company from August 2005July 2013 to June 2007.July 2017. Prior to joining Cooper, Ms. Maloney held multiplehe served as International Tax Director for Intel Corp. (NASDAQ: INTC) from 2010 to 2013 and in various other senior finance and tax positions at Sola International Inc.,over the past 20 years. He holds a global manufacturermasters degree from DePaul University and distributor of eyeglass lenses, including Director of Accounting and Controller – Americas. Prior to Sola, she was VP Finance of IESL, Inc., an environmental services and electroplating company servicing the defense industry. Ms. Maloney is a Certified Public Accountant, a Certified Management Accountant, and a Chartered Global Management Accountant.

 

PRAULOBERT L. REMMELL

PRESIDENTD. AND CHIEF EXECUTIVE OFFICER OF COOPERSURGICALUERBACH, INC.M.D.

 Age: 58AGE: 58            
President, CooperSurgical, Inc.

Mr. Remmell has been Chief Executive Officer of CooperSurgical, our women’s healthcare business, since January 2012 andDr. Auerbach has served as President of CooperSurgical, Inc., the Company’s women’s healthcare division, since December 2004. He previouslyApril 2018. Previously, he served as Executive Vice President, Chief OperatingMedical Officer & Chief Strategy Officer of CooperSurgical from October 2000since May 2005. Prior to January 2012joining CooperSurgical, Dr. Auerbach served as Associate Clinical Professor in the Department of Obstetrics, Gynecology & Reproductive Services at the Yale School of Medicine, New Haven, CT. In 2005 he was the recipient of Yale’s Francis Gilman Blake Award as the most outstanding teacher of the medical sciences and was elected to the Society of Distinguished Teachers. He remains an adjunct faculty member of the School of Medicine and as Vice Presidentan Executive Board member of FinanceYale University’s Center for Biomedical Innovation and Technology. Dr. Auerbach graduated Phi Beta Kappa and Alpha Omega Alpha with highest honors from 1991 to December 2004.

the Lehigh-Hahnemann6-yearBA-MD program in Philadelphia (1984), and completed his internship and a residency in Obstetrics & Gynecology at the Yale School of Medicine, New Haven, CT.

 

19 | Page   


REPORT OF THE ORGANIZATION AND COMPENSATION COMMITTEE

 

The Organization and Compensation Committee of the Board has reviewed and discussed the Compensation Discussion and Analysis with management. Based on this review and discussion, the Organization and Compensation Committee has recommended to the Board that the Compensation Discussion and Analysis be included in this Proxy Statement and incorporated by reference in our Annual Report on Form10-K for the fiscal year ended October 31, 2015.2018.

ORGANIZATION AND COMPENSATION COMMITTEE

Michael H. Kalkstein (Chair)

Colleen E. Jay

Jody S. Lindell

Gary S. Petersmeyer

Allan E. Rubenstein, M.D.

 

20


COMPENSATION DISCUSSION AND ANALYSIS

 

This Compensation Discussion and Analysis describes our compensation program, including our compensation philosophy, strategies, policies and practices for compensating our Named Executive Officers in the positions they held for fiscal 2015 as follows:(“NEOs”).

2015 Named Executive Officers

Name

Title

  Robert S. Weiss

President & Chief Executive Officer

  Daniel G. McBride

Executive Vice President & Chief Operating Officer / President, CooperVision, Inc.

  Albert G. White, III (1)

Senior Vice President & Chief Strategy Officer

  Carol R. Kaufman

Executive Vice President, Secretary, Chief Administrative Officer & Chief Governance Officer

  Greg W. Matz

Senior Vice President, Chief Financial Officer & Chief Risk Officer
(1)Mr. White was promoted to Executive Vice President & Chief Strategy Officer effective December 10, 2015.

The Organization and Compensation Committee, or Compensation Committee of our Board of Directors (referred to below as the “OCC”) oversees our executive compensation program, andprogram. In this capacity, the OCC regularly reviews our program to ensure that we maintain an effective and appropriate link between pay and performance, and that there are no compensation-related risksour compensation practices do not encourage practices that would be likely tocould have a material adverse effect on the Company.

This oversight responsibility is described in more detail throughout this Compensation Discussion and Analysis, includingwhich also includes information regarding our compensation governance policies and practices, the outcome of our annualmost recent stockholder advisory vote on executiveNEO compensation (the “Say-on-Pay”“Say-on-Pay” vote), the use of compensation consultants, and the selection and composition of our compensation peer group.

Our Named Executive Officers

Our NEOs for the 2018 fiscal year are listed below with the titles they held at the end of the fiscal year.

2018 Named Executive Officers

Name

Title

  Albert G. White III

President & Chief Executive Officer

Brian G. Andrews

Senior Vice President, Chief Financial Officer & Treasurer

Daniel G. McBride

Executive Vice President & Chief Operating Officer /

President of CooperVision, Inc.

Holly R. Sheffield

Executive Vice President & Chief Strategy Officer

Robert D. Auerbach, M.D.

President, CooperSurgical, Inc.

Robert S. Weiss

Former President & Chief Executive Officer

Carol R. Kaufman

Former Executive Vice President, Secretary, Chief Administrative Officer & Chief Governance Officer

20 | Page   


The Year in Review

For

Management Transition – Succession Planning Implementation

The 2018 fiscal 2015, we reported record revenueyear included significant management transitions for Cooper. Robert S. Weiss and non-GAAP earnings-per-share (“EPS”). However,Carol R. Kaufman announced their retirements in the second quarter of 2018. Mr. Weiss served as our President & Chief Executive Officer and Ms. Kaufman served as our Executive Vice President, Secretary, Chief Administrative Officer & Chief Governance Officer until May 1, 2018. Both continued as employees, in anon-executive advisory capacity, through the end of December 2018 to assist with the executive transition. Additionally, Paul Remmell stepped down in May 2018 as President of CooperSurgical.

As a result of ongoing succession planning efforts, overseen by the impactOCC, we were able to promote internal talent to address most open positions. Mr. White was promoted to replace Mr. Weiss as President & Chief Executive Officer in May 2018. Mr. Andrews, our Vice President & Treasurer, was selected to succeed Mr. White as Chief Financial Officer, and Dr. Auerbach was promoted from Executive Vice President, Chief Strategy Officer & Chief Medical Officer of foreign exchange rate fluctuations, we did not fully realizeCooperSurgical to take the role of President, CooperSurgical. Additionally, Ms. Sheffield was hired as our Executive Vice President & Chief Strategy Officer, taking on responsibility for corporate strategy, business development and global human resources, and Randal Golden was appointed as our corporate Secretary in addition to his role as our Vice President & General Counsel.

Financial Performance Against 2018 Goals

Our annual targets are set based on both annual and long-term objectives focused on revenue growth, strategic investment, and continued market share growth. We achieved at least 97% of our financial goalstargets for the year and this impacted ourall 2018 executive compensation outcomes. Nonetheless, despite not fully achievingand exceeded our financial goals, we achievedfree cash flow goal. We also continued to set new records for revenue,non-GAAP earnings per share, and cash flow.

2018 Financial Highlights

 

    

Budget Target

 

  

Actual

 

  

Change YoY*

 

  

% of Budget Target

 

       Revenue:

 

  $2.542 billion    

 

  $2.533 billion    

 

  Up 7%

 

  99.4%

 

           CooperVision:

 

  $1.874 billion     

 

  $1.882 billion     

 

  Up 8%

 

  100.1%

 

           CooperSurgical:

 

  $668.2 million     

 

  $650.8 million     

 

  Up 2%

 

  97.5%

 

       EPS(1):

 

     $2.81    

 

  Down 63%

 

   

       Non-GAAP EPS(1):

 

  $11.61    

 

  $11.50    

 

  Up 19%

 

  99.1%

 

       Free Cash Flow:

 

  $463.0 million    

 

  $475.3 million    

 

  Up 2%

 

  102.7%

 

       Stock Price (10/31):

 

     $258.31    

 

  Up 8%

 

   
*

YoY comparison presented pro forma

(1)

Earnings per share were impacted by charges related to the 2017 Tax Cuts & Jobs Act.Non-GAAP earnings per share includes adjustments for these impacts, as well as cost of sales, operating expenses (excluding amortization), amortization of intangibles, interest expense, and other expenses as detailed in our earnings release published on December 6, 2018.

Based on our results for revenue, cash flow and earnings per share, annual cash bonuses under the 2018 Incentive Payment Plan were paid at99-115% of target for our NEOs. (Discussed in more detail below starting on page 29.)

Additionally, performance share awards granted in fiscal 2016 were certified at Target achievement based on growth innon-GAAP earnings per share (EPS) over a numberthree-year period. The NEOs received 100% of significant accomplishments during the year which reflects the leadership and talent of our senior executive officers, including our Named Executive Officers.target shares under these awards. (Discussed in more detail below starting on page 34.)

 

2015 Highlights
  Financial Results:

•    Revenue – Reported revenue of $1.797 billion, an increase of 5% from fiscal 2014. This reflects the impact of foreign exchange rate fluctuations which reduced our results by $153 million, causing us to miss our target revenue of approximately $1.9 billion.

•    Non-GAAP Earnings Per Share– Reported $7.44 in non-GAAP EPS, an increase of 2% from fiscal 2014. The impact of foreign exchange rate fluctuations reduced our non-GAAP EPS by $1.76. Importantly, we note that our non-GAAP EPS increased 26% from fiscal 2014 on a constant currency basis.

21 | Page   

21


2015 Highlights
  Financial Results:

•     Cash Flow – Reported cash flow of $216 million for fiscal 2015, making this our fifth consecutive year with cash flow in excess of $200 million.

  Operational Achievements:

  CooperVision, Inc.

•    Recorded growth at double the rate of the contact lens market due to increased sales of our one-day silicone hydrogel products and new product launches in key markets.

•    Increased sales of clariti® and MyDay® silicone hydrogel products by 45% on a constant currency basis over fiscal 2015 as well as increased sales of specialty lenses.

•    Increased our production capacity for manufacture of one-day silicone hydrogel lenses and achieved regulatory clearance for our MyDay® product in Japan.

•    Substantially completed the global integration of the Sauflon Pharmaceuticals business operations.

•    Expanded manufacturing operations in Hungary, Puerto Rico and the UK and continued construction of new manufacturing facilities in Costa Rica which are expected to launch in early 2016.

  CooperSurgical, Inc.

•    Recorded growth in our in-vitro fertilization business of 3% over fiscal 2014.

•    Successfully completed multiple acquisitions, including the acquisition of Reprogenetics as an entry into the laboratory services market associated with in-vitro fertilization.

•    Continued to expand our profile in the in-vitro fertilization market including launching new products related to the collection and storage of reproductive materials.

  Other Achievements:

•    Continued our ongoing investment in succession planning for our senior management, including a focus on extensive internal promotion and talent development in connection with the integration of the Sauflon Pharmaceuticals business.

•    Continued recognition for our efforts to develop internal management potential including:

¡    one of the “40 Best Companies for Leaders” byChief Executive Magazine for the sixth consecutive year; and

¡    one of the “Top Workplaces” by theBay Area Newsgroup for the fourth consecutive year.

•    Recognition of our Wellness Program as “Best in Class”, resulting in continued savings related to medical benefits, including:

¡    Platinum Achievement “Fit-Friendly Company” from the American Heart Association;

¡    Recognition as one of the “Healthiest Employers” and a “Top Workplace” in our geographic area; and

¡    Awards for occupational health and safety.

22


Executive Compensation HighlightsOperational Performance

Based onBoth the CooperVision and CooperSurgical divisions continued their operational performance in fiscal 2018 with a number of accomplishments including:

CooperVision:

Strong revenue growth across all global regions, supported by prior year product launches, as well as strong operating income and free cash flow

Significant infrastructure investments including important expansion and upgrades to our financial results as described above, our executive compensation actionsdistribution facilities to support premium levels of customer service

Acquisition of Paragon Vision Sciences, expanding the specialty lens care and decisions for fiscal 2015 were as follows:myopia management segment of the CooperVision business

CooperSurgical:

Significant infrastructure investing throughout the company to support continued global growth

  Fiscal 2015 Incentive Payment Plan (“IPP”): Our achievements

Acquisition of the Paragard® intrauterine device product, driving revenue growth for revenue, cash flow and earnings-per-share resulted in cash bonus payments at 79% of target levels for our Named Executive Officers under the 2015 IPP. These amounts, and the Compensation Committee’s decisions regarding the discretionary portion of these awards, are discussed in more detail below starting on page 30.CooperSurgical Office & Surgical Products business

Acquisition of the LifeGlobal Group, expanding the invitro fertilization business globally for CooperSurgical

  Long-Term

Launch of the PGTai(sm) technology platform and ERPeak(sm) endometrial receptivity test through the CooperGenomics business to provide new tools for invitro fertilization

Executive Compensation Highlights – 2018 Fiscal Year

The OCC initially approved target executive compensation for the NEOs for the 2018 fiscal year in December 2017. Due to the executive transitions highlighted above, the OCC subsequently approved adjustments to compensation for Messrs. White, McBride and Andrews and for Dr. Auerbach, as well as an initial compensation package for Ms. Sheffield. The OCC also reviewed and approved the terms of arrangements with Mr. Weiss and Ms. Kaufman in connection with their planned retirements.

CEO Compensation

Target total direct compensation for our CEO recognizes the significant role of the CEO in driving our performance and future growth, as well as overall responsibility for our strategic direction, management, and leadership. The practices of our peer group and our industry sector are also considered.

In setting compensation for fiscal 2018, the OCC considered the following factors:

(i)

Past performance by each of Messrs. Weiss and White against approved objectives;

(ii)

Our financial and operational results for the prior fiscal year and targets for the 2018 fiscal year;

(iii)

Compensation of CEOs at our peer companies; and

(iv)

Advice from the OCC’s independent compensation consultant.

For fiscal 2018, the OCC held target compensation for Mr. Weiss to the same level as approved for fiscal 2017.

Mr. White’s compensation was initially approved in December 2017 based on his role as Executive Vice President, Chief Financial Officer & Chief Strategy Officer and Chief Executive Officer of Cooper Medical, Inc. (the parent of CooperSurgical). His compensation was adjusted in May 2018 in connection with his promotion to CEO.

22 | Page   


Mr. Weiss:

    

2017 Target
  Compensation  

 

 

    

2018 Target
  Compensation  

 

 

  Base Salary

 

  $925,000

 

    $925,000

 

  Annual Cash Incentive

  (Target / % of Base Salary) (1)

 

  $925,000

(100%)

 

    $925,000

(100%)

 

  Equity Awards (Approved GDFV)

 

        

Performance Share Awards

(at Target)

 

  $937,132

(5,046 shares)

 

    $937,132

(4,081 shares)

 

Time-Vested Stock Options (2)

  $3,492,500

(79,370 options)

 

    $3,492,500

(60,322 options)

 

  TOTAL TARGET COMPENSATION

 

 

  $6,279,632

 

 

    $6,279,632

 

 

(1)

Represents the target annual cash incentive opportunity under our Incentive Plan: Based on the compound annual growth in our non-GAAP EPS over the three-year performance period, our Named Executive Officers earned sharesPayment Plan. For both years, target achievement was set at 100% of our common stockMr. Weiss’ base salary. Actual achievement under the performance share awards granted2017 IPP was $1,138,675 (123.1% of $925,000) and achievement under the 2018 IPP was $939,800 (101.6% of $925,000).

(2)

Equity award amounts represent the grant values approved by the OCC and may vary from recognized compensation expense (presented in theSummary Compensation Table on page 37). Options are valued using a Black-Scholes option pricing model.

Mr. White:

   

2018 Target

Compensation

  (December 2017)  

 

 

Adjusted Target
Compensation

(On Promotion) (1)

 

  

2018 Target
Compensation

(Total) (2)

 

  Base Salary

 

 $577,000

 

  

 

$800,000

 

 

 

 $688,500

 

  Annual Cash Incentive

  (Target / % of Base Salary) (3)

 

 

 $461,600

(80%)

 

  

 

$800,000

(100%)

 

 

 

 

 $630,800

(92%)

 

  Equity Awards (Approved GDFV)

 

     

Performance Share Awards

(at Target)

 

 $432,907

(1,885 shares)

 

   $432,907

(1,885 shares)

 

Time-Vested Stock Options (4)

 $2,265,000

(39,121 options)

 

  

 

$2,000,000

(34,479 options)

 

 

 

 

 $4,265,000

(73,600 options)

 

  TOTAL TARGET COMPENSATION

 

 $3,736,507

 

 

     $6,017,207

 

 

(1)

Represents increased salary and target annual cash incentive on promotion to them in fiscal 2013 at the threshold award level, thereby earning 50%CEO. Also represents an incremental grant of the target shares. These awards areequity on promotion discussed in more detail below on page 33.below.

Base salary and time-based equity award grant decisions for our Named Executive Officers for fiscal 2015 were made at the beginning of the year. Our prior year results and performance were considered in setting those compensation amounts. Base salary decisions are discussed in more detail below on page 30 and time-based equity award decisions are discussed in more detail starting on page 35.

Compensation Objectives and Philosophy

The primary objectives of our executive compensation program are to provide competitive compensation packages that will attract and retain top-tier talent and to closely link potential compensation with the performance measures we consider key to our long-term success and drivers of stockholder value.

To meet these objectives, our executive compensation program emphasizes certain principles:

 1.(2)We align significant portions

Represents the actual salary and bonus targets for fiscal 2018 based on a blended rate of executiveinitially approved and subsequently adjusted targets. Also represents the total value of equity awards approved for Mr. White in the 2018 fiscal year.

(3)

Represents the target annual cash incentive opportunity under our Incentive Payment Plan. For the 2018 fiscal year, Mr. White’s base salary, and target achievement as a percentage of salary, were adjusted midyear on his promotion to CEO as detailed above. Actual achievement under the 2018 IPP was determined based on a blended salary and target rate, resulting in payment of $661,709 (104.9% of $630,800).

(4)

Equity award amounts represent the grant values approved by the OCC and may vary from recognized compensation withexpense (presented in the measures we consider to be most correlated with stockholder returns;Summary Compensation Tableon page 37). Options are valued using a Black-Scholes option pricing model.

 

2.We balance the achievement of short-term operational goals and long-term strategic objectives;23 | Page   


Other NEO Compensation

3.We reward the achievement of challenging corporate objectives without encouraging inappropriate risk-taking;

4.We recognize the significant role our executive officers play in our overall performance and market value and the responsibilities associated with their roles; and

5.We design our compensation packages to have sufficient flexibility to allow recognition of significant individual achievements by our executive officers.

By following these principles, we have created a competitive compensation structure that has enabled usCompensation for our other NEOs is determined based on their current role, recent changes to retaintheir responsibilities, and motivateoverall execution of duties throughout the prior fiscal year. Company performance, internal alignment among our executive officers, including our Named Executive Officers,peer group compensation practices, and reward them for their success in achieving positive operating resultscompetitive market changes and creating long-term value for our stockholders.

23


Pay for Performanceconditions are also taken into account.

 

The compensation packages for our executive officers,
including our Named Executive Officers, are designed to
reward the achievement of both short-term and long-
term goals, as reflected in specific financial measures.
Through these measures, we align our executive
officers’ compensation with our overall financial results.
  

Annual MeasuresInitial Fiscal Year Changes

  

Long-Term MeasuresMid-year Changes

(Three to Five Years)

Revenue

  Non-GAAP EPS

Rationale

Brian G. Andrews  

Cash Flow•  4% increase in base salary

  Stock price growth

Non-GAAP EPS•  Additional 20% increase in base salary

  

•  Increase on promotion to CFO

Daniel G. McBride

•  10% increase in base salary

•  Increase annual cash incentive target to 80% from 70%

•  Additional 13% increase in base salary

•  Recognize importance through leadership transition and ongoing critical role within Company

Robert D. Auerbach, M.D.

•  6% increase in base salary

•  Additional 11% increase in base salary

•  Increase annual cash incentive target to 60%

•  Increase on promotion to President, CooperSurgical

Encouraging long-term serviceChanges approved at the beginning of the fiscal year were based on individual performance in prior years, comparison to peers, management recommendations and achievement against these key measures has created strong resultsrecommendations from the OCC’s compensation consultants.Mid-year adjustments to executive compensation for us as athe 2018 fiscal year were primarily driven by promotions and other executive transitions and were based on review of peer compensation and recommendations from management and its compensation consultant.

Ms. Sheffield’s compensation was set at the time of her hire in June 2018 based on management recommendations and alignment to peers.

Amounts discussed below in thisCompensation Discussion and Analysis and the compensation tables starting on page 20 reflect prorated or blended amounts based on start of employment (for Ms. Sheffield) or mid-year adjustments.

Executive Retirements – Mr. Weiss & Ms. Kaufman

Each of Mr. Weiss and Ms. Kaufman resigned their executive titles at the beginning of May 2018. Per agreement with the Company, both Mr. Weiss and we have maintained steady growthMs. Kaufman remained employed with the Company through December 31, 2018 with no change in their respective levels of compensation.

Amounts payable to Mr. Weiss and returns for our investors, as seenMs. Kaufman on retirement are discussed in more detail in the charts below.

We consider the designsection titledPotential Payments Upon Termination or Change In Control below on page 48. Mr. Weiss continues to serve on our Board of our compensation packages toDirectors and will be integral to our success and believe the performance measures used in our executive compensation program servecompensated as significant indicators for our continued success. In addition, our long-term compensation opportunities, through the use of time-based equity awards, encourage stable and continuous leadership from our key talent and provide for additional compensation through growth in our stock price.aNon-Executive Director starting January 1, 2019.

 

 

LOGO

24


Compensation Governance

The Compensation CommitteeOCC works closely with itsmanagement, management’s consultant, the OCC’s independent compensation consultant, and managementsuch other advisors as the Committee considers appropriate to ensure that we maintain sound governance and compensation policies and practices. In designing and overseeing our executive compensation program, we strive to employ several best practices.

 

24 | Page   


THINGS WE DO:

THINGS WE DO:

ü    Entirely independent Compensation Committee

 

Entirely independent OCC

 

üThorough assessment of individual and Company performance and linkage to compensation

 

üIndependent compensation consultant, retained by and reporting only to the Compensation CommitteeOCC

 

üLimited use of employment andchange-in-control agreements; allchange-in-control payments and benefits subject to “double-trigger” requirements

 

üA significant portionmajority of Named Executive OfficerNEO compensation is “at risk”

 

üRobust succession planning process with annual review by the Compensation CommitteeOCC

 

üStock ownership guidelines applicable to our Named Executive Officers,NEOs, with our CEO required to hold threefive times his annual base salary

 

üPerquisites are limited in scope and have specific business rationale

 

Compensation recovery (“clawback”) provision incorporated in our annual incentive plan

 

üAnnual review of executive compensation program and individual paycompensation packages

 THINGS WE DON’T DO:

 

No loans to NEOs

 

No taxügross-ups Compensation recovery (“clawback”) provision incorporated in our Annual Incentive Planfor NEOs

THINGS WE DON’T DO:

v    No loans to executive officers

 

vNo tax gross-ups for Named Executive Officershedging or speculative transactions in Company securities; no purchases of Company securities on margin

 

vNo Supplemental Executive Retirement Plan or other exceptional deferred compensation options. Also no defined benefit or other actuarial plans which are not available generally to our employees

 

vNo hedging or speculativerelated party transactions in Company securities; no purchases of Company securities on marginwithout approval from our Corporate Governance and Nominating Committee

 

vNo stock option repricing, reload options, or option exchanges without stockholder approval

In addition to these policies and practices, the Compensation CommitteeOCC stays informed and regularly assesses the alignment between our compensation packages and our performance as follows:

 

Regular updates on our business results from management throughout the year;management;

Review of our quarterly financial statements, management projections, and long-range plans;

Review of information regarding our compensation peer group, including reported revenues, profit levels, market capitalization, stockholder returns, compensation components, and disclosed governance policies and practices; and

Review of broader, general industry compensation data relative to other companies of ourcomparable size.

25


The Compensation CommitteeOCC considers management input, the advice of its compensation consultant,consultants, and publicly available peer information to be valuable tools in its evaluation of the connectionrelationship between executive compensation and Company performance.

2015 Compensation Objectives / Pay for Performance

Our executive compensation program is designed to provide competitive compensation packages to attract and retaintop-tier talent and closely link potential compensation with our financial performance. To meet these objectives our program emphasizes certain principles:

Connect executive compensation to financial measures that correlate strongly with stockholder returns;

Balance short-term operational goals and long-term strategic objectives;

25 | Page   


Reward achievement of challenging corporate objectives without encouraging inappropriate risk-taking;

Recognize the significant role our executive officers play in our overall performance and the responsibilities associated with their roles; and

Maintain sufficient flexibility to allow recognition of significant individual achievements by our executive officers.

The compensation packages for our NEOs are designed to reward
achievement of both short-term and long-term goals, as reflected
in specific financial measures, and continued service to the
Company. Encouraging long-term service and continued financial
achievement has created strong results for us and we have
maintained steady growth and returns for our stockholders. We
Annual MeasuresLong-Term Measures
Revenue

Non-GAAP EPS

over three-year period

Cash Flow
Non-GAAP EPS

consider our executive compensation program design to be integral to our success and believe the selected performance measures serve as significant indicators for our continued success.

Say-on-Pay Vote

The Compensation CommitteeOCC considers the outcome of our annual stockholder advisory“Say-on-Pay” vote on the compensation of our Named Executive Officers (the “Say-on-Pay” vote) in determining the design of our executive compensation program and the composition and levels of our individual compensation packages.

At our 2017 Annual Meeting of Stockholders, 94% of the votes cast on ourSay-on-Pay proposal were voted in favor of the compensation program for our NEOs. The OCC viewed this result as a strong affirmation of our program structure and considered these results when developing the compensation packages for fiscal 2018 as described in this Compensation Discussion and Analysis.

At our 2015 Annual Meeting of Stockholders, 95% of the votes cast on our Say-on-Pay proposal were voted in favor of the compensation program for our Named Executive Officers. We have been pleased to have received a consistently positive response to our executive compensation program (as reflected in the accompanying chart) since 

Fiscal Year

 

  Meeting Date

 

  Vote in Favor

 

 2014  March 16, 2015  95%
 2013  March 17, 2014  95%
 2012  March 21, 2013  93%
 2011  March 20, 2012  93%
the Say-on-Pay vote was implemented. The Compensation Committee took this historically positive result into consideration when developing the compensation packages for fiscal 2015 as described in this Compensation Discussion and Analysis.

Stock Ownership Guidelines

 

The Compensation Committee has implementedWe maintain guidelines for stock ownership by our
NEOs and certain other senior executive officers, including our Named Executive Officers.

These stock ownershipexecutives. Under
these guidelines further provide that the covered executive officersdesignated executives are
expected to retainhold a percentageportion of the

Name        Target Ownership
Value
Hold on Vesting/Exercise  
Robert S. Weiss3x base salary    100%

Daniel G. McBride

Albert G. White, III

Carol R. Kaufman

2x base salary    50%
Greg W. Matz1x base salary    25%
shares of our common stock acquired
upon the exercise of stock options or vesting of full-value stock awards if their ownership level is below the established threshold. All Named Executive Officers complied with the guidelines during fiscal 2015.full-
NameTarget ValueHold on
Vest/Exercise

Albert G. White, III

5x base salary

100%

Other Sec. 16 officers

2x base salary

50%

value stock awards if their ownership level is below the established guidelines.

The OCC reviewed and updated the guidelines in fiscal 2018. As amended, the guidelines require minimum ownership equal to 2 times base salary for all Section 16 identified officers and 5 times base salary for the CEO. In addition to directly held shares, the potential value of vested stock options and unvested restricted stock units are credited in consideration of whether ownership requirements have been met.

All NEOs were in compliance with the applicable ownership guidelines during fiscal 2018.

Use of Compensation Consultants

The Compensation CommitteeOCC retains Compensia, a national compensation consulting firm, to provide support with matters related toadvice on compensation of our executive officers and thenon-employee members of our Board of Directors. The Compensation CommitteeUnder this engagement, the OCC also maintains sole authority to determine the terms of Compensia’s retention and services, and management interaction with Compensia is generally limited to communication of information provided by management to the Compensation Committee. Under this engagement, Compensia reports directly to the Compensation Committee and does no other work for the Company.

Management separately retains Frederic W. Cook & Co., Inc. (“Frederic Cook”) to serve as its compensation consultant and assist in the preparation of information provided to the Compensation Committee, including a competitive market analysis of executive compensation. Our CEO, Mr. Weiss, has final authority for the retention of Frederic Cook and Frederic Cook does not do any work directly for the Compensation Committee, although aservices. A representative of the firm generally attends Compensation Committee meetings as an invited guest.

OCC meetings.

 

26 | Page   


Under this engagement, each year management provides the Compensation Committee with a report analyzing executive officer compensation and presenting comparative information based on compensation peer group data, as well as information regarding key trends in executive compensation for other comparable publicly-traded companies. The Compensation Committee uses this information as one factor in evaluating the design of our executive compensation program and the compensation elements and levels provided to our executive officers. At the request of the Compensation Committee, Compensia evaluates the recommendations provided by management and reviews the work done by Frederic Cook and advises the Compensation Committee on these findings.

The Compensation CommitteeOCC has reviewed the nature of the relationship between itself and Compensia as an independent consulting firm, and its relationship with the members of Compensia as individuals, for potential conflicts of interest. In conducting this review, the Compensation CommitteeOCC gave consideration to the factors identified by the SEC and the NYSE as possibly contributing to conflicts, including the scope of work performed for the Compensation CommitteeOCC by Compensia, the fees paid to Compensia for services, and any personal or business relationships between our executive officers or members of the Compensation CommitteeOCC and Compensia or its individual members. Based on its review, the Compensation CommitteeOCC has determined there are no conflicts of interest or potential conflicts of interest arising in connection with the Compensation Committee’sOCC’s engagement of Compensia.

Management separately retains Frederic W. Cook & Co., Inc. (“Frederic Cook”) to serve as its compensation consultant and assist in the preparation of information provided to the OCC. Mr. White has final authority for the retention of Frederic Cook. A representative of the firm generally attends OCC meetings as an invited guest and the OCC considers recommendations from Frederic Cook on the same basis as recommendations from management.

Role of Management

Our CEO, Mr. Weiss,On behalf of management, Frederic Cook provides an annual report analyzing executive officer compensation. This report presents comparative compensation information based on peer group data and contains information regarding key trends in executive compensation for other comparable publicly-traded companies. This information is one factor in evaluating the design of our executive compensation program and the compensation elements and levels provided to our executive officers. Compensia evaluates the recommendations provided by Frederic Cook and advises the OCC on these findings.

In addition to the annual compensation report, management also provides recommendations to the Compensation CommitteeOCC regarding: (i) selection of companies for the compensation peer group (as described further below), (ii) base salary levels and base salary increases for our executive officers (other than himself), (iii) appropriate targets and achievement of awards under our Incentive Payment Plans, (iv) overall annual equity award levels, design and allocation, and (v) special compensation awards to executives who have demonstrated outstanding performance during the year or on special projects, employment terms and arrangements and stock ownership guidelines. Mr. Weiss does not participate in discussions of his own compensation.

Mr. Weiss

(i)

selection of companies for our peer group (as described further below);

(ii)

appropriate structure for our Incentive Payment Plans, including financial targets and calculation of achievement;

(iii)

overall compensation packages for executive officers, including the NEOs;

(iv)

annual equity award levels, plan design and specific award allocations for employees, including the NEOs; and

(v)

employment terms and arrangements, stock ownership guidelines, and special compensation awards to executive officers who have demonstrated outstanding performance during the fiscal year or on special projects.

Management uses Frederic Cook’s analyses and guidance to develop these recommendations. The Compensation CommitteeOCC gives full consideration to histhese recommendations and reviews these recommendationsthem with Compensia before making its own decisions on the compensation of our executive officers. The Compensation Committee believes these recommendations provide valuable insightCEO does not generally participate in making compensation decisions, but retains its exclusive authority to determine and approve the compensation and benefitsdiscussions of our executive officers.his own compensation.

Compensation Peer Group

The Compensation Committee has responsibility for the selection of an appropriateOCC uses a peer group for understanding and assessing competitive compensation levels and practices within our industry. It reviews this compensation peer group annually, with consideration given to the recommendations and input of management, Frederic Cook, and Compensia.

The companies comprising the compensation

27 | Page   


Our peer group areis drawn from publicly-traded companies headquartered in the United States. Recommendations for inclusion in the peer group companies are based on similarity of product lines or industry and similarity in company size as measured by annual revenue, market capitalization, operating margins, and other financial measures of organizational scope and complexity. For fiscal 2015,2018, companies were considered for inclusion in the compensation peer group that: (i) had revenue and/or a market capitalization between 0.5x and 2.0x of the Company in the past

27


fiscal year, (ii) were in the medical device industry, and (iii) were identified as a peer by at least three other current peer companies, used the Company as a peer, or had been identified as a peer by one of the major proxy advisory firms.

The compensation peer group for fiscal 20152018 was comprised of the following companies:

 

Bio-Rad Laboratories, Inc.

Hologic, Inc.Resmed, Inc.
Bruker CorporationIDEXX LaboratoriesSirona Dental Systems, Inc
Conmed CorporationIllumina, Inc.Steris Corporation
Dentsply International, Inc.

  Integra Lifesciences Holding Corporation

Bruker Corporation

Mettler-Toledo International, Inc.

Conmed Corporation

PerkinElmer, Inc.

Dentsply Sirona International, Inc.

Resmed, Inc.

Edwards Lifesciences Corporation

Steris Corporation plc

Haemonetics Corporation

  Teleflex, Inc.
Edwards Lifesciences CorporationMettler-Toledo International,

Hologic, Inc.

  Varian Medical Systems, Inc.
Haemonetics CorporationPerkinElmer, Inc.

IDEXX Laboratories

  Waters Corporation

Illumina, Inc.

  West Pharmaceutical Services, Inc.

The Compensation Committee has reviewed this compensation peer group as part of its consideration of compensation planning for fiscal 2016 and determined that the peer group continues to be appropriate for purposes of compensation comparisons. Therefore, the compensation peer group has been retained with no changes for use in review of executive compensation for fiscal 2016.

Compensation Elements

The primary elements of our executive compensation program are as follows:are:

 

Type of Compensation

Purpose

At Risk?

Base Salary

(cash)

Provide a fixed, minimum level of competitive compensation for our executives and to attract strong talent.Not at risk

Annual Incentive

(cash)

Reward achievement of annual performance objectives and encourage our executives to meet short-term business goals as reflected in our annual operating plan.At risk

Performance-Based Equity Awards

(performance share awards)

Incentivize achievement of financial results and growth in long-term stockholder value through increases in EPS over a three-year period.At risk

Time-Based Equity Awards

(stock options and/or RSUs)

Encourage executive retention and link compensation to realization of stockholder value through stock price growth.At risk

Cash salary intended to provide a minimum level of competitive compensation for our executives;

Annual cash incentive designed to encourage achievement of short-term business goals as reflected in our annual operating plan; and

Equity awards granted in the form of time-vested stock options, time-vested restricted stock units, and performance based awards, intended to connect executive compensation to long-term stockholder value, support alignment between executives and stockholders, and encourage executive retention.

Each of these primary elements, other than base salary, require achievementdepend on specific financial metrics (in the case of strong financial resultsperformance based equity and annual bonus) and significant increases in our stock price (in the case of time-based equity), creating a link between our performance and NEO compensation. Additionally, compensation is balanced between short-term and long-term factors to realize significant (or any) amountsencourage attention to both annual objectives and long-term strategic goals.

28 | Page   


In the 2018 fiscal year, approximately 70% of compensation.Mr. Weiss’s, and approximately 88% of Mr. White’s, total direct compensation was long-term equity awards providing value over a three- to five-year time frame. Approximately 84%69% of our CEO’sother NEO’s target total direct compensation for fiscal 2015 and approximately 76% of our other Named Executive Officers target total direct compensation for fiscal 2015 was “at risk” (that is, either performance-based or subject to stock price fluctuations).long-term equity awards.

 

LOGO

28


Chief Executive Officer Compensation

The Compensation Committee structures compensation for our CEO to reflect his overall responsibility for, and significant role in, our strategic direction, management, leadership, and operating results, taking into consideration the practices of our compensation peer group and our industry sector.

In setting Mr. Weiss’ compensation for fiscal 2015, the Compensation Committee considered the following factors:

LOGO

 i.*Its assessment

“Other Compensation” represents 3% of his performance against previously approved business objectivescompensation for the Companyaverage NEO and 1% for the fiscal year;Mr. Weiss.

��

 

ii.His personal assessment of his own performance against his approved objectives;

iii.An analysis of his compensation relative to the compensation of chief executive officers at companies in our compensation peer group prepared by Frederic Cook; and

iv.The input of Compensia.

Based on these factors, and our overall performance and growth in the prior fiscal year, the Compensation Committee approved an approximately 3% increase in Mr. Weiss’ overall target total direct compensation for fiscal 2015. Mr. Weiss’ target annual cash bonus opportunity was maintained at 100% of his annual base salary.

   2014 CEO
    Compensation    
 2015 CEO
    Compensation    
 Change Year over Year
         ($)             (%)      

Salary (1)

 $840,000 $875,000 $35,000 4%

Cash Bonus (Actual) (2)

 $907,200 $689,500 ($217,700) (24%)

Equity Awards (GDFV)

     

Performance Share Awards (at Target)

 $851,938

(7,106 shares)

 $851,938

(5,398 shares)

 $-0- 0%

Stock Options (1)

 $3,053,718

(73,178 Options)

 $3,174,997

(65,195 options)

 $121,279 4%
(1)Base salary and stock option award decisions for Mr. Weiss were made at the beginning of the fiscal year and prior year results were considered in setting these compensation amounts.

(2)Presents the actual bonuses paid to Mr. Weiss under each of the 2014 and 2015 Incentive Payment Plans. For both years, target achievement was set at 100% of Mr. Weiss’ base salary. Achievement under the 2014 IPP represents 108% of Mr. Weiss’ base salary of $840,000 and achievement under the 2015 IPP represents 79% of his base salary of $875,000.

Other Named Executive Officer Compensation

Adjustments to annual compensation for our other Named Executive Officers is based, in part, on changes in their responsibilities, overall execution of duties throughout the prior fiscal year, Company performance relative to pre-determined performance objectives, and internal alignment among our executive officers. Peer group compensation practices and competitive market changes and conditions are also taken into account.

29


Base Salary

For fiscal 2015, the Compensation Committee approved an increase of 3% for Ms. Kaufman, equivalent to the average increase for our employees generally, based on her individual performance during fiscal 2014. Messrs. McBride, Matz and White each received a 10% increase. The increases for Messrs. White and Matz recognized promotions for each of them and Mr. McBride’s base salary was increased to better align his compensation with other executives of the same level within our compensation peer group.

   2014
Base
Salary
 Approved
Increase
  2015
Base
Salary
 Basis for Amount of Increase

Daniel G. McBride

 $450,000 $45,000  (10%)   $495,000 Alignment to compensation peers

Albert G. White, III

 $386,131 $38,869  (10%)   $425,000 Promotion to Senior Vice President

Carol R. Kaufman

 $440,644 $13,356  (3%)   $454,000 Executive performance

Greg W. Matz

 $386,131 $38,869  (10%)   $425,000 Promotion to Senior Vice President

Incentive Payment Plan (IPP)(“IPP”)

As

Fiscal 2018 Performance Measurement

At the beginning of each fiscal year, the OCC approves an annual Incentive Payment Plan, or IPP, to provide annual performance-based cash incentive opportunities. Target levels for thepre-established performance measures used in the IPP are based on budgeted goals reflected in our annual operating plan. The IPP is discussed in more detail in the narrative to theGrants of Plan Based Awards Table on page 39, each year39.

Each NEO’s opportunity under the Compensation Committee adopts an Incentive Payment Plan, or IPP to provide performance-based cash bonus opportunities which are based onis allocated into two components:

(i)

75% of the target award is tied to quantitative,pre-established financial performance targets; and

(ii)

25% of the target award is at the discretion of the OCC and intended to recognize other strategic, operational, and individual accomplishments not specifically quantified elsewhere in the IPP.

Taken together, the budgeted goals reflected in our annual operating plan. We believe cash bonuses linked to specific, measurable, annual objectives provide an effective incentive tool to encourageIPP encourages our executive officers, including our Named Executive Officers, to meet our short-term business goals. Compensation based on these measures encourages our executive officersNEOs, to focus on both immediate business objectives generating annual growth, and stockholder returns.financial performance, as well as other factors that support longer-term performance.

The majority of the target cash bonus opportunities for each Named Executive Officer under the IPP are based on quantitative, pre-establishedFinancial targets for financial performance. In addition, a portion of their target annual cash bonus opportunities under the 2018 IPP recognizes other strategic, operational and individual accomplishments not specifically quantified elsewhere in the IPP, including market share growth, new product launches, business development and executive leadership. This component is awarded at the discretion of the Compensation Committee and allows for flexibility to reward individual and business achievements, or to recognize special circumstances. The Compensation Committee believes this flexibility is important to reward executive achievement in individual roles.

Under the 2015 IPP, the cash bonuses payable to our Named Executive Officers were dependent on our actual achievement against pre-established target levels for revenue, cash flow and non-GAAP EPS, weighted as set forth in the accompanying chart. The weighting of each performance measure was based on the Compensation Committee’s prioritization of each quantitative measure for fiscal 2015.

The target level for each of these quantitative financial

Award Measures – 2015 IPPWeighting
    Quantitative Factors
        Revenue30%      
        Non-GAAP EPS30%      
Cash flow15%
75%      
    Discretionary Award25%      
    Total Target Bonus100%

measures was based on our annual operating plan, as approved by our Board of Directors at the beginning of fiscal 2015,2018. Targets were subject to adjustment in the event offor acquisitions and/or divestitures that were subsequently approved by our Board of Directors or such other items during the fiscal year as determined atby the

30


discretion Board. The table below describes the relationship between the earned award and Company performance for each of the Compensation Committee. Our reported non-GAAP EPS for fiscal 2015 excludedfinance measures included in the impact of amortization, costs associated to acquisitions and related business integration, facility start-up costs, and specific litigation settlement and legal costs. For purposes of achievement under the 2015 IPP, our reported results provided a baseline calculation of non-GAAP EPS which could be adjusted at the discretion of the Compensation Committee.

Minimum achievement thresholds were set at 85% of the target level for cash flow and non-GAAP EPS and at 90% of the target level for revenue.2018 IPP. No bonus amountaward was payable with respect to any financial performance measure that did not reach its minimum achievement threshold. In addition, both revenue and non-GAAP EPS mustFor each NEO, the incentive that can be paid for any individual financial performance measure was capped at 200%.

IPP Achievement Required to Attain Payout (1)

       Performance Measure   Threshold  Target    Maximum  

           Revenue

 90%  100%  110%

           Earnings Per Share

 85%  100%  120%

           Cash Flow

 85%  100%  120%
(1)

The IPP threshold payout is equal to approximately 10% of Target achievement, as presented in theGrants of Plan Based Awards table on page 39. Target achievement provides for payout of 100% of target bonus amounts and Maximum is capped at 200% of Target.

29 | Page   


Further, any two of the three quantitative measures were required to exceed 95% of their target levelachievement before bonus amountsawards for any quantitative performance measure could exceed 100% of target. For each Named Executive Officer, the maximum total bonus that can be paid based on the financial performance measures was capped at 200% of his or her target cash bonus opportunity.

In addition to approving the quantitatively assessed portioncalculation of bonusesachievement based on financial results under the 20152018 IPP is subject(discussed in more detail below), the OCC also has the separate authority to adjustment at the Compensation Committee’s discretion. Regardless of actual financial achievement,reduce the quantitative portion of bonuses could be reducedthe bonus by up to 25% if the Compensation Committee determined that calculated bonuses. This determination would be based on actual achievement levels were not merited due to suchany facts and circumstances as itthe OCC considered to be in the Company’s best interests. Additionally, awardAward payments could also be reduced or cancelled inby the event thatOCC if a review of the results for the first two months of fiscal 2016 reflect2019 reflected anomalous negativeunfavorable events that were attributable to fiscal 2015.2018. The OCC did not determine that any adjustments to awards for fiscal 2018 were necessary under these provisions.

The discretionary portioncomponent of individual IPP awards is based entirely on the OCC’s assessment of executive performance during the fiscal year. The discretionary component allows the OCC the flexibility to recognize factors such as:

The personal contributions of the bonus also could be withheld, in full or in part, if the Compensation Committee determined that an award at the target level was not warranted based on an executive’s individual performance orNEOs to the performance of the Company. The Committee’sCompany during the fiscal year;

Leadership and operational achievements of each NEO, including those that may not be explicitly reflected in current year financial results (e.g. leadership development and succession planning, identification and/or execution of business development opportunities, etc);

Business achievements that may not be fully reflected in the Company’s financial performance during the fiscal year; and

Special circumstances that may have impacted the determination regarding the discretionary component of the annual bonuses is discussed in more detail below.

Determination of Financial Achievement

The Compensation Committee closely reviews the financial results presented by management before approving achievement of bonuses for the quantitative portionsportion of the IPP. bonus.

The termsOCC believes this flexibility, which can account for factors that impact our results either positively or negatively, is important to connect cash incentive awards with its assessment of the 2015executive achievement in individual roles.

2018 IPP also permit adjustment of the specified performance target levels at the Compensation Committee’s discretion. Results

Financial Measure Achievement

In approving the actual achievement levels for fiscal 2015,2018, the Compensation CommitteeOCC reviewed management’s presentation of our financial results and gave consideration to the events during the fiscal year whichthat impacted budget targets and which should be included or excluded as appropriate. The Compensation Committee considered events related totargets. On review, the integration of the Sauflon Pharmaceuticals operations and the impact of foreign exchange rate fluctuations in particular in making its determinations for fiscal 2015.

Based on our financial performance in fiscal 2015 and the terms of the 2015 IPP, the Compensation Committee determined that total quantitativeOCC approved achievement under the 20152018 IPP met threshold achievement levels but did not meet or exceed the target level for any ofbased on the financial performance measures. Accordingly, the bonuses earned by our Named Executive Officers were below target levels.

In assessing quantitative achievement under the 2015 IPP, the Compensation Committee took into consideration various items, including complexities encountered in the global integration of the Sauflon acquisition, which it felt were not reflected in the quantitative results as calculated under the terms of the 2015 IPP. As a result, it chose to reduce quantitative achievement for awards under the 2015 IPP by 5% overall, believing that this was the most effective way to accountreported for the adjustments it believed appropriate to align executive compensationCompany with financial performance in the 2015 fiscal year.no adjustments.

31


The target levels for each of the financial performance measures, and our actual achievement compared toas approved by the threshold and target levels for such measures,OCC, and the associated bonusaward amounts earned with respect to each of these measures under the 20152018 IPP is set out below, and a full discussion of our financial results can be found in Item 7,Management’s Discussion and Analysis ofFinancial Condition and Results of Operations of our Annual Report on Form10-K for the fiscal year ended October 31, 2015.2018.

30 | Page   


Corporate Achievement by Division

(Basis of Awards Paid to NEOs)

Corporate:

Award Factor Adjusted
Budget Target
($ in Thousands;
except EPS) (1)
 Adjusted Actual
Achievement
($ in Thousands;
except EPS)
(% of Target) (1)
 

Achievement
Under

2015 IPP

  Target
Achievement /
Weighting
  Weighted
Achievement
 

Revenue

 $1,920,215 $1,814,594 (94.5%)  63.2%    30%    19.0%  

Non-GAAP EPS

 $7.49 $7.44 (99.3%)  97.7%    30%    29.3%  

Cash Flow (consolidated)

 $237,813 $216,406 (91%)  69.9%    15%    10.5%  

  Less: Compensation Committee Discretionary Adjustment (2)

  

      (5.0%)  

Total Achievement

          75%    53.8%  
(1)Budget targets and actual achievement reflect adjustments to exclude the impact of amortization, costs associated with acquisitions and related business integration, facility start-up costs, litigation settlement and legal costs. Revenue was also adjusted to reflect achievement in constant currency.

 

(2)Reflects Compensation Committee exercise of authority to reduce awards by 5%.
Award Factor   Budget Target  
($ in Millions;
except EPS)
  

  Achievement  
($ in Millions;

except EPS)

(% of Target)

  

  Achievement  
Under  

2018 IPP  

 Target  
Achievement  
/ Weighting  
 Weighted  
Achievement  

Revenue

  $2,542.3   $2,527.9 (99.4%)    96.2% 25% 24.1%

EPS(Non-GAAP)

  $11.61   $11.50 (99.1%)    96.8% 25% 24.2%

Cash Flow (consolidated)

  $463.0   $475.3 (102.7%)    113.3% 25% 28.3%

    Total Achievement

           75% 76.6%

CooperVision:

Award Factor   Budget Target  
($ in Millions;
except EPS)
  

Achievement
($ in Millions;

except EPS)

(% of Target)

  

  Achievement  
Under  

2018 IPP  

 Target  
  Achievement  
/ Weighting  
 Weighted  
Achievement  

Revenue

  $1,874.1   $1,876.1 (100.1%)    101.1% 25% 25.3%

Operating Income

  $549.7   $542.3 (98.6%)    95.5% 20% 19.1%

EPS(Non-GAAP)

  $11.61   $11.50 (99.1%)    96.8% 5% 4.8%

Cash Flow

  $443.0   $434.7 (98.1%)    93.8% 25% 23.4%

    Total Achievement

           75% 72.6%

CooperSurgical:

Award Factor 

  Budget Target  

($ in Millions;
except EPS)

  

  Achievement  
($ in Millions;

except EPS)

(% of Target)

  

  Achievement  
Under  

2018 IPP  

   Target  
Achievement  
/ Weighting  
   Weighted  
Achievement  

Revenue

  $668.2   $651.8 (97.5%)    83.6% 25% 20.9%

Operating Income

  $227.2   $207.1 (91.2%)    70.4% 20% 14.1%

EPS(Non-GAAP)

  $11.61   $11.50 (99.1%)    96.8% 5% 4.8%

Cash Flow

  $73.5   $94.2 (128.2%)    200% 25% 50.0%

    Total Achievement

           75% 89.8%

Discretionary AwardsAward Determinations

As discussed above, the 20152018 IPP also providedprovides for 25% of each NEO’s target annual cash incentive opportunity to be entirely at the Compensation Committee withdiscretion of the authorityOCC and not linked to awardthe quantitative financial measures under the 2018 IPP. The IPP achievement of the discretionary portion (25%)may range from 0% to a percentage deemed appropriate by the OCC, subject to a cap on the total bonus earned by any NEO equal to 200% of each Named Executive Officer’stheir target annual cash bonus opportunity. award.

In determining whether this component of the possible executive bonuses should be awarded,discretionary payout for each NEO, the Compensation Committee considers itsOCC made an independent assessment of individual performance and leadership, operational achievements not otherwise includedenumerated in the quantitative portion of awards,2018 IPP, and such other factors as the Compensation CommitteeOCC considers indicative of executive performance.performance, including operational achievement indicators such as market share growth, new product launches, business development, and executive leadership.

This determination

31 | Page   


There is no formulaic relationship between the OCC’s assessment of discretionary awards is entirely subject toeach NEO and the judgment and discretionpayout of the Compensation Committee and is not linked todiscretionary component of the quantitative achievement levels under the 2015 IPP. The Compensation Committee generally considers anOCC does not rely on a formal performance evaluation or consider achievement ofpre-established goals for each NEO, other than the Chief Executive Officer. The OCC does consider, among other factors, the input of our Chief Executive Officer regarding recommended award levels (other than in respect to his own IPP award) and the performance of the target 25% to be a reflectionother NEOs, and each executive’s self-assessment of satisfactory performance by the accomplishments within their area of responsibility.

Named Executive Officers duringOfficer Awards Under the fiscal year.2018 IPP

For fiscal 2015,2018, the Compensation Committee chose to make discretionaryOCC approved the following awards at the 25% target level for all Named Executive Officers. In making this determination the Compensation Committee reviewed management’s individual performance and our operational achievements in fiscal 2015 separate from the quantitative award measures, including those described under “The Year in Review” on page 21 above. Based on this review and its own assessment of the performance of our Named Executive Officers, the Compensation Committee concluded that discretionary awards at 25% were warranted.

each NEO.

 

32


Awards to the Named Executive Officers Under the 2015 IPP

Executive Adjusted
Quantitative
Factor
Achievement
  Discretionary
Award
  Total Award
Achievement
  Target Award     Actual Bonus Paid 
 ($) (% of Base 
Salary)
     ($) (% of Base 
Salary)
 

Executive (1)

 

Quantitative
Factor
Achievement 

 

 

Discretionary  
Award  

 

 

Total Award

Achievement (1)

 

 

Target Award

 

 

 

Actual Award Paid

 

 

($)  (% of Base 
Salary)
 ($) (% of Base
Salary)

Albert G. White III

 79.9% 25% 104.9% $630,800  92%  $661,709  96.1% 

Brian G. Andrews

 76.6% 25% 101.6% $147,899  45%  $150,265  45.7% 

Daniel G. McBride

 74.6% 25% 99.6% $490,800  80%  $488,837  79.7% 

Holly R. Sheffield

 76.6% 25% 101.6% $124,462  60%  $126,453  61%

Robert D. Auerbach, M.D.

 89.8% 25% 114.8% $201,000  53%  $230,748  60.7% 

Robert S. Weiss

 53.8 25 78.8 $840,000   100   $689,500   79 76.6% 25% 101.6% $925,000  100%  $939,800  101.6% 

Daniel G. McBride (1)

 53.9 25 78.9 $346,500   70   $273,389   55

Albert G. White III

 53.8 25 78.8 $233,750   55   $184,195   43

Carol R. Kaufman

 53.8 25 78.8 $272,400   60   $214,651   47 76.6% 25% 101.6% $289,224  60%  $293,852  61%

Greg W. Matz

 53.8 25 78.8 $233,750   55   $184,195   43
 (1)

Mr. McBride’s achievement reflects weighting based on CooperVision performance due to his role as President of CooperVision.CooperVision and Mr. White’s achievement reflects weighting based on CooperSurgical performance based on his role as Chief Executive Officer of Cooper Medical through May 2018. Dr. Auerbach’s achievement is wholly determined by CooperSurgical results and all other NEOs are wholly determined by Corporate results.

Long-Term Incentive Compensation

The Compensation Committee provides long-term incentive compensation in the form of annual equity awards to our Named Executive Officers. The Compensation CommitteeOCC uses a combination of performance share awardsperformance-based and time-vested stock options and restricted stock unitequity awards to deliver these long-term incentive compensation opportunities.to our executive officers, including our NEOs. The Compensation CommitteeOCC believes that a “portfolio” of awards consisting of awards requiring achievement of pre-established financial objectives and awards requiring continued servicelong-term equity compensation should be designed to the Company effectively maximizes theirmaximize retention value, while connecting long-termeffectively link NEO compensation opportunities to stockholder gains, and controllingcontrol cost to the Company. The OCC discusses appropriate award design with its compensation consultant and management to drive long-term focus on strategic objectives.

Grant ProcessIn setting equity compensation for our executive officers, including our NEOs, the OCC considers recommendations from management and Timing

Frederic Cook, as well as advice from Compensia. The decision toOCC also reviews historical grant equity awards during a given fiscal year is made by the full Boardlevels based on the recommendationrole and position of the Compensation Committee. The Compensation Committee’s recommendation addresses whether and to what extent equity awards should be granted based on business conditions, an analysis based on the economic value of an estimated total award amount, accounting costs, and stock price volatility. The Compensation Committee considers the total economic and financial accounting value of potential awards, effectivenesseach executive officer, as a retention tool, and the effect on stockholder dilution in determining the recommended total amount of awards to be made for the fiscal year. The Compensation Committee also considerswell as economic and accounting implications, when determining the type and appropriate size of awards.

If the Board agrees to grant equity, it does so in the aggregate and the Compensation Committee is charged with determining the specific allocation of awards to the operating units and to individual recipients, including the Named Executive Officers. In setting award amounts for the Named Executive Officers, the Compensation Committee considers recommendations from management and from its compensation consultant, as well as historical grant levels based on the role and position of each executive officer.awards. Equity awards are generally granted in the first quarter of theeach fiscal year, after financial results for the prior fiscal year are available.available, and vest over three to five years.

The Compensation CommitteeOCC may also grant equity awards periodically to new hires, upon a promotion or in other circumstances, in its discretion. Additional equity awards may also be grantedor to accomplish specific retention goals. When such awards are approved, the grant date is set as the date that the award is approved by the Compensation Committee, unless the award is approved for a promotion or new hire which will occur in the future. In such case, the grant date will be tied to the date of hire or promotion.OCC. Grant dates are never set prior to the date of approval by the Compensation Committee.

OCC.

 

33

32 | Page   


Performance Share AwardsTime-Vested Stock Options and Restricted Stock Units

Our Named Executive Officers receive an annual performance share award that may be settled for sharesThe OCC also uses equity awards with time-based vesting to encourage executive retention while maintaining a link to long-term Company performance. Time-based vesting requires continued service to benefit from these equity awards, and the potential compensation realizable by our executive officers, including our NEOs, is dependent on increases in the market price of our common stock over time.

In fiscal 2018 our NEOs were granted either time-vested stock option awards or a combination of time-vested stock options and time-vested RSUs. The OCC believes that is earnedthese award types have strong retention value while also closely linking executive compensation to stockholder gains. Stock options only have value to the recipient if we also see growth in our stock price, putting a portion of the executives’ compensation at risk of no return, and RSUs provide guaranteed value if the executive remains with the Company. Both award types provide the opportunity for long-term gain tied to stockholder returns while also encouraging longevity and stable management for the Company.

The amount of equity grants was determined based on target accounting value and our stock price at the time of grant. In setting award levels, the OCC considered competitive market practices and the recommendations provided by Compensia. In addition, the OCC considered recommendations provided by Mr. White and input from Frederic Cook. These awards generally vest ratably over a five-year period starting on the first anniversary of the date of grant.

Equity compensation awarded to both Mr. White and Mr. McBride in December 2017 consisted of two components. The first was a stock option to purchase 21,849 shares with a target Black Scholes value of $1,265,000 and vesting in five equal annual installments. The second grant was a stock option with a target Black Scholes value on the grant date equal to $1M and vests 100% on the third anniversary of the grant date. When finalizing this equity compensation, the OCC considered the recommendations of Mr. Weiss, who was CEO at the time, and the desire to retain Mr. White and Mr. McBride during a critical succession period in the leadership of the Company as well as to recognize their strong performance and expected contributions to the ongoing success of the Company.

Separately, in connection with Mr. White’s promotion to CEO in May 2018, the OCC approved an option grant with a target Black Scholes value of $2M. This grant vests in equalone-third installments on the third, fourth and fifth anniversaries of the grant date. This option was awarded to recognize Mr. White’s promotion and to better align his compensation with competitive market practice as a Chief Executive Officer.

Grants to NEOs in 2018 Fiscal Year (1)
Name  Stock Options RSUs
  Grant Date
    Fair Value    
 Options
    Granted    
 Grant Date
    Fair Value    
 RSUs
    Granted    

Albert G. White III

  $4,265,000 73,600 -- -0-

Brian G. Andrews

  $575,000 9,975 $125,000 544

Daniel G. McBride

  $2,265,000 39,121 -- -0-

Holly R. Sheffield

  $1,000,000 17,528 $1,000,000 4,419

    Robert D. Auerbach, M.D.    

  $350,000 6,057 $500,000 2,116

Robert S. Weiss

  $3,492,500 60,322 -- -0-

Carol R. Kaufman

  $956,641 16,523 -- -0-
(1)

Amounts represent the grant values approved by the OCC and may vary from recognized compensation expense (presented in theSummary Compensation Table on page 37).

33 | Page   


Performance Share Awards

In 2018, our NEOs received performance based equity awards that require achievement of specifiedpre-established increases in non-GAAP EPS over a three-year performance period. These awards are designed to reflect the direct influence of our Named Executive OfficersNEOs on our long-term achievement and the Compensation Committeefinancial performance. The OCC has selected non-GAAPcompounded EPS growth over a three-year period as the performance measure for these awards due to its belief that this measure provides a strong link to stockholder returns.

Fiscal 20152018 Performance Share Awards

The performance share awards granted in fiscal 20152018 are based on compounded GAAP EPS growth over the designated three-year performance cycle. The awards have three possible achievement levels of achievement as set out below. Failure to meet the specified threshold level of growth in non-GAAP EPS will result inand no shares beingwill be earned under these awards.awards unless threshold achievement is reached. Once this threshold is achieved, the number of shares awarded will be prorated between achievement levels depending on actual achievement. The Compensation Committee seeks to set the target levelsmaximum payout under these awards is capped at 150% of Target shares.

2018 Performance Share Award Targets
Performance
Level
 Award
    Achievement    
       Required EPS      
Growth:

FY2018 - 20

   GAAP EPS Target for  
Achievement
Outstanding 150% 15% ³ $11.44
Target 100% 12% $10.57 to < $11.44
Threshold 50% 9% $9.74 to < $10.57

In setting targets for the performance share awards, to require significantly challenging, but attainable, levels of growth before any shares are earned. In setting the target levels, the Compensation CommitteeOCC considers the Company’sour ongoing performance and the level of achievement under prior performance share awards.

Performance
Level
  Award
Achievement
 

Required EPS
Growth:

FY2015 - 2017

Outstanding

  150% 15%

Target

  100% 12%

Threshold

    50% 10%

Target levels are set to require significantly challenging, but attainable, levels of growth. The Compensation CommitteeOCC reviews these target achievement levels with its compensation consultant to ensure reasonableness.that they are reasonable and appropriate. The Compensation CommitteeOCC also considers the Board of Directors’ objectives for long-term growth set by our Board of Directors, the Company’s historical achievements, and the Compensation Committee’sOCC’s goals for executive compensation in setting target achievement levels. For the fiscal 2015compensation. The amount of these performance share awards the Compensation Committeewas determined that increases in the “target” and “maximum” achievement levels for the awards over the corresponding levels for awards granted in fiscal 2014 would be appropriate in order to promote continued exceptional growth without encouraging inappropriate risk taking by management.

34


Results for Fiscal 2013 Performance Share Awards

The performance period for the awards granted in fiscal 2013 was completed at the end of fiscal 2015. Based on our growth in non-GAAP EPS over the performance period, the Compensation Committee approved achievement of the “threshold” level for these awards and our Named Executive Officers received 50% of the target number of shares of common stock subject to these awards.

Achievement under 2013 Performance Share Awards
(Performance Cycle: November 2012 to October 2015)
Name Target Shares
 

Threshold

(8% non-GAAP
EPS growth)

 

Target

(10% non-GAAP
EPS growth)

 Maximum
(12% non-GAAP
EPS growth)

Robert S. Weiss

 3,750 7,500 11,250

Daniel G. McBride

 1,238 2,475 3,713

Albert G. White III

 1,238 2,475 3,713

Carol R. Kaufman

 1,688 3,375 5,063

Greg W. Matz

 1,238 2,475 3,713

In making this determination, the Compensation Committee considered our reported non-GAAP EPS for fiscal 2015 and management recommendations regarding possible adjustment to account for foreign exchange rates and other impacts on non-GAAP EPS achievement. The Compensation Committee elected, in its discretion, to adjust non-GAAP EPS to include the amortization of intangible assets, which were otherwise excluded from our reported non-GAAP EPS. This adjustment reduced achievement to threshold levels under the terms of the awards. The Compensation Committee decided not to adjust non-GAAP EPS for foreign exchange rate fluctuations.

Time-Vested Awards

The Compensation Committee considers time-based vesting requirements to be an effective award structure for encouraging executive retention while maintaining a link to Company performance. Time-based vesting requires our executive officers to continue their service to benefit from these awards and any increase in the market value of our common stock during the term of the awards directly increases the compensation potential for our Named Executive Officers.

Our Named Executive Officers, other than Mr. Weiss, received a combination of time-vested restricted stock unit (“RSU”) awards and stock option awards in fiscal 2015. Mr. Weiss, as our Chief Executive Officer, receives only stock options. The Compensation Committee believes that, as the individual responsible for our overall success, the CEO’s long-term compensation should be entirely dependent on stock price growth and the achievement of stockholder returns over time.

35


The size of the RSU awards and stock option grants for the Named Executive Officers in fiscal 2015 were calculated based on their target accounting values, which the Compensation Committee determined to reflect competitive executive compensation levels.value. In setting award levels, the Compensation CommitteeOCC considered competitive market practices and the analysesrecommendations provided by Frederic Cook and Compensia. These awards vest ratably over a five-year period.

 

Grants to NEOs in 2015 Fiscal Year 
2018 Performance Share Awards2018 Performance Share Awards
Name 

Total

Time-Vested
Equity
Compensation

  

Restricted Stock Units

  

Stock Options

   Grant Date Fair Value Shares at Achievement
 Grant Date
Fair Value
 Units
Awarded
  Grant Date
Fair Value
 Options
Granted
  Threshold  Target  Maximum Threshold Target Maximum

Albert G. White III

  $216,454  $432,907  $649,361 943 1,885 2,828

Daniel G. McBride

  $216,454  $432,907  $649,361 943 1,885 2,828

Robert S. Weiss

 $4,026,909    $-0-   -0-   $3,174,997   65,195    $468,566  $937,132  $1,405,698 2,041 4,081 6,122

Daniel G. McBride

 $1,543,562   $574,958   3,543   $575,001   11,807  

Albert G. White III

 $1,009,210   $367,077   2,262   $367,052   7,537  

Carol R. Kaufman

 $1,214,432   $434,910   2,680   $434,842   8,929    $189,576  $379,152  $568,728 826 1,651 2,477

Greg W. Matz

 $1,009,210   $367,077   2,262   $367,052   7,537  

Results for Fiscal 2016 Performance Share Awards

Performance share awards granted in fiscal 2016 completed their performance cycle at the end of fiscal 2018. Based on ournon-GAAP EPS growth over the three-year performance period, the OCC certified achievement of the “Target” level for these awards.

As granted, these awards provide for achievement based onnon-GAAP EPS, as modified by the Committee for extraordinary,non-recurring, and/or unusual events. Compounded EPS growth was confirmed at $10.53 and

34 | Page   


achievement was certified to be at or above the requirements for Target payout. As granted, these awards do not provide for proration between levels of achievement. Therefore, the NEOs will receive 100% of the target shares with no adjustments as follows:

Achievement under 2016 Performance Share Awards
(Performance Cycle: November 2015 to October 2018)
Name Possible Shares
 

Threshold    

(10% growth)    

$9.90 to <$10.45    

 

Target    

(12% growth)    

$10.45 to <$11.32    

 

Maximum    

(15% growth)    

³ $11.32    

Albert G. White III

 1,651     3,301     4,952    

Brian G. Andrews

 786     1,571     2,357    

Daniel G. McBride

 1,651     3,301     4,952    

Robert D. Auerbach, M.D.

 943     1,885     2,828    

Robert S. Weiss

 3,573     7,145     10,718    

Carol R. Kaufman

 1,446     2,891     4,337    

Employee Benefits & Perquisites

Our Named Executive OfficersNEOs are eligible to receive benefits under programs provided to our employees generally, including participation in our 401(k) plan (with matching contributions up to a specified dollar value, set annually), benefits under our Retirement Income Plan (a defined benefit plan), health, life and disability insurance, and severance payments and benefits in accordance with our standard separation policy. Matching contributions to our 401(k) plan are equal to the matching contributions provided to employees generally. Benefits under the Retirement Income Plan are discussed in more detail in the Narrative to the Pension Benefits Table on page 46.

Our Named Executive OfficersWith the exception of Mr. White and Dr. Auerbach, our NEOs also participate in ourChange-in-Control Severance Plan, under which they have change in control agreements that provide for severance benefits if the participating executives were to be terminated within a specified time after a change in control.control of the Company. Mr. White has a separate change in control agreement outside theChange-in-Control Severance Plan, and Dr. Auerbach has an employment agreement with terms controlling his separation from the Company. These agreements are discussed in more detail in the section titledPotential Payments on Termination or a Change in Controlon page 48.

The Named Executive OfficersOur NEOs also receive limited perquisites or other personal benefits, generally in the form of automobile allowances and expenses, income attributable to life insurance policies, and some limited reimbursement for spousal travel to business functions. In 2018, Ms. Sheffield also received amounts in connection with her relocation to California from New York. In all cases, the Compensation CommitteeOCC reviews these amounts and takes them into consideration when reviewing overall executive compensation. We only provide perquisites or other personal benefits to our executive officers, including our Named Executive Officers,NEOs, in situations where we believe it is appropriate to assist an individual in the performance of his or her duties, to make our executive officers more efficient and effective, and for recruitment and retention purposes.

Conclusion

35 | Page   


Tax Deductibility of Compensation

Section 162(m) of the Internal Revenue Code generally provided that publicly held companies may not deduct compensation in excess of $1 million paid in any fiscal year to its chief executive officer and the other three most highly compensated NEOs employed at the end of the year (other than its chief financial officer). For years prior to 2017 there was an exception to this deduction limit with respect to “qualified performance-based compensation.”

The Compensation CommitteeOCC has historically considered ways to maintain the tax deductibility of the compensation for our NEOs under this qualified performance based compensation rule without limiting its discretion to compensate our executive officers in ways that will incentivize stockholder returns.

However, as part of the 2017 Tax Cuts & Jobs Act (“2017 Tax Reform”), the ability to rely on the qualified performance-based compensation exception was eliminated and the limitation on deductibility generally was expanded to include all NEOs. As a result of the 2017 Tax Reform, for compensation awarded or materially modified after November 2, 2017 the Company will no longer be able to deduct any compensation paid to any of its NEOs in excess of $1 million. The OCC continues to assess the impact of the 2017 Tax Reform to determine what adjustments to our executive compensation practices, if any, it considers appropriate and the impact on the deductibility of compensation awarded prior to the enactment of 2017 Tax Reform. The OCC has the discretion to provide compensation which may not be deductible under the Internal Revenue Code.

Conclusion

The OCC believes that each element of executive compensation and the total compensation provided to each of our Named Executive OfficersNEOs is reasonable, competitive, and appropriate. The amount of compensation payable to our Named Executive OfficersNEOs depends largely on our financial performance and returns to our stockholders. The Compensation CommitteeOCC believes that our executive compensation program provides an appropriate mix of elements that will allow us to continue to attract, retain, and motivate a top performing management team, without encouraging excessive or inappropriate risk-taking by our executives.

executive officers and that its compensation arrangements create incentives that drive our continued strong financial performance.

 

36 | Page   


EXECUTIVE COMPENSATION TABLES

Summary Compensation Table

The table below shows compensation paid to the individuals who served as our Named Executive Officers during the past fiscal year.

 

Name and Principal

Position

 Year  Salary  Bonus
(1)
  Option
Awards (2)
  Stock
Awards (2)
  Non-Equity
Incentive Plan
Compensation
(1)
  Change
in
Pension
Value (3)
  All Other
Compensation
(4)
  Total
Compensation  
 
  Robert S. Weiss  2015   $875,000    $218,750    $3,174,997    $851,912    $470,750    $81,407    $73,613    $5,746,429  
  President & Chief Executive
  Officer
  2014   $840,000    $252,000    $3,053,718    $851,938    $655,200    $42,286    $25,535    $5,720,678  
  2013   $800,000    $200,000    $2,903,848    $1,077,075    $787,200    ($50,781  $59,105    $5,776,446  
                                     
  Daniel G. McBride  2015   $495,000    $86,625    $575,001    $968,561    $186,764    $49,632    $49,526    $2,411,109  
  Executive Vice President &
  Chief Operating Officer
  President, CooperVision
  2014   $450,000    $94,500    $499,967    $882,031    $245,700    $39,426    $17,092    $2,228,716  
  2013   $367,744    $101,130    $325,693    $681,190    $199,023    ($5,477  $16,364    $1,685,667  
                                    
                                     
  Albert G. White, III  2015   $425,000    $58,438    $367,052    $642,158    $125,758    $38,870    $17,146    $1,674,420  
  Executive Vice President &
  Chief Strategy Officer
  2014   $386,131    $113,619    $342,019    $608,801    $165,650    $31,477    $18,837    $1,666,535  
  2013   $367,744    $50,565    $325,693    $681,190    $199,023    ($5,376  $14,911    $1,633,750  
                                     
  Carol R. Kaufman  2015   $454,000    $68,100    $434,842    $779,589    $146,551    $75,245    $59,334    $2,017,661  
  Executive Vice President,
  Secretary, Chief
  Administrative Officer &
  Chief Governance Officer
  2014   $440,644    $79,316    $434,785    $779,525    $206,221    $80,358    $27,657    $2,048,506  
  2013   $419,661    $62,949    $422,106    $906,945    $247,768    $9,652    $62,346    $2,131,426  
         
                                    
                                     
  Greg W. Matz  2015   $425,000    $58,438    $367,052    $642,158    $125,758    $39,844    $17,012    $1,675,260  
  Senior Vice President, Chief
  Financial Officer & Chief
  Risk Officer
  2014   $386,131    $63,712    $342,019    $608,801    $165,650    $31,421    $17,463    $1,615,197  
  2013   $367,744    $50,565    $325,693    $681,190    $199,023    $2,461    $15,604    $1,642,280  
                                    
                                     

Name and Principal Position

 

 

Year

 

  

Salary

 

  

Bonus (1)

 

  

Option
Awards (2)

 

  

Stock
Awards (2)

 

  

Non-Equity
Incentive Plan
Compensation
(1)

 

  

Change in
Pension
Value (3)

 

 

All Other
Compensation
(4)

 

  

Total

Compensation

 

 
Albert G. White III  2018   $688,500   $165,427   $4,265,233   $432,909   $496,282  -  $18,769   $6,067,120 
President & Chief Executive Officer  2017   $525,000   $98,662   $1,264,912   $432,890   $295,985  $28,074  $15,583   $2,661,105 
  2016   $475,000   $110,972   $1,999,862   $432,926   $332,916  $48,059  $19,164   $3,418,900 
                                   
                                   

Brian G. Andrews

  2018   $328,664   $37,566   $578,027   $124,935   $112,699  -  $15,588   $1,197,479 
Senior Vice President, Chief Financial Officer & Treasurer         
         
         
                                   
                                   

Daniel G. McBride

  2018   $613,500   $122,209   $2,265,106   $432,909   $366,628  -  $30,856   $3,831,208 

Executive Vice President &

Chief Operating Officer /President, CooperVision, Inc.

  2017   $525,000   $112,902   $1,264,912   $432,890   $338,707  $34,564  $32,622   $2,741,597 
  2016   $495,000   $108,671   $2,264,825   $432,926   $326,013  $56,270  $28,004   $3,711,709 
         
                                   
                                   

Holly R. Sheffield

  2018   $207,436   $31,613   $999,972   $1,000,020   $94,840  -  $255,553   $2,589,434 
Executive Vice President & Chief Strategy Officer         
                                   
                                   

Robert D. Auerbach, M.D.

  2018   $380,000   $57,687   $350,022   $485,961   $173,061  $9,033  $11,200   $1,466,964 

President, CooperSurgical, Inc.

         
                                   
                                   
                                   

Robert S. Weiss

  2018   $925,000   $234,950   $3,492,644   $937,242   $704,850  $12,693  $89,887   $6,397,267 
President & Chief Executive Officer (Former)  2017   $925,000   $284,669   $3,492,280   $937,093   $854,006  -  $64,066   $6,557,113 
  2016   $875,000   $279,344   $3,492,255   $937,067   $838,031  $35,700  $51,205   $6,508,603 
                                   
                                   

Carol R. Kaufman

  2018   $482,040   $181,922   $956,682   $379,169   $111,930  -  $763,278   $2,875,020 
Executive Vice President, Secretary, Chief Administrative Officer & Chief Governance Officer (Former)  2017   $468,000   $86,398   $956,560   $379,220   $259,193  $18,072  $65,213   $2,232,656 
  2016   $454,000   $86,964   $956,584   $379,155   $260,891  $51,681  $42,956   $2,232,230 
         
         
                                   
(1)

Amounts shown in the “Bonus” and “Non-Equity Incentive Plan Compensation” columns reflect the cash incentive bonuses awarded under our 2015 Incentive Payment Plan.the 2018 IPP. Amounts shown in the “Bonus” column represent the portion of the award based on the discretion of our Compensation Committee and amounts shown in the “Non-Equity Incentive Plan Compensation” column represent the portion of the bonus determined by quantitative factors. The structure of our Incentive Payment Plan is discussed in more detail below in the narrative discussion following theGrants of Plan Based Awards Table on page 39 as well as in ourCompensation Discussion and Analysis on page 21.

Under the terms of her Separation Agreement and Mutual Release disclosed on Form 8-K in April 2018, Ms. Kaufman was guaranteed half of her cash incentive under the 2018 IPP at actual achievement and half at the greater of target or actual achievement. Amounts shown in the “Bonus” column for Ms. Kaufman reflect amounts attributable to the portions of her cash incentive which were either guaranteed by her Separation Agreement or the portion of awards based on the discretion of the Compensation Committee. Amounts shown in the “Non-Equity Incentive Plan Compensation” column are attributable to the portion of her bonus determined by quantitative factors.

The structure of our Incentive Payment Plan is discussed in more detail below in the narrative discussion following theGrants of Plan Based Awards Table on page 39. as well as in ourCompensation Discussion and Analysis on page 20.

 

(2)

Amounts shown in the “Option Awards” and “Stock Awards” columns reflect the aggregate grant date fair value of stock option, restricted stock unit, and performance share awards granted to each Named Executive Officer with respect to the 2015, 20142018, 2017, and 20132016 fiscal years in accordance with FASB Accounting Standards Codification Topic 718 (ASC 718),Compensation-Stock Compensation. For a discussion of valuation assumptions, see Note 9,Stock Plans, in our Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended October 31, 2015.2018. These awards are discussed in more detail below in the narrative discussion following theGrants of Plan Based AwardsTable on page 3939. and in theCompensation Discussion and Analysison page 21.20.

 

37 | Page   


(3)

Change in value of accumulated pension benefits for the 20152018 fiscal year was calculated as the difference between the value of accumulated benefits at October 31, 20152018 and the value of accumulated benefits at October 31, 2014.2017. The value of benefits at October 31, 20152018 is based on a 4.25%4.42% discount rate and the adjusted RP-2014 base mortality rates with projection scale MP-2015;MP-2018; the value of benefits at October 31, 20142017 is based on a 4.25%3.75% discount rate and the RP2000 Mortality Tablesadjusted RP-2014 base mortality rates with fourteen years of projected mortality improvement using Scale AA;projection scale MP-2017; and the value of benefits at October 31, 20132016 is based on a 4.75%3.74% discount rate and the RP2000 Mortality Tablesadjusted RP-2014 base mortality rates with thirteen years of projected mortality improvement using Scale AA.projection scale MP-2016.

For the period from October 31, 2017 to October 31, 2018, the accumulated value of pension benefits reduced for the following Named Executive Officers:

NameBenefit Reduced By:
White$8,194
Andrews$10,717
McBride$3,333
Kaufman$24,329

 

37


(4)

Amounts included in the All Other Compensation column include the following:

 

Name Year Company’s
401(k)
Contributions
 Automobile
allowance
and expenses
 Income
associated
to life
insurance
 Personal
/ Spousal
Travel
 Other  

Year

 

Company’s
401(K)
Contributions 

 

Automobile
Allowance
and Expenses 

 

Income
Associated 
to Life
Insurance

 

Relocation
and Housing 

 

Severance / 
Retirement 
Payments 

 

Personal
Travel /
Other

Robert S. Weiss

 2015   $3,700   $9,754   $11,430   $48,652   $77  

Albert G. White III

 2018 $4,000 $13,280 $1,350 - - $139
 2014   $3,700   $10,339   $11,430   $-0-   $66  ��2017 $4,000 $10,123 $1,350 - - $110
 2013   $3,500   $9,939   $11,430   $34,235   $-0-   2016 $3,700 $12,102 $1,344 - - $0

Brian G. Andrews

 2018 $4,000 $10,860 $718 $0 $0 $10

Daniel G. McBride

 2015   $3,700   $11,283   $2,156   $32,387   $-0-   2018 $4,000 $9,106 $2,070 $0 $0 $15,680
 2014   $3,700   $11,431   $1,950   $-0-   $11   2017 $4,000 $8,967 $2,070 - - $17,585
 2013   $3,500   $11,617   $1,225   $-0-   $22   2016 $3,700 $11,283 $2,156 - - $32,387

Albert G. White, III

 2015   $3,700   $12,102   $1,344   $-0-   $-0-  

Holly R. Sheffield

 2018 $4,000 $5,403 $562 $245,549 $0 $39

Robert D. Auerbach, M.D.

 2018 $4,000 $7,200 - - - -
              
              

Robert S. Weiss

 2018 $4,000 $8,884 $18,541 $0 $0 $58,462
 2014   $3,700   $13,904   $1,222   $-0-   $11   2017 $4,000 $9,256 $4,064 - - $46,745
 2013   $3,500   $10,594   $817   $-0-   $-0-   2016 $3,700 $9,754 $11,430 - - $48,729

Carol R. Kaufman

 2015   $3,700   $10,234   $11,430   $33,970   $-0-   2018 $4,000 $8,512 $11,430 $0 $711,811 $27,525
 2014   $3,700   $13,442   $10,515   $-0-   $-0-   2017 $4,000 $12,990 $11,430 - - $36,793
 2013   $3,500   $10,372   $5,940   $42,533   $-0-   2016 $3,700 $10,233 $11,430 - - $33,970

Greg W. Matz

 2015   $3,700   $9,350   $3,852   $110   $-0-  
 2014   $3,700   $10,326   $3,426   $-0-   $11  
 2013   $3,500   $10,225   $1,879   $-0-   $-0-  

Personal and spousal travelTravel / Other amounts represent airfare, food, lodging, and other expenses paid for these executives and their spouses in connection with Company events and other amounts which were determined to have insufficient business purposenot be inherently related to be considered reimbursable expensesthe performance of these executive’s duties. Amounts in the “Relocation and Housing” column represent non-recurring amounts paid by the Company in connection with Ms. Sheffield’s relocation from New York to California at the time of her hire in 2018. Amounts in the “Severance” column represent one-time amounts guaranteed to Ms. Kaufman under IRS regulations.her Separation Agreement and Mutual Release.

38 | Page   


Performance Share Awards

Amounts included in the “Stock Awards” column of theSummary Compensation Table include the value of deferred share awards granted both in the form of Restricted Stock Units (“RSUs”) andto certain executives as Performance Share Awards. The RSUs are time-based awards generally vesting in equal portions over five years. The performance shareThese awards are designed to deliver a variable number of shares depending on the achievement of specified levels of growth in our non-GAAP earnings per share over a three-year period.

The value of the awards granted in the 2015 fiscal year as presented in the Summary Compensation Table is based on the target level of achievement. If these awards do not achieve at least the threshold level of achievement, no shares will be distributed todistributed.

The value of the executives.awards presented in the Summary Compensation Table for fiscal 2018 is based on the target level of achievement. The following table shows the grant date value of these awards at each level of possible achievement:achievement. Each of these awards is subject to interpolation between levels of achievement.

 

Name  Threshold
Achievement
   Target
Achievement
   Maximum
Achievement
  

Threshold
Achievement

(50% of Target)

 Target
Achievement
 

Maximum
Achievement

(150% of Target)

Albert G. White III $216,445 $432,890 $649,335
Daniel G. McBride $216,445 $432,890 $649,335

Robert S. Weiss

   $425,956     $851,912     $1,277,869   $468,546 $937,093 $1,405,639

Daniel G. McBride

   $196,802     $393,603     $590,404  

Albert G. White III

   $137,540     $275,080     $412,620  

Carol R. Kaufman

   $172,339     $344,679     $517,018   $189,610 $379,220 $568,830

Greg W. Matz

   $137,540     $275,080     $412,620  

Equity award grants to our Named Executive Officers are discussed in more detail in theCompensation Discussion and Analysis beginning on page 20.

 

38


 

Grants of Plan Based Awards Table

This table presents information regarding the possible awards payable under our 20152018 Incentive Payment Plan and the value of certain equity awards made in the 20152018 fiscal year. Our equity grant practices and calculation of awards under the 20152018 Incentive Payment Plan are discussed in more detail in the Narrative section to this table below and in theCompensation Discussion and Analysison page 21.20.

 

     

 

Estimated Future Payouts Under
Non-Equity Incentive Plan Awards  (1)

 

Estimated Future Payouts Under

Equity Incentive Plan Awards (2)

 All Other
Stock
Awards:
Number
of Shares
of Stock
or Units (3)
 All Other
Option
Awards:
Number of
Securities
Underlying
Options (4)
 Grant
Date Fair
Value of
Stock and
Option
Awards (5)
    

Estimated Future Payouts Under
Non-Equity Incentive Plan
Awards

(1)

 

Estimated Future Payouts
Under
Equity Incentive Plan Awards

(2)

 

All Other
Stock
Awards:
Number
of Shares
of Stock or
Units

(3)

 

All Other
Option
Awards:
Number of
Securities
Underlying
Options

(4)

 Exercise
or Base
Price of
Option
Awards
($/share)
 

Grant Date
Fair Value

of Stock

and
Option
Awards

(5)

Name Grant Date   Threshold   Target   Maximum   Threshold   Target   Maximum   Grant Date Threshold Target    Maximum    Threshold Target Maximum

Robert S. Weiss

 12/9/2015   $65,363 $875,000 td,750,000 -- -- -- -- -- --
 2/2/2015   -- -- -- 2,699 5,398 8,097 -- -- $851,912
 12/9/2014   -- -- -- -- -- -- -- 65,195 $3,174,997

Albert G. White III

 12/12/2017 $62,828 $630,800 $1,261,600 - - - - - - -
 12/12/2017 - - - - - - - 21,849 $229.66 $1,265,057
 12/12/2017 - - - - - - - 17,272 $229.66 $1,000,049
 12/12/2017 - - - 943 1,885 2,828 - -   $ 432,909
 5/1/2018

 

 -

 

 -

 

 -

 

 -

 

 -

 

 -

 

 -

 

 34,479

 

 $230.09

 

 $2,000,127

 

Brian G. Andrews

 12/12/2017 $18,413 $147,899 $295,798 - - - - -    
 12/12/2017 - - - - - - - 5,665 $229.66 $ 328,004
 12/12/2017 - - - - - - 544 -   $ 124,935
 5/1/2018

 

 -

 

 -

 

 -

 

 -

 

 -

 

 -

 

 -

 

 4,310

 

 $230.09

 

 $ 250,023

 

Daniel G. McBride

 12/9/2015   td5,884 $346,500 $693,000 -- -- -- -- -- -- 12/12/2017 $36,663 $490,800 $981,600 - - - - - - -
 2/2/2015   -- -- -- 1,247 2,494 3,741 -- -- $393,603
 12/9/2014   -- -- -- -- -- -- -- 11,807 $575,001
 12/9/2014   -- -- -- -- -- -- 3,543 -- $574,958

Albert G. White III

 12/9/2015   td7,461 td33,750 $467,500 -- -- -- -- -- --
 2/2/2015   -- -- -- 872 1,743 2,615 -- -- td75,080
 12/9/2014   -- -- -- -- -- -- -- 7,537 $367,052
 12/9/2014   -- -- -- -- -- -- 2,262 -- $367,077

Carol R. Kaufman

 12/9/2015   td0,348 td72,400 $544,800 -- -- -- -- -- --
 2/2/2015   -- -- -- 1,092 2,184 3,276 -- -- $344,679
 12/9/2014   -- -- -- -- -- -- -- 8,929 $434,842
 12/9/2014   -- -- -- -- -- -- 2,680 -- $434,910

Greg W. Matz

 12/9/2015   td7,461 td33,750 $467,500 -- -- -- -- -- --
 2/2/2015   -- -- -- 872 1,743 2,615 -- -- td75,080
 12/9/2014   -- -- -- -- -- -- -- 7,537 $367,052
 12/9/2014   -- -- -- -- -- -- 2,262 -- $367,077
 12/12/2017 - - - - - - - 21,849 $229.66 $1,265,057
 12/12/2017 - - - - - - - 17,272 $229.66 $1,000,049
 12/12/2017

 

 -

 

 -

 

 -

 

 943

 

 1,885

 

 2,828

 

 -

 

 -

 

   $ 432,909

 

 

39 | Page   


      

Estimated Future Payouts Under
Non-Equity Incentive Plan
Awards

(1)

 

Estimated Future Payouts
Under
Equity Incentive Plan Awards

(2)

 

All Other
Stock
Awards:
Number
of Shares
of Stock or
Units

(3)

 

All Other
Option
Awards:
Number of
Securities
Underlying
Options

(4)

 Exercise
or Base
Price of
Option
Awards
($/share)
 

Grant Date
Fair Value

of Stock

and
Option
Awards

(5)

Name Grant Date Threshold Target Maximum Threshold Target Maximum

Holly R. Sheffield

 6/4/2018 $15,495 $124,462 $248,923           
  6/4/2018 - - - - - - - 17,528 $226.30 $ 999,972
  6/4/2018

 

       -

 

 -

 

 -

 

 4,419

 

 -

 

   $1,000,020

 

Robert D. Auerbach, M.D.

 12/12/2017 $5,005 $201,000 $402,000 - - - - -    
  12/12/2017 - - - - - - - 4,318 $229.66 $ 250,012
  12/12/2017 - - - - - - 2,116 -   $ 485,961
  6/1/2018

 

 -

 

 -

 

 -

 

 -

 

 -

 

 -

 

 -

 

 1,739

 

 $228.11

 

 $ 100,010

 

       
                       
                       

Robert S. Weiss

 12/12/2017 $115,163 $925,000 $1,850,000 - - - - - - -
  12/12/2017 - - - - - - - 60,322 $229.66 $3,492,644
  12/12/2017

 

 -

 

 -

 

 -

 

 2,041

 

 4,081

 

 6,122

 

 -

 

 -

 

 -

 

 $ 937,242

 

Carol R. Kaufman

 12/12/2017 $36,008 $289,224 $578,448 - - - - - - -
  12/12/2017 - - - - - - - 16,523 $229.66 $ 956,682
  12/12/2017

 

 -

 

 -

 

 -

 

 826

 

 1,651

 

 2,477

 

 -

 

 -

 

 -

 

 $ 379,169

 

(1)

Amounts represent the threshold, target, and maximum cash bonus amounts which could have been paid to each Named Executive Officer under our 20152018 Incentive Payment Plan, or IPP. The final award amounts for the 2015 IPP, werewhich was approved on the date indicated in the “Grant Date” columncolumn. The final award amounts for the 2018 IPP were approved on December 11, 2018 and the value of the final award amounts are included in the “Bonus” and “Non-Equity“Non-Equity Incentive Plan Compensation” columns of theSummary Compensation Table on page 37.

 

(2)

Amounts represent the threshold, target, and maximum amounts of shares distributable under performance share awards granted on February 2, 2015December 12, 2017 under our 2007 Long-Term Incentive Plan. Awards will vest on the achievement of specified levels of non-GAAP earnings per share in the 20172020 fiscal year.

 

(3)Stock awards

Awards listed in this column represent grants ofwere granted on the date indicated in the Grant Date column as restricted stock units made on December 9, 2014. These grantsunits. The awards granted to Mr. Andrews and Dr. Auerbach vest and shares will be released, in equal portions over five years Dr. Auerbach also received an award which will vest in full on eachthe 3rd anniversary of January 8, 2016, January 8, 2017, January 8, 2018, January 8, 2019 and January 8, 2020. Due to provisions in the award allowing this grant to continue vesting after her retirement, RSUsdate. The award granted to Ms. Kaufman were considered vested for accounting purposesSheffield will vest in equal portions over five years starting on the firstsecond anniversary of the date of grant but release of shares under this award will occur on the same schedule as other grants on this date. If Ms. Kaufman provides services to, or owns more than 5% of, a competitor after her date of retirement, she will forfeit any right to the remaining outstanding shares.

 

39


(4)

Option awards listed in this column were granted at 100% of fair market value on the date listed in the Grant Date column and will expire on the tenth anniversary of the grant date.

Messrs. White and McBride each received a grant on December 12, 2017 of approximately $1,000,000 target value which will vest in full on the 3rd anniversary of the grant date. Mr. Andrews also received a grant of approximately $100,000 target value which will vest in full on the 3rd anniversary of the grant date. All other listed awards will vest as follows:

Grant Date

Vesting

December 12, 2017In equal portions on the 1st – 5th anniversaries of the date of grant
May 1, 2018In equal portions on the 3rd – 5th anniversaries of the date of grant
June 1, 2018In equal portions on the 3rd – 5th anniversaries of the date of grant
June 4, 2018In equal portions on the 2nd – 5th anniversaries of the date of grant

Due to provisions in the awards allowing the grants to continue vesting after their retirement, options granted to Mr. Weiss and Ms. Kaufman were considered vested for accounting purposes on the first anniversary of the date of grant, but exercisability of these awards is restricted to the same vesting schedule as other grants on this date. If either Mr. Weiss or Ms. Kaufman provides services to, or owns more than 5% of, a competitor after their date of retirement, they will forfeit any remaining outstanding options.

(5)

Amounts included in the “Grant Date Fair Value of Stock and Option Awards” column represent the grant date fair value recognized with respect to the 2018 fiscal year in accordance with ASC 718. For a discussion of valuation assumptions, see Note 9,Stock Plans, in our Notes to Consolidated Financial Statements included in our Annual Report on Form10-K for the year ended October 31, 2018.

40 | Page   


AnnualNon-Equity Incentives

The Compensation Committee adopts an annual Incentive Payment Plan, or IPP, to provide for short-term cash incentive awards tied to the achievement of our business goals. Financial targets are derived from our approved fiscal year budget. The IPP is governed by the 2017 Executive Incentive Plan (the “2017 EIP”), as approved by stockholders in March 2017.

Participation levels in the IPP are set by the Compensation Committee for our executives. Targets represent a designated percentage of base salary for the fiscal year and that percentage controls the potential award that can be achieved under the IPP as follows:

LOGO

As presented in theGrants of Plan Based Awards Table, target amounts represent the potential bonus that would be paid on 100% achievement of both quantitative factors and the discretionary portion of awards. Threshold amounts represent the minimum achievement necessary for payment on only the lowest weighted quantitative factor and no award of discretionary amounts. All awards are capped at a maximum of 200% of the target bonus opportunity.

Specific budget targets and actual achievement under the 2018 IPP are discussed in more detail in theCompensation Discussion and Analysis on page 20.

Equity Awards

We grant equity incentive awards as a tool to promote retention and to connect compensation with our long-term performance and stockholder returns. These awards are granted under our 2007 Long-Term Incentive Plan (as restated and amended in March 2016) and may vest based on continued service over time and/or performance criteria.

The Compensation Committee utilizes a mixture of equity award types, including stock options and performance shares. Stock options are granted at 100% of fair market value on the date of grant and have a10-year life. Options vest over a five-year period. Performance share awards vest on the achievement of specified levels of earnings per share over a three-year performance period.

Equity award grants to our Named Executive Officers are discussed in more detail in theCompensation Discussion and Analysis beginning on page 20.

41 | Page   


Outstanding Equity Awards at Fiscal Year End Table

This table provides information regarding the equity award holdings of the Named Executive Officers as of the end of the 2018 fiscal year.

   Option Awards    Stock Awards
Name Number of
Securities
Underlying
Unexercised
Options
(Exercisable)
 Number of
Securities
Underlying
Unexercised
Options
(Unexercisable)
 Option
Exercise
Price
 Option
Expiration
Date
       Number of
Shares or
Units of
Stock That
Have
Not Vested
 Market
Value of
Shares or
Units of
  Stock That
Have
Not Vested
 Equity
Incentive
Plan
Awards:
Number of
Unearned
Shares,
Units or
Other
Rights
That Have
Not Vested
 Equity
Incentive
Plan
Awards:
Market or
Payout
Value of
Unearned
Shares,
Units or
Other
Rights
That Have
Not Vested

Albert G. White

 10,310 - $95.74 12/12/2022 (1)      
  6,557 1,639 $119.89 12/11/2023 (2)      
      (3)  570 $147,237   
  4,523 3,014 $162.28 12/9/2024 (4)      
      (5)  904 $233,512   
  10,741 16,110 $131.60 12/9/2025 (6)      
  - 26,851 $131.60 12/9/2025 (7)      
      (9)    4,952 $1,279,151
  5,750 22,998 $175.31 12/13/2026 (10)      
      (12)    3,497 $903,310
  - 21,849 $229.66 12/12/2027 (14)      
  - 17,272 $229.66 12/12/2027 (17)      
      (15)    2,828 $730,501
  -

 

 34,479

 

 $230.09

 

 5/1/2028

 

 (20)

 

          

Brian G. Andrews

 1,917 479 $119.89 12/11/2023 (2)      
      (3)  166 $42,879   
  1,541 1,026 $162.28 12/9/2024 (4)      
      (5)  308 $79,559   
  1,343 2,013 $131.60 12/9/2025 (6)      
      (8)  570 $147,237   
      (9)    2,357 $608,837
  569 2,272 $175.31 12/13/2026 (10)      
      (11)  570 $147,237   
      (13)  555 $143,362   
  - 3,886 $229.66 12/12/2027 (14)      
  - 1,779 $229.66 12/12/2027 (18)      
      (16)  544 $140,521   
  -

 

 4,310

 

 $230.09

 

 5/1/2028

 

 (20)

 

          

Daniel G. McBride

 9,585 2,396 $119.89 12/11/2023 (2)      
      (3)  834 $215,431   
  7,085 4,722 $162.28 12/9/2024 (4)      
      (5)  1,417 $366,025   
  13,587 20,379 $131.60 12/9/2025 (6)      
  - 26,851 $131.60 12/9/2025 (7)      
      (9)    4,952 $1,279,151
  5,750 22,998 $175.31 12/13/2026 (10)      
      (12)    3,497 $903,310
  - 21,849 $229.66 12/12/2027 (14)      
  - 17,272 $229.66 12/12/2027 (17)      
          (15)       2,828 $730,501

42 | Page   


   Option Awards    Stock Awards
Name Number of
Securities
Underlying
Unexercised
Options
(Exercisable)
 Number of
Securities
Underlying
Unexercised
Options
(Unexercisable)
 Option
Exercise
Price
 Option
Expiration
Date
       Number of
Shares or
Units of
Stock That
Have
Not Vested
 Market
Value of
Shares or
Units of
  Stock That
Have
Not Vested
 Equity
Incentive
Plan
Awards:
Number of
Unearned
Shares,
Units or
Other
Rights
That Have
Not Vested
 Equity
Incentive
Plan
Awards:
Market or
Payout
Value of
Unearned
Shares,
Units or
Other
Rights
That Have
Not Vested

Holly R. Sheffield

 - 17,528 $226.30 6/4/2028 (22)      
      (23)  4,419 $1,141,472   

Robert D. Auerbach M.D.

     (3)  750 $193,733   
      (5)  1,109 $286,466   
  1,208 3,624 $131.60 12/9/2025 (6)      
      (8)  1,026 $265,026   
      (9)    2,828 $730,501
  1,023 4,090 $175.31 12/13/2026 (10)      
      (11)  1,254 $323,921   
      (13)  666 $172,034   
  - 4,318 $229.66 12/12/2027 (14)      
      (16)  435 $112,365   
      (19)  592 $152,920   
      (16)  1,089 $281,300   
  - 1,739 $228.11 6/1/2028 (21)      
                     
                     
                     

Robert S. Weiss

 - 14,635 $119.89 12/11/2023 (2)      
  39,117 26,078 $162.28 12/9/2024 (4)      
  37,511 56,266 $131.60 12/9/2025 (6)      
      (9)    10,718 $2,768,567
  15,874 63,496 $175.31 12/13/2026 (10)      
      (12)    7,569 $1,955,148
   60,322 $229.66 12/12/2027 (14)      
          (15)       6,122 $1,581,374

Carol R. Kaufman

 8,336 2,083 $119.89 12/11/2023 (2)      
      (3)  725 $187,275   
  5,358 3,571 $162.28 12/9/2024 (4)      
      (5)  1,072 $276,908   
  10,275 15,412 $131.60 12/9/2025 (6)      
      (9)    4,337 $1,120,290
  4,348 17,392 $175.31 12/13/2026 (10)      
      (12)    3,063 $791,204
  - 16,523 $229.66 12/12/2027 (14)      
          (15)

 

       2,477

 

 $639,834

 

(1)

Options were granted on December 9, 2014 at an exercise price of $162.28. The options granted will vest12, 2012 and became vested and exercisable in equal portions on each of the first through fifth anniversaries of the date of grant. The options

(2)

Options were granted at 100%on December 11, 2013 and become vested and exercisable in equal portions on each of fair market value onthe first through fifth anniversaries of the date of grant and expire on December 9, 2024.grant. Due to provisions in the awardthese awards allowing this grantthese grants to continue vesting after theirtermination due to retirement, the options granted to Mr. Weiss and Ms. Kaufman were considered vested for accounting purposes on the first anniversary of thetheir date of grant, but exercisability of this awardthese awards is restricted to the same vesting schedule as other grants on this date. If either Mr. Weiss or Ms. Kaufman provides services to, or owns more than 5% of, a competitor after their date of retirement, they will forfeit any remaining outstanding options.

 

(5)
Amounts included in the “Grant Date Fair Value of Stock and Option Awards” column represent the grant date fair value recognized with respect to the 2015 fiscal year in accordance with ASC 718. For a discussion of valuation assumptions, see Note 9,Stock Plans, in our Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended October 31, 2015.43 | Page   

Annual Non-Equity Incentives

The Compensation Committee adopts an Incentive Payment Plan, or IPP, annually to govern cash bonuses payable for the corresponding fiscal year. The IPP terms tie potential annual bonus compensation to the achievement of business goals derived from our approved fiscal year budget.

Participation levels in the IPP are set by the Compensation Committee and represent a designated percentage of base salary for the fiscal year. That percentage controls the potential award that can be achieved under the IPP as follows:

LOGO

As presented in theGrants of Plan Based Awards Table, target amounts represent the bonus opportunity for the Named Executive Officers at 100% achievement of quantitative factors and award of 100% of the target discretionary portion of awards. Threshold amounts represent the minimum achievement necessary to achieve payment on only the lowest weighted quantitative factor and no award of discretionary amounts. All awards are capped at a maximum of 200% of the target bonus opportunity.

Specific targets and actual achievement under the 2015 IPP are discussed in more detail in theCompensation Discussion and Analysis on page 21.

Equity Awards

We provide our Named Executive Officers with equity incentive awards as a tool to promote retention and to connect compensation with our long-term performance and stockholder returns. These awards are granted under our 2007 Long-Term Incentive Plan and may vest based on continued service over time and/or based on performance criteria. Stock options generally have a 10-year term and any stock options are awarded at 100% of fair market value on the date of grant.

The Compensation Committee utilizes a mixture of equity award types, including stock options, restricted stock units and performance shares. Stock options and restricted stock units generally vest over time. Performance share awards vest on the achievement of specified levels of earnings per share over a three-year performance period.

Equity award grants are discussed in more detail in theCompensation Discussion and Analysis beginning on page 21.

40


Outstanding Equity Awards at Fiscal Year End

This table provides information regarding the equity award holdings of the Named Executive Officers as of the end of the 2015 fiscal year.

   Option Awards Stock Awards
Name Number Of
Securities
Underlying
Unexercised
Options
(Exercisable)
 Number Of
Securities
Underlying
Unexercised
Options
(Unexercisable)
 Option
Exercise
Price
 Option
Expiration
Date
    Number
of
Shares or
Units of
Stock That
Have
Not
Vested
 Market
Value of
Shares or
Units of
Stock That
Have
Not Vested
 Equity
Incentive
Plan
Awards:
Number
of
Unearned
Shares,
Units or
Other
Rights
That
Have
Not
Vested
 Equity
Incentive
Plan
Awards:
Market or
Payout
Value of
Unearned
Shares,
Units or
Other
Rights
That Have
Not Vested

Robert S. Weiss

 22,500 - $58.07 12/13/2020 (1)     
  - 10,000 $58.07 12/13/2020 (2)     
  72,514 24,171 $65.96 12/14/2021 (3)     
  36,770 55,153 $95.74 12/12/2022 (4)     
      (5)   11,250 $1,142,700
  14,636 58,542 $119.89 12/11/2023 (6)     
      (8)   10,659 $1,082,670
  - 65,195 $162.28 12/9/2024 (9)     
          (10)     8,097 $822,439

Daniel G. McBride

 30,000 - $42.65 10/25/2017 (11)     
  6,000 - $13.10 12/11/2018 (12)     
      (13) 1,975 $300,911   
  4,124 6,186 $95.74 12/12/2022 (4)     
      (5)   3,713 $377,091
      (14) 2,041 $310,967   
  2,397 9,584 $119.89 12/11/2023 (6)     
      (8)   4,781 $485,571
      (7) 3,336 $508,273   
  - 11,807 $162.28 12/9/2024 (9)     
      (15) 3,543 $539,811   
          (10)     3,741 $379,986

41


   Option Awards Stock Awards
Name Number Of
Securities
Underlying
Unexercised
Options
(Exercisable)
 Number Of
Securities
Underlying
Unexercised
Options
(Unexercisable)
 Option
Exercise
Price
 Option
Expiration
Date
    Number
of
Shares or
Units of
Stock That
Have
Not
Vested
 Market
Value of
Shares or
Units of
Stock That
Have
Not Vested
 Equity
Incentive
Plan
Awards:
Number
of
Unearned
Shares,
Units or
Other
Rights
That
Have
Not
Vested
 Equity
Incentive
Plan
Awards:
Market or
Payout
Value of
Unearned
Shares,
Units or
Other
Rights
That Have
Not Vested

  Albert G. White III

 8,000 - $13.21 12/10/2018 (17)     
  12,000 - $13.10 12/11/2018 (12)     
      (13) 1,975 $300,911   
  4,124 6,186 $95.74 12/12/2022 (4)     
      (5)   3,713 $377,091
      (14) 2,041 $310,967   
  1,640 6,556 $119.89 12/11/2023 (6)     
      (8)   3,338 $339,001
      (7) 2,282 $347,686   
  - 7,537 $162.28 12/9/2024 (9)     
      (15) 2,262 $344,638   
      (10)   2,615 $265,563

  Carol R. Kaufman

 33,000 - $42.65 10/25/2017 (11)        
  16,500 - $15.83 10/30/2018 (16)     
  16,500 - $13.21 12/10/2018 (17)     
  33,000 - $13.10 12/11/2018 (12)     
      (13) 2,667 $406,344   
  5,345 8,017 $95.74 12/12/2022 (4)     
      (5)   5,063 $514,215
      (14) 2,646 $403,145   
  2,084 8,335 $119.89 12/11/2023 (6)     
      (8)   4,313 $438,035
      (7) 2,901 $441,996   
  - 8,929 $162.28 12/9/2024 (9)     
      (15) 2,680 $408,325   
          (10)     3,276 $332,754

42


   Option Awards Stock Awards
Name Number Of
Securities
Underlying
Unexercised
Options
(Exercisable)
 Number Of
Securities
Underlying
Unexercised
Options
(Unexercisable)
 Option
Exercise
Price
 Option
Expiration
Date
    Number
of
Shares or
Units of
Stock That
Have
Not
Vested
 Market
Value of
Shares or
Units of
Stock That
Have
Not Vested
 Equity
Incentive
Plan
Awards:
Number
of
Unearned
Shares,
Units or
Other
Rights
That
Have
Not
Vested
 Equity
Incentive
Plan
Awards:
Market or
Payout
Value of
Unearned
Shares,
Units or
Other
Rights
That Have
Not Vested

Greg W. Matz

 13,750 - $38.89 5/3/2020 (18)     
      (13) 1,975 $300,911   
  4,124 6,186 $95.74 12/12/2022 (4)     
      (5)   3,713 $377,091
      (14) 2,041 $310,967   
  1,640 6,556 $119.89 12/11/2023 (6)     
      (8)   3,338 $339,001
      (7) 2,282 $347,686   
  - 7,537 $162.28 12/9/2024 (9)     
      (15) 2,262 $344,638   
          (10)     2,615 $265,563

(1)Options were granted on December 13, 2010 and became vested and exercisable in equal portions on each of the first through fifth anniversaries of the date of grant.

(2)Options were granted on December 13, 2010 and become vested and exercisable in equal portions on each of the first through fourth anniversaries of the date of grant.

(3)Options were

Award granted as RSUs on December 14, 201111, 2013 and became vested and exercisable in equal portions on each of the first through fourth anniversaries of the date of grant.

(4)Options were granted on December 12, 2012 and will become vested and exercisable in equal portions on each of the first through fifth anniversaries of the date of grant. Due to provisions in the award allowing this grant to continue vesting after their retirement, options granted to Mr. Weiss and Ms. Kaufman were considered vested for accounting purposes on the first anniversary of the date of grant, but exercisability of this award is restricted to the same vesting schedule as other grants on this date. If either Mr. Weiss or Ms. Kaufman provides services to, or owns more than 5% of, a competitor after their date of retirement, they will forfeit any remaining outstanding options.

(5)Performance share awards granted on December 12, 2012 which will vest depending on the achievement of specified levels of growth in non-GAAP earnings per share for the 2015 fiscal year. Share amounts represent maximum payout amounts and are valued at $152.36$258.31 per share, the closing price of our stock on October 31, 2015.

(6)Options were granted on December 11, 2013 and will become vested and exercisable in equal portions on each of the first through fifth anniversaries of the date of grant. Due to provisions in the award allowing this grant to continue vesting after their retirement, options granted to Mr. Weiss and Ms. Kaufman were considered vested for accounting purposes on the first anniversary of the date of grant, but exercisability of this award is restricted to the same vesting schedule as other grants on this date. If Mr. Weiss or Ms. Kaufman provides services to, or owns more than 5% of, a competitor after her date of retirement, they will forfeit any remaining outstanding options.

43


(7)Award granted as RSUs on December 11, 2013 and valued at $152.36 per share, the closing price of our stock on October 31, 2015.2018. The units will vest in equal portions on each of January 8, 2015, January 8, 2016, January 8, 2017, January 8, 2018 and January 8, 2019. Due to provisions in the award allowing this grant to continue vesting after hertermination due to retirement, RSUs granted to Ms. Kaufman were considered vested for accounting purposes on the first anniversary of the date of grant, but release of shares under this award will occur on the same schedule as other grants on this date. If Ms. Kaufman provides services to, or owns more than 5% of, a competitor after her retirement, she will forfeit any right to the remaining outstanding shares.shares under this award.

 

(8)(4)Performance share awards granted on December 11, 2013 which will vest depending on the achievement of specified levels of growth in non-GAAP earnings per share for the 2016 fiscal year. Share amounts represent maximum payout amounts and are valued at $152.36 per share, the closing price of our stock on October 31, 2015.

(9)Options were granted on December 9, 2014 and will become vested and exercisable in equal portions on each of the first through fifth anniversaries of the date of grant. Due to provisions in the awardthese awards allowing this grantthese grants to continue vesting after theirtermination due to retirement, the options granted to Mr. Weiss and Ms. Kaufman were considered vested for accounting purposes on the first anniversary of thetheir date of grant, but exercisability of this awardthese awards is restricted to the same vesting schedule as other grants on this date. If either Mr. Weiss or Ms. Kaufman provides services to, or owns more than 5% of, a competitor after hertheir date of retirement, they will forfeit any remaining outstanding options.

 

(10)(5)Performance share awards

Award granted as RSUs on February 2, 2015 which will vest depending on the achievement of specified levels of growth in non-GAAP earnings per share for the 2017 fiscal year. Share amounts represent maximum payout amountsDecember 9, 2014 and are valued at $152.36$258.31 per share, the closing price of our stock on October 31, 2015.

(11)Options were granted on October 25, 2007 and became vested and exercisable as follows:

a.    one-quarter on each of October 25, 2008, October 25, 2009 and October 25, 2010; and

b.    one-quarter on March 10, 2011.

(12)Options were granted on December 11, 2008 and became vested and exercisable in equal portions on each of the first through fifth anniversaries of the date of grant.

(13)Award granted as RSUs on December 14, 2011 and valued at $152.36 per share, the closing price of our stock on October 31, 2015.2018. The units vest in equal portions on each of January 8, 2013, January 8, 2014, January 8, 2015 and January 8, 2016.

(14)Award granted as RSUs on December 12, 2012 and valued at $152.36 per share, the closing price of our stock on October 31, 2015. The units vest in equal portions on each of January 8, 2014, January 8, 2015, January 8, 2016, January 8, 2017, January 8, 2018, January 8, 2019 and January 8, 2018.2020. Due to provisions in the award allowing this grant to continue vesting after hertermination due to retirement, RSUs granted to Ms. Kaufman were considered vested for accounting purposes on the first anniversary of the date of grant, but release of shares under this award will occur on the same schedule as other grants on this date. If Ms. Kaufman provides services to, or owns more than 5% of, a competitor after her retirement, she will forfeit any right to the remaining outstanding shares.shares under this award.

 

(15)(6)Award

Options were granted as RSUs on December 9, 20142015 and valued at $152.36 per share, the closing price of our stock on October 31, 2015. The units vestbecome vested and exercisable in equal portions on each of January 8, 2016, January 8, 2017, January 8, 2018, January 8, 2019, and January 8, 2020.the first through fifth anniversaries of the date of grant. Due to provisions in the awardthese awards allowing this grantthese grants to continue vesting after hertermination due to retirement, RSUsthe options granted to Mr. Weiss and Ms. Kaufman were considered vested for accounting purposes on the first anniversary of thetheir date of grant, but releaseexercisability of shares under this award will occur onthese awards is restricted to the same vesting schedule as other grants on this date. If either Mr. Weiss or Ms. Kaufman provides services to, or owns more than 5% of, a competitor after hertheir date of retirement, shethey will forfeit any right to the remaining outstanding shares.options.

 

(16)(7)Options were granted on October 30, 2008 and became fully vested on March 29, 2009.

(17)Options were granted on December 10, 20089, 2015 and became fullybecome vested and exercisable in equal portions on December 10, 2012.each of the third, fourth and fifth anniversaries of the date of grant.

 

(18)(8)

Award granted as RSUs on December 9, 2015 and valued at $258.31 per share, the closing price of our stock on October 31, 2018. The units vest in equal portions on each of January 8, 2017, January 8, 2018, January 8, 2019, January 8, 2020, and January 8, 2021.

(9)

Performance share awards granted on January 29, 2016 which will vest depending on the achievement of specified levels of growth in earnings per share for the 2018 fiscal year. Share amounts represent maximum payout amounts (150% of target) and are valued at $258.31 per share, the closing price of our stock on October 31, 2018.

(10)

Options were granted on May 3, 2010December 13, 2016 and becamebecome vested and exercisable in equal portions on each of the first through fourthfifth anniversaries of the date of grant.

44


Option Exercises and Stock Vested

The following table details the number of shares acquired on exercise of stock options and release of shares upon vesting of performance share awards and awards of Restricted Stock Units during the 2015 fiscal year by the Named Executive Officers.

 

    Option Awards    Stock Awards
Name    Number of
Shares
Acquired on
Exercise
    Value Realized
on Exercise
    Number of
Shares
Acquired on
Vesting (1)
     Value
Realized
on Vesting (1)

Robert S. Weiss

    133,500    $17,881,448     30,000      $4,810,500

Daniel G. McBride

    22,500    $2,015,777     5,740      $934,931

Albert G. White, III

    6,375    $1,082,231     15,377      $2,479,559

Carol R. Kaufman

    35,500    $4,091,672     13,499      $2,164,562

Greg W. Matz

    20,000    $2,815,870     10,529      $1,689,917
(1)Includes shares issued Due to provisions in connection with performance sharethese awards allowing these grants to continue vesting after termination due to retirement, the options granted to Mr. Weiss and Ms. Kaufman were considered vested for accounting purposes on December 9, 2009the first anniversary of their date of grant, but exercisability of these awards is restricted to the Named Executive Officers for which release was previously deferred. These awards vested in February 2013 and the following Named Executive Officers electedsame vesting schedule as other grants on this date. If either Mr. Weiss or Ms. Kaufman provides services to, defer receiptor owns more than 5% of, the indicated shares until January 8, 2015 as provided by the termsa competitor after their date of the underlying award agreements:retirement, they will forfeit any remaining outstanding options.

 

Name  Number of Shares
Acquired on Vesting
  Value Realized
on Vesting
  Value at October 31,    
2015

Robert S. Weiss

  15,000  $1,532,850  $2,443,200

Albert G. White, III

  4,950  $ 505,841  $ 806,256

Also includes shares issued in connection with performance share awards granted on December 14, 2011. The following Named Executive Officers elected to defer receipt of these shares until January 2017 as provided by the terms of the underlying award agreements:

Name  Number of Shares Acquired
on Vesting
   Value at Vesting         

Daniel G. McBride

   4,950    $781,209  

Non-Qualified Deferred Compensation Table

The table below sets forth certain information as of October 31, 2015 with respect to the non-qualified deferred compensation plans in which our Named Executive Officers participate.

Name Plan Name Registrant
Contributions
in Last Fiscal
Year (1)
 Aggregate
Earnings in
Last Fiscal
Year (2)
 Aggregate
Withdrawals /
Distributions
(3)
 Aggregate
Balance at Last
Fiscal Year End
(4)

Robert S. Weiss

 2007 Long-Term Incentive Plan $-0- $525,900 $2,443,200 $2,285,400

Daniel G. McBride

 2007 Long-Term Incentive Plan $781,209 $146,520 $-0- $1,508,364

Albert G. White III

 2007 Long-Term Incentive Plan $-0- $173,547 $806,256 $754,182

Carol R. Kaufman

 -- $-0- $-0- $-0- $-0-

Greg W. Matz

 -- $-0- $-0- $-0- $-0-

45


(11)(1)Represents the value

Award granted as RSUs on December 13, 2016 and valued at vesting of performance share awards granted to the Named Executive Officer which were deferred by the executive under the terms of the award agreement.

(2)Represents the change in value of shares previously deferred and not yet released to the Named Executive Officer under the terms of performance share awards from the date of deferral by the Named Executive Officer through the end of the 2015 fiscal year. Calculated by taking the difference in the stock price on the date of deferral and the last day of the 2015 fiscal year and multiplying by the number of shares deferred by the executive.
(3)Represents the value at release to the Named Executive Officer of previously deferred shares at the end of the deferral period.
(4)Represents the value at the end of the 2015 fiscal year of shares that have been previously deferred under the terms of performance share award agreements and which have not yet been released to the Named Executive Officer. Valued at $152.36$258.31 per share, the closing price of our stock on October 31, 2015.2018. The units vest in equal portions on each of January 8, 2018, January 8, 2019, January 8, 2020, January 8, 2021, and January 8, 2022.

 

(12)

Performance share awards granted on February 1, 2017 which will vest depending on the achievement of specified levels of growth in earnings per share for the 2019 fiscal year. Share amounts represent maximum payout amounts (150% of target) and are valued at $258.31 per share, the closing price of our stock on October 31, 2018.

 

(13)

Award granted as RSUs on February 1, 2017 and valued at $258.31 per share, the closing price of our stock on October 31, 2018. The units vest in full on February 1, 2020.

44 | Page   


(14)

Options were granted on December 12, 2017 and become vested and exercisable in equal portions on each of the first through fifth anniversaries of the date of grant. Due to provisions in these awards allowing these grants to continue vesting after termination due to retirement, the options granted to Mr. Weiss and Ms. Kaufman were considered vested for accounting purposes on the first anniversary of their date of grant, but exercisability of these awards is restricted to the same vesting schedule as other grants on this date. If either Mr. Weiss or Ms. Kaufman provides services to, or owns more than 5% of, a competitor after their date of retirement, they will forfeit any remaining outstanding options.

(15)

Performance share awards granted on December 12, 2017 which will vest depending on the achievement of specified levels of growth in earnings per share for the 2020 fiscal year. Share amounts represent maximum payout amounts (150% of target) and are valued at $258.31 per share, the closing price of our stock on October 31, 2018.

(16)

Award granted as RSUs on December 12, 2017 and valued at $258.31 per share, the closing price of our stock on October 31, 2018. The units vest in equal portions on each of January 8, 2019, January 8, 2020, January 8, 2021, January 8, 2022, and January 8, 2023.

(17)

Options were granted on December 12, 2017 and become vested and exercisable in full on the third anniversary of the date of grant.

(18)

Award granted as options on December 12, 2017 and valued at $258.31 per share, the closing price of our stock on October 31, 2018. The units vest in full on February 1, 2021.

(19)

Award granted as RSUs on December 12, 2017 and valued at $258.31 per share, the closing price of our stock on October 31, 2018. The units vest in full on February 1, 2021.

(20)

Options were granted on May 1, 2018 and become vested and exercisable in equal portions on each of the third through fifth anniversaries of the date of grant.

(21)

Options were granted on June 1, 2018 and become vested and exercisable in equal portions on each of the third through fifth anniversaries of the date of grant.

(22)

Options were granted on June 4, 2018 and become vested and exercisable in equal portions on each of the second through fifth anniversaries of the date of grant.

(23)

Award granted as RSUs on June 4, 2018 and valued at $258.31 per share, the closing price of our stock on October 31, 2018. The units vest in equal portions on the second through fifth anniversaries of the date of grant.

Option Exercises and Stock Vested Table

The following table details the number of shares acquired by the Named Executive Officers on exercise of stock options or release of shares upon vesting of Performance Share and Restricted Stock Unit awards during the 2018 fiscal year.

    Option Awards  Stock Awards
Name  Number of
Shares
Acquired on
Exercise
  Value Realized
on Exercise
  Number of
Shares
Acquired on
Vesting
  Value
Realized
   on Vesting   

  Albert G. White, III

  -  -  3,447  $819,344

  Brian G. Andrews

  -  -  2,272  $541,917

  Daniel G. McBride

  10,310  $1,739,327  4,716  $1,122,290

  Holly R. Sheffield

  -  -  -  -

  Robert D. Auerbach, M.D.

  -  -  4,429  $1,044,707
 

 

   

 

   

 

   

 

   

 

 

 

   

 

   

 

   

 

   

 

  Robert S. Weiss

  127,812  $18,588,461  5,398  $1,315,007

  Carol R. Kaufman

  13,362  $1,979,476  4,327  $1,028,470

45 | Page   


Pension Benefits Table

Credited service and value of the accumulated benefits payable to our Named Executive Officers as of October 31, 20152018 under our Retirement Income Plan at the normal retirement age of 65 are as follows:

 

Name  Number of
Years of
Credited
Service
  Present
Value of
Accumulated
Benefit (1)
  Payments
During
Last Fiscal Year
 Number of Years of
Credited Service
 Present Value of
Accumulated Benefit (1)
 Payments During
Last Fiscal Year

Robert S. Weiss (2)

   37.75    $883,759     $-0- 

Albert G. White, III

 11.50 $215,732 -

Brian G. Andrews

 11.50 $127,430 -

Daniel G. McBride

   9.67    $202,531     $-0-  12.67 $290,032 -

Albert G. White, III

   8.5    $147,793     $-0- 

Carol R. Kaufman (2)

   20.07    $680,352     $-0- 

Greg W. Matz

   4.5    $121,186     $-0- 

Holly R. Sheffield

 - - -

Robert D. Auerbach, M.D.

 12.50 $352,186 -
   

 

 

 

   

 

 

 

   

 

 

 

Robert S. Weiss

 40.75 $932,032 -

Carol R. Kaufman

 23.07 $725,776 -
 (1)

Present value is calculated as of the October 31, 20152018 measurement date and is based on a 4.25%4.42% discount rate and the adjustedRP-2014 base mortality rates with projection scale MP-2015.MP-2018.

 

 (2)

Mr. Weiss and Ms. Kaufman are both over age 65 and therefore the present value of their individual accumulated benefits reflects the actual annual accrued benefit as of October 31, 2015.the end of the last fiscal year.

Narrative to Pension Benefits Table

OurThe Company’s Retirement Income Plan (the “Plan”) was adopted in December 1983. The majority of the Company’s U.S. employees who work at least 1,000 hours per year are covered by the Plan. For services performed after December 31, 1988, members are entitled to an annual retirement benefit equal to 0.60% of base annual compensation up to $10,000 and 1.20% of base annual compensation which exceeds $10,000 but is not in excess of the applicable annual maximum compensation permitted to be taken into account under Internal Revenue Service guidelines for each year of service. Furthermore, current active members are entitled to an annual retirement benefit equal to 1.20% of base annual compensation up to the applicable annual maximum compensation for each year of service in excess of 35 Plan Years of service. For service prior to January 1, 1989, members are entitled to an annual retirement benefit equal to 0.75% of base annual compensation up to the Social Security Wage Base in effect that year and 1.50% of base annual compensation in excess of the Social Security Wage Base for each year of service.

46


Credited service and value of the accumulated benefits payable as of October 31, 2015 under the Company’s Retirement Income Plan at the normal retirement age of 65 are basedBased on the current accumulated benefits for the Named Executive Officers. TheOfficers, the estimated annual benefits payable under this Plan upon retirement (at the normal retirement age of 65) are as follows:

 

Officer Estimated Annual
Benefits Payable (1)

Robert S. WeissAlbert G. White, III

 $74,47386,461

Brian G. Andrews

$110,461

Daniel G. McBride

 $71,40973,539

Albert G. White, IIIHolly R. Sheffield (2)

 $83,46154,175

Robert D. Auerbach, M.D.

$57,801

Robert S. Weiss

$89,470

Carol R. Kaufman

 $49,415

Greg W. Matz

$40,82158,935
 (1)

Mr. Weiss and Ms. Kaufman are both over age 65 and therefore the present value of their individual accumulated benefits reflects the actual annual accrued benefit as of October 31, 2015.the end of the last fiscal year.

 

(2)

As of fiscal year end, Ms. Sheffield is not yet vested in the retirement income plan.

46 | Page   


CEO Pay Ratio

 

The ratio of our CEO’s total annual compensation to the median annual total compensation of all employees excluding the CEO (the “CEO Pay Ratio”) is a reasonable estimate calculated in a manner consistent with Item 402(u) of RegulationS-K.

To determine the CEO Pay Ratio, we identified the median employee as of November 30, 2018 using base salary for all employees globally. We believe this measure most reasonably reflects the typical annual compensation of our employee population and was consistently applied for all employees.

Salary amounts were converted from local currency to USD for comparison purposes. Conversions were based on exchange rates at November 30, 2018. Once the median employee was identified, we calculated the median employee’s total annual compensation in accordance with the requirements of the Summary Compensation Table. Additionally, we annualized Mr. White’s compensation to reflect his compensation as if he had served as CEO for the full fiscal year.

As calculated, we determined:

The total compensation of our median-paid employee was $37,289.

The total compensation of Mr. White was $6,356,111 (as described above in theSummary Compensation Table and annualized to reflect compensation as CEO for the full 2018 fiscal year).

The ratio of CEO compensation to the median employee was 170 : 1.

47 | Page   


POTENTIAL PAYMENTS UPON TERMINATION OR CHANGE IN CONTROL

 

During the 2015 fiscal year, we had

We have agreements in place with our Named Executive Officers that govern the terms ofprovide for post-employment compensation in the event of a termination of their employment. All except theemployment terminates for specified reasons. If their employment terminates other than as provided for in their agreements, our standard severance policies for all employees will apply.

Mr. White and Dr. Auerbach each have individual agreements with Messrs. Weiss and Whitethe Company. All other agreements with the Named Executive Officers are subject to our Change in Control Severance Plan adopted onin May 21, 2007. The Change in Control Severance Plan provides severance benefits to certain of our key employees as recommended by management.if specific events occur. Agreements under this plan require prior approval of the Organization & Compensation Committee before they are offered to executives. The Change in Control Severance Planemployees and the plan is designed to be an “employee welfare benefit plan,” as defined in Section 3(1) of the Employee Retirement Income Security Act of 1974, as amended, or ERISA. At the time of this Proxy Statement, approximately 30 employees have agreements in place under this plan.

The following tables providetable provides estimated amounts payablepayments to each of theour Named Executive Officers assumingif termination of employment occurred on October 31, 2015. The tables assume that the value at termination of outstanding equity awards is $152.36, which was the fair market value of our common stock on October 31, 2015.2018. Upon termination of employment, all amounts due to the Named Executive Officers will be paid in monthly installments.

Robert S. Weiss

Our severance agreement with Mr. Weiss originally took effectAmounts Payable on Termination or a Change in August 1989. Under the agreement, Mr. Weiss would be entitled to a payment of up to 150% of his base salary in the event of his: (i) termination without cause, (ii) termination within 90 days of a change in control event, (iii) voluntary resignation with good reason, or (iv) separation after a request to relocate more than 50 miles from his current workplace. He would also be entitled to a prorated portion of his bonus under the applicable Incentive Payment Plan, or IPP, immediate vesting in his outstanding equity awards and his accrued benefits under the Retirement Income Plan, and continued coverage under our benefits program for up to 18 months.

The agreement with Mr. Weiss also provides for certain limited payments in the event that he voluntarily resigns his position without good reason. Mr. Weiss is required to provide a minimum of 45 days’ notice of his resignation to receive these payments. Upon proper notice, he can receive a percentage of his current annual base salary equal to the number of days’ notice provided divided by 360, to a maximum of 25%.Control

 

   Voluntary
Resignation
  Termination
without Cause or
Resignation for
Good Reason
  Termination after
Change of Control or
Separation After
Request to Relocate
  Retirement  Death 

Severance Payment(1)

  $218,750    $1,312,500    $875,000    $-0-    $1,312,500  

Incentive Payment Plan (2)

  $689,500    $689,500    $689,500    $689,500    $689,500  
Present Value of Accumulated Pension Benefits(3)  $802,352    $802,352    $802,352    $802,352    $802,352  

Equity Awards(4)

  $-0-    $22,046,588    $23,159,273    $18,911,628    $13,009,732  

Benefits (5)

  $-0-    $60,096    $40,064    $-0-    $1,040,000  
Total Payable on Separation  $1,710,602    $24,911,036    $25,566,190    $20,403,480    $16,854,084  
  

 

 

 
     

 

   Termination
without Cause (1)
 

Change in Control

(2)

 

        Death        

(3)

Albert G. White

 $5,957,853 $9,202,861 $7,076,697

Brian G. Andrews

 $999,690 $4,091,479 $1,293,280

Daniel G. McBride

 $5,231,089 $19,334,701 $6,327,810

Holly R. Sheffield

 $149,609 $2,828,996 $126,453

Robert D. Auerbach, M.D.

 $763,756 $1,276,551 $1,062,282
(1)Represents 25% of base salary for the 2015 fiscal year, the maximum amount allowed under the agreement, in the event of a voluntary resignation with a minimum of 45 days’ notice. Represents 150% of base salary for the 2015 fiscal year in the event of

Amounts payable on termination without cause or resignationrepresent severance (including benefits coverage under COBRA) in accordance with good reason. Represents 100% of base salary for the 2015 fiscal year upon termination within 90 days of a change in control or after a request to relocate.

48


Mr. Weiss’ severance agreement provides that if he is entitled to payment for any of the above reasons, his estate will receive the same payments in the event of his death. For purposes of estimating payments on death for the above table, the maximum payout of 150% of base salary has been used on the assumption that severance at this level was triggered immediately prior to his death and his estate is entitled to such paymentsstandard company policy, annual cash bonus earned under the agreement. No severance is automatically paid upon retirement or death under Mr. Weiss’ agreement or Company policy.

(2)Representsterms of the bonus award payable to Mr. Weiss under the 2015 Incentive Payment Plan, which was earned in full but not yet paid as of October 31, 2015. Upon voluntary resignation prior to the date that awards are paid under the 2015 IPP, this award would be forfeit.

(3)Mr. Weiss is fully vested in all benefits due under our Retirement Income Plan and will retain his accrued benefits after termination of employment. For further information on the Retirement Income Plan, see thePension Benefits Table on page 46. In the event of the executive’s death, benefits are payable to the estate.

(4)Represents the realizable value on the sale of the shares underlying equity awards which were outstanding, at October 31, 2015 at aexercisable stock price of $152.36; includes shares which were either vested at that date or would be subject to accelerated vesting upon a termination of employment. For purposes of estimatingoptions, and the value of performance shares which have not completed their performance period, it is assumed that target award levels will be achieved and paid accordingly, except in the event of a change in control which may trigger certain provisions to require payout at maximum achievement.

Upon termination without cause, voluntary resignation with good reason, termination after a change in control, or separation after a request to relocate, Mr. Weiss’ outstanding equity awards which were not vested will immediately become fully vested and exercisable.accumulated pension benefits. All unvested stock options and all restricted stock unit and performance share awards willwould be entirely forfeit on voluntary resignation without good reason regardless of notice provided.

In the event of retirement or death, outstanding equity awards will be treatedtermination in accordance with the terms of their associatedunderlying agreements. TerminationDr. Auerbach’s agreement includes a provision requiring 12 months’ notice prior to termination other than for retirement or upon death will result in payment of a pro rata portion of performance shares which have not completed their performance cycle basedCause and presented amounts assume that such notice was provided on the portion of the performance cycle completed at termination.October 31, 2017.

 

 For awards prior to the 2013 fiscal year, outstanding stock options that are unvested at the date of Mr. Weiss’ retirement or death will be forfeit. Vested options will remain outstanding and exercisable for a term of three years from the date of retirement or one year from the date of death. For awards made(2)

Amounts payable on change in fiscal 2013 and after, granted stock options will continue to vest after his date of retirement on the normal vesting dates indicated in the award agreement and will remain exercisable until their expiration date. If Mr. Weiss provides services to, or owns more than 5% of, a competitor after his retirement, he will forfeit the right to any remaining outstanding options.

(5)Mr. Weiss and his dependents will be eligible to continue participation in our insurance benefit plans until all severance benefits have been paid. Amounts reflect the value of benefits over the severance period or benefits payable under our life insurance policies in the event of Mr. Weiss’ death.

49


Albert G. White, III

Our Change in Control Agreement with Albert G. White, III originally took effect in January 2007 and was amended in September 2008. Under the agreement, Mr. White would be entitled to a payment of 100% of his base salary in the event of his termination within 90 days of a change in control event, provided he is not terminated for cause and does not voluntarily resign his position.

He would also be entitled to a prorated portion of his bonus under the applicable Incentive Payment Plan and continued coverage under the Company’s benefits program for up to 12 months from the date of termination in the event of termination for any of these reasons. As of the end of the last fiscal year, Mr. White is not retirement eligible.

   Termination
without
Cause
  Termination
after Change
of Control
  Death 

Severance Payment(1)

  $94,517    $850,000    $-0-  

Incentive Payment Plan (2)

  $184,195    $184,195    $184,195  
Present Value of Accumulated Pension
Benefits(3)
  $108,923    $108,923    $108,923  

Equity Awards(4)

  $3,071,072    $6,278,099    $4,410,773  

Benefits (5)

  $10,012    $37,137    $1,600,000  

Total Payable on Separation

          $3,468,719    $7,458,354    $6,303,891  
  

 

 

 
             

(1)Represents the severance due per Company policy for all employees in the event of termination without cause. Representscontrol represent 100% of base salary for each of Messrs. White and Andrews and 200% of base salary for Mr. McBride and Ms. Sheffield, in accordance with underlying agreements for these executives. Amounts also represent the 2015 fiscal year invalue of the event of termination without cause within 90 days of a change in control. No severance is due upon retirement or death.

(2)Represents theannual cash bonus award payable to Mr. Whiteearned under the 2015terms of the Incentive Payment Plan, which was earned in full but not yet paid as of October 31, 2015. Upon voluntary resignation prior to the date that awards are paid under the 2015 IPP, this award would be forfeit.

(3)Mr. White is fully vested in all benefits due under our Retirement Income Plan and will retain his accrued benefits after termination of employment. For further information on the Retirement Income Plan, see thePension Benefits Table on page 46. In the event of the executive’s death, benefits are payable to the estate.

(4)Represents the realizable value on the sale of the shares underlying equity awards which were outstanding at October 31, 2015 at a stock price of $152.36. Includes shares which were either vested at that date or would be subject to accelerated vesting upon a termination of employment. For purposes of estimating the value of outstanding stock options, restricted stock units and performance sharesshare awards which have not completed their performance period, it is assumed that target award levels will be achieved and paid accordingly, except in the event ofwould accelerate vesting on a change in control, which may trigger certain provisions to require payout at maximum achievement.and the value of accumulated pension benefits for these executives.

 

 Upon termination after a

Amounts payable on change in control or resignationfor Dr. Auerbach represent severance in accordance with good reason after a change in control, allstandard company policy, annual cash bonus earned under the terms of the Incentive Payment Plan, realizable value of outstanding, equityexercisable stock options and of performance share awards will immediately become fully vested. Terminationwhich would accelerate vesting on a change in control, will resultand the value of accumulated pension benefits. All unvested stock options and all restricted stock units held by Dr. Auerbach would be forfeit on termination in immediate paymentaccordance with the terms of performance shares at either target or maximum award levels depending on how much of the performance cycle has been completed.their underlying agreements.

 

 In the event of the executive’s termination without cause, retirement or death, outstanding equity awards will be treated in accordance with the terms of the associated award agreements. Performance share awards will be entirely forfeit on voluntary resignation or termination without cause. Termination for death, disability or retirement will result in payment of a pro rata portion of the performance shares based(3)

Amounts payable on the portiondeath of an executive represent the performance cycle completed at termination.

50


Generally, stock options that are unvested at the date of the holder’s termination will be forfeit. Vested options will remain outstanding and exercisable for a term of three months from the termination date in the case of a termination without cause, three years from the date of retirement or one year from the date of death. Outstanding unvested RSUs would be immediately forfeitedannual cash bonus earned under the terms of the associated award agreement upon any terminationIncentive Payment Plan, realizable value of employment.outstanding, exercisable stock options and of performance share awards which would prorate, the value of accumulated pension benefits, and amounts payable under life insurance policies held through the Company.

 

(5)
In the event that Mr. White’s employment is terminated, he and his dependents will be eligible to continue participation in our insurance benefit plans for up to 24 months after the date of termination. Amounts reflect the value of benefits over the severance period or benefits payable under our life insurance policies in the event of Mr. White’s death.48 | Page   


Other Named Executive Officers

We have Change in Control agreements in place under our Change in Control Severance Plan with eachRetirement of Messrs. Matz and McBride and Ms. Kaufman. The agreements with Mr. McBrideWeiss and Ms. Kaufman took effect in June 2007

Mr. Weiss and Ms. Kaufman each announced their retirement during the 2018 fiscal year. Per agreement with the Company, both Mr. Matz took effectWeiss and Ms. Kaufman remained employed with the Company through December 31, 2018, in June 2010. Theseanon-executive capacity, to assist with the executive transition. Mr. Weiss continues to serve on our Board of Directors and will be compensated as aNon-Executive Director starting January 1, 2019.

As of December 31, 2018, Mr. Weiss and Ms. Kaufman were eligible to receive the following amounts:

   Severance
Payment
 Cash Bonus Current Value
of Pension
 Outstanding
Equity Awards
 Total

Robert S. Weiss

  $932,400 $932,032 $20,680,303 $22,544,735

Carol R. Kaufman

 $711,811 $345,591 $725,776 $10,086,536 $11,869,534

Equity award value is based on a stock price of $254.50, which was the closing price of our stock on December 31, 2018. Provisions in the award agreements continue in effect untilfor outstanding stock option and restricted stock unit awards granted to Mr. Weiss and Ms. Kaufman allow for continued vesting after retirement, however if either Mr. Weiss or Ms. Kaufman provides services to, or owns more than 5% of, a competitor after their date of retirement, they will forfeit any remaining outstanding equity awards.

Outstanding performance share awards will be released at the executive’s employment terminates and all severance obligations have been fulfilled. Under the agreements, each of these executives would be entitled to a payment of 200%end of their respective performance periods. Awards granted to Mr. Weiss will be prorated based on the amount of the performance cycle completed at December 31, 2018 as per the underlying agreements. Performance share awards granted to Ms. Kaufman will be released in full with no proration in accordance with the terms of her Separation Agreement and Mutual Release disclosed on Form8-K in April 2018.

Ms. Kaufman will also receive a severance payment equivalent to 10 months of her 2018 base salary, in the event50% of either termination without cause or voluntary resignation with good reason within one year of a change in control event.

Each executive would also be entitled to a pro rata portion of their bonustarget annual cash incentive under the applicable2019 Incentive Payment Plan immediate vesting in their outstanding equity awards(based on 2018 salary and their currently accruedtarget cash incentive), and the value of 10 months of benefits under the Retirement Income Plan, continued coverage under our benefits program for up to 24 months, and payment of all salary and vacation which was accrued but unpaid at the date of termination.COBRA.

51


If employment terminates for these executives other than as provided for in their Change in Control agreements, the standard Company severance policies for all employees will apply. The following table provides information regarding the amounts payable to these executives in the event of a termination of employment. As of the end of the last fiscal year, Messrs. McBride and Matz were not retirement eligible.

    Termination
without Cause
   Termination or
Resignation
with Good
Reason After a
Change in
Control
   Death 

Daniel G. McBride

       

Severance Payment(1)

   $130,374     $990,000     $-0-  

Incentive Payment Plan(2)

   $273,389     $273,389     $273,389  

Present Value of Accumulated Pension Benefits(3)

   $152,899     $152,899     $152,899  

Equity Awards(4)

   $4,438,191     $8,433,577     $5,232,292  

Benefits(5)

   $20,487     $85,487     $1,600,000  

Total Payable on Separation

   $5,015,341     $9,935,352     $7,258,580  
   

 

 

 
        

Greg W. Matz

       

Severance Payment(1)

   $106,362     $850,000     $-0-  

Incentive Payment Plan(2)

   $184,195     $184,195     $184,195  

Present Value of Accumulated Pension Benefits(3)

   $81,342     $81,342     $81,342  

Equity Awards(4)

   $286,752     $5,053,992     $955,155  

Benefits(5)

   $13,355     $81,699     $1,600,000  

Total Payable on Separation

   $672,005     $6,251,228     $2,820,692  
   

 

 

 
                

    Termination
without Cause
   Termination or
Resignation
with Good
Reason After a
Change in
Control
   Retirement   Death 

Carol R. Kaufman

         

Severance Payment(1)

   $542,025     $908,000     $-0-     $-0-  

Incentive Payment Plan(2)

   $214,651     $214,651     $214,651     $214,651  
Present Value of Accumulated Pension Benefits(3)   $605,107     $605,107     $605,107     $605,107  

Equity Awards(4)

   $13,135,031     $17,280,530     $15,837,529     $14,022,833  

Benefits(5)

   $24,540     $37,532     $-0-     $1,170,000  

Total Payable on Separation

   $14,521,355     $19,045,821     $16,657,287     $16,012,591  
   

 

 

 
                     

52


(1)Represents the severance due per Company policy for employees in the event of other termination without cause. Represents 200% of base salary for the 2015 fiscal year in the event of termination without cause or resignation for good reason within one year of a change in control. No severance is due upon retirement or death of the executive.

 

(2)
Represents the bonus award payable under the 2015 Incentive Payment Plan which was earned in full but not yet paid as of October 31, 2015. Upon voluntary resignation prior to the date that awards are paid under the 2015 IPP, this award would be forfeit.49 | Page   

(3)Upon termination without cause, retirement, or death, executives who are vested in the Retirement Income Plan will retain accrued benefits. These benefits will be paid upon the executive’s application for retirement benefits in accordance with the terms of the Retirement Income Plan, or in the event of the executive’s death, benefits are payable to the estate. For further information on the Retirement Income Plan, see thePension Benefits Table on page 46.

Upon termination without cause or resignation with good reason after a change in control, all benefits due under our Retirement Income Plan will vest in full. If the terms of the Retirement Income Plan prevent immediate vesting the executive will receive substantially equivalent benefits.

As of October 31, 2015, Mr. Matz was not vested in the Retirement Income Plan.

(4)Represents the realizable value on the sale of the shares underlying equity awards which were outstanding at October 31, 2015 at a stock price of $152.36. Includes shares which were either vested at that date or would be subject to accelerated vesting upon a termination of employment. For purposes of estimating the value of performance shares which have not completed their performance period, it is assumed that target award levels will be achieved and paid accordingly, except in the event of a change in control which may trigger certain provisions to require payout at maximum achievement.

Upon termination after a change in control or resignation with good reason after a change in control, all outstanding equity awards will immediately become fully vested. Termination on a change in control will result in immediate payment of performance shares at either target or maximum award levels depending on how much of the performance cycle has been completed.

In the event of the executive’s termination without cause, retirement or death, outstanding equity awards will be treated in accordance with the terms of the associated award agreements. Performance share awards will be entirely forfeit on voluntary resignation or termination without cause. Termination for death, disability or retirement will result in payment of a pro rata portion of the performance shares based on the portion of the performance cycle completed at termination.

Generally, stock options that are unvested at the date of the holder’s termination will be forfeit. Vested options will remain outstanding and exercisable for a term of three months from the termination date in the case of a termination without cause, three years from the date of retirement or one year from the date of death. Outstanding unvested RSUs would be immediately forfeited under the terms of the associated award agreement upon any termination of employment.

For Ms. Kaufman’s awards in fiscal 2013 and after, her stock option and RSU awards will continue to vest after her date of retirement based on the vesting schedule provided in the award agreements. In the event of termination of Ms. Kaufman’s employment without cause, or by reason of her death, the outstanding unexerciseable stock options and unreleased RSUs would be subject to forfeiture. Additionally, if Ms. Kaufman provides services to, or owns more than 5% of, a competitor after her date of retirement, she will forfeit any remaining outstanding awards.

(5)Upon termination after a change in control or resignation with good reason after a change in control, the executive and their dependents will be eligible to continue participation in our insurance benefit plans for up to 24 months after the date of termination. Amounts reflect the value of benefits over the severance period or benefits payable under our life insurance policies in the event of the executive’s death.

53


DIRECTOR COMPENSATION

 

The Compensation Committee reviews and recommends compensation amounts for our Non-Employee Directors, and the full Board has responsibility for the approval of compensation amounts based on these recommendations. This compensation applies only to our Non-Employee Directors. Members of the Board who are also our employees receive no additional compensation for their service as directors.

Directors of a publicly traded company have substantial responsibilities and time commitments, and with ongoing changes in corporate governance standards, highly qualified and experienced directors are in high demand; therefore, we seek to provide suitable economic incentives for our directors and to compensate them appropriately for their continued performance, increased responsibilities, and dedication. This compensation applies only to ourNon-Employee Directors. Members of the Board who are also our employees receive no additional compensation for their service as directors.

The Organization & Compensation Committee takesreviews and recommends compensation amounts for ourNon-Employee Directors, and the full Board approves compensation based on these factors into account in making recommendations to the Board with regard to changes in the Non-Employee Director compensation program.

recommendations. The Organization & Compensation Committee also receives an analysisconsiders director responsibilities, compensation practices of our peer companies, and recommendations from its independent compensation consultant regardingin makingNon-Employee Director compensation of the Non-Employee Directors. The Compensation Committee reviews and analyzes this information in determining whether to recommend changesprogram recommendations to the Board. The Board sets total Non-Employee Director compensation at levels it considers appropriate given the competitive market for qualified directors, peer group compensation of directors, and the time commitment and responsibilities expected of our Non-Employee Directors. Compensation levels are reviewed at least annually and modified as the Board considers necessary or appropriate.

Components of Director Compensation

Cash Compensation

OurNon-Employee Directors receive cash compensation in the form of an annual stipend for their service. Additionally,service, and directors who also serve as the Chair of a committee of the Board receive an additional annual stipend in recognition of this additional responsibility.

TheNon-Employee Directors also receive payment for each meeting attended, as well as compensation for time spent on company business, and reimbursement for one day of travel in connection with meetings. These payments are as follows:

 

Annual Retainer for service as a Director:Retainer:

Directors

  $30,000 

Non-ExecutiveLead Director

  $40,000 

Chairman of the Board

  

$125,000

 

 

CashAnnual Retainer for serviceService as a Committee Chair:

 

Audit Committee

  $17,500 

Corporate Governance and Nominating Committee

  $10,000 

Organization and Compensation Committee

  $12,000 

Science and Technology Committee

$10,000

Attendance at Meetings of the Board:

  $10,0001,000 – $2,000 (per meeting)     
 

Attendance at Meetings of the Board (per meeting):

 

In-Person Meetings & Telephonic Meetings lasting more than 2 hoursAdditional Cash Compensation for Service:

 $2,000

Telephonic meetings lasting less than 2 hours

$1,000

54


Other Compensation:

 

Travel Days (one per set of scheduled meetings)

  $2,000 

Other time spent on Company business (per hour)

  $250 

Directors appointed to, or resigning from, the Boardmid-year are entitled to a prorated portion of the annual stipend based on the number of months of service provided for the fiscal year in which they enter or leave service.

Equity Compensation

TheNon-Employee Directors are also participate in the 2006 Directors’ Plan, which provides foreligible to receive annual equity awards. These awards may be made in the form of restricted stock awards, restricted stock units, stock options, or any combination thereof. The Board believes that Non-Employee Director compensation should contain a significant equity component toNon-Employee Director compensation serves to align director and stockholder interests.

50 | Page   


Grant terms, including grant dates, award amounts, form of awards, and vesting criteria for these annual equity awards are set by the terms of the 2006 Directors’ Plan.

The 2006 Directors’ Plan, which was originally approved by stockholders on March 21, 2006 and was amended and restated in March 2009 and in March 2011. As currently in force, theThe 2006 Directors’ Plan provides for two equity awards to each Non-Employee Director to be made annuallywas most recently amended in November in the form of one grant of stock options and one grant of restricted shares. Awards under theMarch 2018.

The 2006 Directors’ Plan, as most recently amended, provides for a grant to eachNon-Employee Director of Restricted Stock Units (“RSUs”) with a total grant date value of $270,000 (or $283,500 and $297,000 in the case of the Lead Director and Chairman, respectively). These grants are currently set as follows:

  Equity Awards:Target Grant
Date Fair
Value(1)
Annual Grant
Date
Vesting /
Restriction
Period

Stock Options (Directors)

$135,000November 1st1 year

Lead Director & Chairman of the Board

$148,500

November 1st

1 year

Restricted Stock (Directors)

$135,000November 15th1 year

Chairman of the Board

$148,500November 15th1 year

(1) Grant Date Fair Value of equity awards represents a target compensation amountawarded annually and is used to calculate the actual number of options and restricted shares received. Amounts are divided by the approximate fair value based on the closing price of our stock on the date of grant and rounded to the nearest whole number to set the number of options or restricted shares. Actual compensation may be slightly above or below the amount shown depending on rounding.

All awards are designed to vest in full on the first anniversary of the date of grant. UponIf a director ends their term of service prior to the vesting all stock options become exercisable and restrictions prohibiting sale are removed fromdate, the grantnumber of restricted stock. Stock options are granted with an exercise price equalshares released under the award will be prorated according to 100%the amount of the fair market valueyear actually served and the prorated amount of our common stockshares will be released on the date of grant.original vesting date.

The 2006 Directors’ Plan also provides that, uponon appointment to the Board, newNon-Employee Directors will receive a grant of stock options and restricted stockRSUs as specified in the terms of the 2006 Directors’ Plan,above, prorated for the number of months of service remaining inuntil the fiscal year in which they were appointed.date of the next Annual Meeting. Additional awards under the 2006 Directors’ Plan may be made at the Board’s discretion.

When a Non-Employee Director ceases to serve on the Board, unless they are terminated for cause, restrictions are immediately lifted on any outstanding restricted stock awards and unvested stock options become immediately vested. Outstanding stock options remain exercisable for three years from the date of cessation of service.

Stock Ownership Requirements

 

55


Stock Ownership Requirements

The Board has adopted stock ownership requirements forNon-Employee Directors. The Board considersadopted this equity ownership requirement to strengthen the relationship between the Directorsdirector and stockholder interests.

interests, and under the current requirementsNon-EmployeeDirectors must hold Cooper common stock valued at five times their annual retainer.

Shares held must be free of restrictions to meet the requirements. Untilownership requirements, and until the required ownership values are met theNon-Employee Directors must retain 100% of shares received on vesting of restricted stock andawards or on exercise of stock options. AsAll of the date of this Proxy Statement, all ofNon-Employee Directors were in compliance with the Non-Employee Directors hold stock equal to, or in excess of, the minimum level of required ownership.applicable ownership requirements during fiscal 2018.

Director Compensation Table

The following table sets forth the total cash and equity compensation paid to theNon-Employee Directors for their service on the Board and its committees during the 20152018 fiscal year. At present, theNon-Employee Directors are not eligible to participate in our pension programs and no deferred compensation ornon-equity incentive plans are available to theNon-Employee Directors.

 

Name  

Fees Earned

or Paid in

Cash (1)

   

Stock Awards

(2)(3)

   

Option

Awards

(2)(4)

   Total   Fees Earned or
Paid in Cash (1)
   Stock Awards (2)   Other
Compensation
   Total 

A. Thomas Bender

   $190,000     $148,462     $148,502     $486,964     $193,500    $297,080    $993    $491,572 

Allan E. Rubenstein, M.D.

   $106,000     $135,056     $148,502     $389,558     $95,000    $283,469    -    $378,469 

Colleen E. Jay

   $92,000    $270,094    -    $362,094 

Michael H. Kalkstein

   $100,000     $135,056     $135,010     $370,067     $110,000    $270,094    -    $380,094 

William A. Kozy

   $87,500    $270,094    -    $357,594 

Jody S. Lindell

   $87,500     $135,056     $135,010     $357,567     $108,000    $270,094    -    $378,094 

Gary S. Petersmeyer

   $81,000     $135,056     $135,010     $351,067     $94,000    $270,094    -    $364,094 

Steven Rosenberg

   $69,250     $135,056     $135,010     $339,317  

Stanley Zinberg, M.D.

   $73,000     $135,056     $135,010     $343,067     

 

$80,000

 

 

 

   

 

$270,094

 

 

 

   

 

-

 

 

 

   

 

$350,094

 

 

 

 (1)

Fees earned represent the total feesall cash compensation paid to theNon-Employee Directors for their service during the most recent fiscal year, including: (i) annual retainers paid to each Non-Employee Director for their service on the Board; (ii) annual retainers paid to Committee Chairs; (iii) fees for all Board and committee meetings attended during the designated fiscal year; and (iv) compensation for travel days and other time spent substantially on Company business.year.

 

 (2)

Represents the aggregate grant date fair value of restricted stock units granted on November 15, 2017 under the 2006 Directors’ Plan. The amounts shown are thereflect compensation costs recognized in our

51 | Page   


financial statements for fiscal 2015 in accordance with ASC 718. For a discussion of valuation assumptions, see Note 9,Stock Plans,, in our Notes to Consolidated Financial Statements included in our Annual Report onForm 10-K for the year ended October 31, 2015.2018.

(3)Represents the aggregate grant date fair value of restricted stock awards granted on November 15, 2014 under the 2006 Directors’ Plan. Each director received an award providing the right to purchase 816 restricted shares, or 897 restricted shares in the case of the Chairman of the Board, of our common stock at par value of $0.10 per share.

At October 31, 2015, each Non-Employee Director held 816 shares of our common stock subject to restrictions, inclusive of the shares in the Director Compensation Table, with the exception of Mr. Bender who held 897Each director received an award providing the right to receive 1,151 shares on the satisfaction of vesting criteria. Dr. Rubenstein, as Lead Director, received an award providing the right to receive 1,208 shares and Mr. Bender, as Chairman of the Board, received an award providing the right to receive 1,266 shares.

(4)Represents the aggregate grant date fair value of stock options granted on November 1, 2014 under the 2006 Directors’ Plan. Each Non-Employee Director was granted an option to purchase 2,782 shares of our common stock, or 3,060 shares for Mr. Bender and Dr. Rubenstein. These options have an exercise price equal to the fair market value of our common stock on the date of grant, which was $165.51 per share.

At October 31, 2018, eachNon-Employee Director also had the following stock options outstanding from awards in prior years:

56


The Non-Employee Directors had the following stock options outstanding at October 31, 2015:

 

Name 

Outstanding

 Stock Options

    

A. Thomas Bender

 48,90014,950

Allan E. Rubenstein, M.D.

 22,100-

  Colleen E. Jay

1,766

Michael H. Kalkstein

 36,59126,591

  William A. Kozy

1,766

Jody S. Lindell

 49,09134,091

Gary S. Petersmeyer

 12,8415,864

Steven Rosenberg  Stanley Zinberg, M.D.

 20,091

64,091

Stanley Zinberg, M.D.

46,59152 | Page   

57


PROPOSAL 1 — ELECTION OF DIRECTORS

 

Our Bylaws require that we have a minimum of six and maximum of eleven directors serving on the Board. The Board sets the size of the board annually prior to the Annual Meeting. The BoardMeeting and has fixed the number of directors to be elected at the 2019 Annual Meeting at seven.nine.

The names of the nominees presented for election as directors at the Annual Meeting are listed below, along with information regarding when they joined the Board, their present principal occupation, recent business experience, and their service on other companies’ boards of directors.

Each nominee, if elected, will serve as a director until the next Annual Meeting andor until his or her successor is duly elected and qualified. All of the nominees listed below have given their consent to be named as nominees for election and have indicated their intention to serve if they are elected. The Board does not anticipate that any of the nominees will be unable to serve as a director, but in the event that a nominee is unable to serve, the Board may either propose an alternate nominee or elect to reduce the size of the Board. If an alternative nominee is proposed, proxies will be voted for the alternative nominee.

Dr. Stanley Zinberg has indicated his intention to retire and will not be standing forre-election at the 2019 Annual Meeting.

The Nominees

Each nominee listed below currently serves on the Board and there are no family relationships between any of the nominees, or between the nominees and any of our officers.

 

A. THOMAS BENDER  AGE: 7679  JOINED THE BOARD: 1994

INDEPENDENT DIRECTOR,DIRECTOR; CHAIRMAN OF THE BOARD

Business Experience: Mr. Bender has served on our Board since 1994 and was elected Chairman in July 2002. He also served as our President and Chief Executive Officer from May 1995 until his retirement in October 2007. He previously served as President of CooperVision, our contact lens subsidiary, from June 1991 to December 2004. Between 1966 and June 1991, Mr. Bender held a variety of management positions at Allergan, Inc., a manufacturer of eye and skin care products, including Corporate Senior Vice President, and President and Chief Operating Officer of Herbert Laboratories, Allergan’s dermatology division.

Other Directorships and Memberships: Mr. Bender serves on the board of directors of Allegro Ophthalmics LLC, a private ophthalmic company focused on pharmaceutical treatment of eye disease. Mr. Bender currently serves on the compensation and audit committees at Allegro. He also serves on the board of Mission Hospital Foundation in Mission Viejo, CA.

Qualifications to Serve: Mr. Bender served as our CEO for 13 years, providing him with unique understanding of our operations and business, which is valuable to the Board, and his 10 year15-year tenure as Chairman of the Board has provided leadership continuity and stability to our Company. In addition to his history with the Company, Mr. Bender has over 4550 years of experience in the pharmaceutical industry, providing him with a strong background and knowledge that assists the Board in analysis of our peer companies, markets, and industry. Additionally, Mr. Bender has served on the boards of other public and private medical device companies, including service as chairman of the compensation and organization committees for several medical device companies, allowing him to gain insight and perspective regarding business and regulatory issues facing our industry. Additionally, Mr. Bender has served as chairman of the compensation and organization committees for several medical device companies. The Corporate Governance and Nominating Committee considers these factors important to their decision to recommend Mr. Bender forre-election to the Board.

 

58

53 | Page   


 COLLEEN E. JAY                    AGE: 56JOINED THE BOARD: 2016    

INDEPENDENT DIRECTOR

Business Experience: Ms. Jay served as a Global Division President for Procter and Gamble as a member of the Top 30 Global Executive Committee until her retirement in October 2017. Her most recent operational assignment was President, Global Beauty Specialty Business at Procter & Gamble from 2015 where she was responsible for the Wella Professional Salon, Cosmetics, Retail Hair Color, and Fragrance businesses, and the successful divestiture of them. Prior to taking leadership of the Beauty Specialty Business, Ms. Jay led the Global Retail Hair Care and Color division of Procter & Gamble from 2012 to 2015 and the Global Female Beauty division from 2010 to 2012. She also served as Vice President & General Manager, Greater China Feminine Care, Personal Cleansing, Oral Care & Entire China Marketing Function, based in Guangzhou, China, from 2006 to 2009, where she was responsible for businesses with a combined value of over $1 Billion. She has worked in various positions with Procter & Gamble since July 1985 and has led operational units in the United States, Canada, China, and Switzerland (including leading global businesses) during the course of her career. Ms. Jay also volunteers at Catalyst, Inc., anon-profit organization dedicated to improving workplace inclusion for women.

Other Directorships and Memberships: Ms. Jay serves on the board of Treasury Wine Estates (ASX:TWE), a publicly traded company making and selling wine for the global market.

Qualifications to Serve: Ms. Jay has almost 35 years of experience within the consumer goods industry, including over 15 years of experience as a senior executive. She has first-hand experience with leading international business operations, including direct responsibility for operations in China and Europe, giving her a strong background in international business, including sales and marketing, regulatory challenges, and cultural differences in various markets. She brings a global perspective to the Board that assists with understanding and analyzing our market and global expansion. The Corporate Governance and Nominating Committee considers these factors important to their decision to recommend Ms. Jay forre-election to the Board.

MICHAEL H. KALKSTEIN  AGE: 7376  JOINED THE BOARD: 1992

INDEPENDENT DIRECTOR

Business Experience: Mr. Kalkstein was a partner at Dechert LLP, an international law firm, from June 2003 through June 2007, and wasCo-chair of the firm’s Intellectual Property Practice Group. He also served as the Managing Partner of Dechert’s Palo Alto office from June 2003 through December 2005. As of June 30, 2007, he hasHe retired from active practice in June 2007 and continues to be “Of Counsel” to Dechert at its Mountain View, CA office. Previously, from September 1999 through May 2003, he was a partner at Oppenheimer, Wolff & Donnelly, LLP, an international law firm, and a member of its Policy and Technologies Committees.

Other Directorships and Memberships: Mr. Kalkstein currently serves as a director on the board of the Merola Opera Program, anon-profit arts organization affiliated with the San Francisco Opera, and sits on its finance and governance committees and on San Francisco Opera’s Medallion Society committee. He also serves as Bailli of the Hillsborough Bailliage of the Chalne des Rôtisseurs, a non-profit food and wine organization. Previously he served as a member of the Board of Trustees of Opera San Jose from 1984 to October 2010, serving as its President from 1992 to 1994. He was a member of the Alliance of CEOs from 2001 to June 2007 and was a member of the board of directors of the Law Foundation of Silicon Valley from 2002 to June 2007. Until January 2007, he also served as a director of the Northern California Chapter of the National Association of Corporate Directors.

Qualifications to Serve: As a licensed attorney with experience in intellectual property law, Mr. Kalkstein brings the Board insight and perspective on the legal and regulatory issues that face our business and industry. Mr. Kalkstein also brings

54 | Page   


management experience, having served as a managing partner for a key office of an international law firm. His continued connections with the legal community, as well as his involvement with groups such as the Alliance of CEOs and National Association of Corporate Directors, and participation in NYSE/Euronext Corporate Board Member programs, provides the Board with insight into current issues facing both business executives and independent board members. Additionally, through his long-term service on our Board, Mr. Kalkstein has gained a good working knowledge and understanding of our business which provides efficiency and continuity for our Board. The Corporate Governance and Nominating Committee considers these factors important to their decision to recommend Mr. Kalkstein forre-election to the Board.

 

 WILLIAM A. KOZY                    AGE: 67JOINED THE BOARD: 2016    

INDEPENDENT DIRECTOR

Business Experience:Mr. Kozy served as the Chief Operating Officer of Becton Dickinson (NYSE: BDX) from 2012 until his retirement in 2016, and as its Executive Vice President from 2006 until 2016. He also served as a member of the corporate Leadership Team for Becton Dickinson and in various executive roles since 1988, including Senior Vice President of Company Operations from 1998 until 2002, President of BD Diagnostics from 2002 through 2006, President of the BD Biosciences segment from 2006 to 2009 and head of BD Medical from 2009 through 2011.

Other Directorships and mentorships: Mr. Kozy is a member of the board of directors of LivaNova PLC (NASDAQ:LIVN), a publicly traded medical device company focused on neurological and cardiovascular medicine. He also serves on the nominating and corporate governance committee. He also serves as a senior advisor to McKinsey & Company, a global management firm, with a focus on mergers and acquisitions, and he is an active benefactor and volunteer for the Karen Ann Quinlan Hospice organization and the Immokalee Child Care Center (Naples, Florida).

Qualification to serve:Mr. Kozy has over 40 years of experience in the medical technology industry. Prior to serving as Chief Operating Officer for Becton Dickinson, key business worldwide leadership assignments included responsibilities for the Biosciences, Diagnostic, and Medical segments of the company. He is the only leader in Becton Dickinson history to have led all three segments of the company in his career. He also brings corporate experience leadership from Becton Dickinson in other areas: innovation systems, company manufacturing, and Becton Dickinson’s first ERP implementation. Overall, Mr. Kozy brings depth of general management experience in business strategy, operations, and financial performance to this role. Additionally, he has significant experience in merger and acquisition activity, with integration as an area of executive focus. The Corporate Governance and Nominating Committee considers these factors important to their decision to recommend Mr. Kozy forre-election to the Board.

JODY S. LINDELL  AGE: 6467  JOINED THE BOARD: 2006

INDEPENDENT DIRECTOR,DIRECTOR; AUDIT COMMITTEE FINANCIAL EXPERT

Business Experience: Ms. Lindell is President and Chief Executive Officer of S.G. Management, Inc., an asset management company she has headed since 2000. Until May 2000, Ms. Lindell was a partner with KPMG LLP where she served asPartner-In-Charge of the Industrial Markets and Healthcare and Life Sciences practices for the Western Area. Ms. Lindell is also a Certified Public Accountant (inactive).

Other Directorships and Memberships: Through September 2007, she served as a director and on the audit and director’s loan committees for First Republic Bank, a publicly traded financial institution. First Republic Bank

55 | Page   


was acquired in 2007, underwent a management led buyout inmid-2010 and again became publicly traded (NYSE: FRC) in December 2010. Ms. Lindell continuescontinued to serve as a director chairs the audit committee and serves on the director’s loan committee for First Republic Bank. She also currently serves on the board of directors and the audit, nominating and corporate governance, and compensation committees of PDL BioPharma (NasdaqGS: PDLI).Bank through May 2017.

59


Qualifications to Serve: Ms. Lindell’s experience as a partner with KPMG and her accounting background bring valuable knowledge of finance and accounting regulations to our Board and Audit Committee. She is qualified as an Audit Committee Financial Expert under the SEC rules, and has experience with the review and analysis of financial statements and operational risk, both through her accounting background and her experience with public company audit committees. Ms. Lindell has also gained a good working knowledge and understanding of our business and operations during her term of service on the Board, which provides efficiency and continuity. The Corporate Governance and Nominating Committee considers these factors important to their decision to recommend Ms. Lindell forre-election to the Board.

 

GARY S. PETERSMEYER  AGE: 6871  JOINED THE BOARD: 2013

INDEPENDENT DIRECTOR

Business Experience: Mr. Petersmeyer currently serves as a consultant to companies in the pharmaceutical and medical device industries. Most recently heco-founded Aesthetic Sciences Corporation in 2004 and served as the Chief Executive Officer and Chairman until December 2010. Prior to that he served as President and Chief Operating Officer of Pherin Pharmaceuticals, Inc. from 2000 to 2001 and as President and Chief Operating Officer of Collagen Corporation, Inc. from 1995 to 2000.1997 and as Chief Executive Officer from 1997 to 1999. From 1976 to 2000 he served in various management positions for pharmaceutical and medical device companies.

Other Directorships and Memberships: Mr. Petersmeyer serves as a director and member of the compensation and audit committees of Omnicell, Inc. (NASDAQ: OMCL). He also served as director and chairman of the board of Cardica, Inc. (NASDAQ: CRDC) through November 2015. He has previously served on the boards of Visx Incorporated and Roxro Pharmaceuticals prior to their acquisitions. He also serves as chairman of the board for Positive Coaching Alliance, anon-profit organization dedicated to improving youth sports.

Qualifications to Serve: Mr. Petersmeyer has served as the CEO or President of four companies in the medical device and pharmaceuticals industry and has over 35 years of industry experience in leadership positions. He has extensive knowledge and experience in global markets, including the United States, Asia, and Europe. His expertise includes financial, research and regulatory strategy, and business development with an emphasis on growth, new product lines, and leadership development. He has extensive experience as a director and has experience with service on a compensation committee. The Corporate Governance and Nominating Committee considers these factors important to their decision to recommend Mr. Petersmeyer forre-election to the Board.

 

ALLAN E. RUBENSTEIN, M.D.  AGE: 7174  JOINED THE BOARD: 1992

INDEPENDENT DIRECTOR,DIRECTOR; VICE CHAIRMAN AND LEAD DIRECTOR

Business Experience: Dr. Rubenstein has served as our Vice Chairman and Lead Director since July 2002, and previously served as Chairman of the Board from July 1994 through July 2002. He served as Acting Chairman of the Board from April 1993 through June 1994. He is also Clinical Professor of Neurology and Pediatrics at New York University Langone Medical Center. Formerly, he was Chief Executive Officer of NexGenix Pharmaceuticals in NYC from 2003 to 2011.

60


Other Directorships and Memberships: He currently serves as chairman of the scientific advisory board for CalAsiaPlex Pharmaceuticals since September 2012.2017. He is also a trustee of the Connecticut River Museum in Essex,

56 | Page   


Connecticut. Previously, he served as a director of BioClinica (NASDAQ: BIOC), a specialty clinical trials company, from 2000 to 2003. He is also Medical Director Emeritus of the Children’s Tumor Foundation and a consultant to the National Institutes of Health, the U.S. Food and Drug Administration and the U.S. Department of Defense, where he served as Chair of the Army Neurofibromatosis Research Program Integration Panel in 2001.

Qualifications to Serve: As a leading academic scientist and clinician, Dr. Rubenstein provides valuable insight into human physiology and medical practices and techniques that aid the Board in making determinations regarding new technologies to develop or acquire. He also brings experience with clinical trials and a knowledge and understanding of the development of medical devices to his service. His experience as the head of a medical technology company provides perspective on operations of a medical device company. Additionally, through his long-term service on our Board, Dr. Rubenstein has gained a good working knowledge and understanding of our business and operations, which provides efficiency and continuity. The Corporate Governance and Nominating Committee considers these factors important to their decision to recommend Dr. Rubenstein forre-election to the Board.

 

ROBERT S. WEISS  AGE: 6972  JOINED THE BOARD: 1996

NON-INDEPENDENT DIRECTOR, DIRECTOR; FORMER CHIEF EXECUTIVE OFFICER

Business Experience: Mr. Weiss has served as our President sincefrom March 2008 and as our Chief Executive Officer sincefrom November 2007. He also served as President of CooperVision, our contact lens subsidiary, from March 2007 to February 2008. He previously served as our Chief Operating Officer from January 2005 to October 2007 and as Executive Vice President from October 1995 to October 2007. He served as our Chief Financial Officer from September 1989 to January 2005. He served as our Treasurer from 1989 to March 2002. Since joining us in 1977, he has held a number of finance positions both with us and Cooper Laboratories, Inc. (our former parent).

Other Directorships and Memberships: Mr. Weiss is also a director of Accuray Incorporated (Nasdaq: ARAY), a company that develops, manufactures, and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. He serves on its nominating and governance committee and on its audit committee. He is also a member of the Board of Trustees of the University of Scranton in Pennsylvania and serves on its finance, advancement, and audit committees.

Qualifications to Serve: As our currentformer Chief Executive Officer and with over 40 years of experience with Cooper, Mr. Weiss provides a key connection between the senior executives and our Board, enabling oversight of our operations with the benefit of management’spersonal perspective on our business. He has day to daybusiness, awareness of our businesspeers and our industry, and an understanding of the strategic visiongoals for our Company that areis important to the Board in making decisions regarding the direction of our business. He provides leadership, extensive knowledge of our Company, and business, operating, and policy experience to our Board. The Corporate Governance and Nominating Committee considers these factors important to their decision to recommend Mr. Weiss forre-election to the Board.

 

61


 STANLEY ZINBERG, M.D., M.S.
 ALBERT G. WHITE III  AGE: 8149  JOINED THE BOARD: 19972018    

INDEPENDENTPRESIDENT & CHIEF EXECUTIVE OFFICER; DIRECTOR

Business Experience: Dr. Zinberg is a retired obstetrician-gynecologist whoMr. White has served as DeputyPresident & Chief Executive Officer, and as a member of our Board of Directors, since May 2018. Previously, he served as Chief Financial Officer from November 2016 until his appointment as CEO and he also served as Executive Vice President and Vice PresidentChief Strategy Officer, positions he held from December 2015 and July 2011, respectively. From August 2015 to May 2018, Mr. White also directed our women’s

57 | Page   


healthcare business and served as Chief Executive Officer of Practice Activities forCooper Medical, Inc., the American College of Obstetricians and Gynecologists (ACOG) in Washington, D.C. from 1993 through his retirement in December 2007. From 1981 until 1993parent company to CooperSurgical, Inc. Previously, he served as Chief, ObstetricsVice President, Investor Relations from November 2007 through March 2013 and Gynecology,as Vice President and Director, OB-GYN Residency Program at NY Downtown Hospital, whereTreasurer from 1990April 2006 through 1992 he also served as President ofDecember 2012. Prior to joining the Medical Staff andCompany, Mr. White was a memberDirector with KeyBanc Capital Markets for three years and held a number of leadership positions within KeyBank National Association over the Board of Trustees until June 2013. He is certified by the American Board of Obstetrics and Gynecology and is a member of the faculty of the Departments of Obstetrics and Gynecology at New York University School of Medicine, the Cornell University College of Medicine and the Georgetown University School of Medicine. He is the author of numerous editorials, scientific papers and book chapters in the field of women’s healthcare. In addition, Dr. Zinberg obtained a Master’s Degree in Health Administration, with an emphasis on not-for-profit finance, in 1990 from the Graduate School of Public Administration of New York University.prior eight years.

Other Directorships and Memberships: Currently, Dr. Zinberg is a director on the Peconic Bay Medical Center board and serves on its finance committee, investment committee, and strategic planning committee. He is also a director on the Peconic Bay Medical Center Foundation board. He is also President-Elect of the American Gynecologic Club and will assume the presidency in 2017. Additionally, he serves as a director and chairman of the board of the Westhampton Beach Performing Arts Center and a member of the Southampton Town Board of Ethics in Southampton, NY.Mr. White does not hold any external directorships.

Qualifications to Serve: Dr. Zinberg’s extensive background in obstetrics and gynecologyAs our current Chief Executive Officer, Mr. White provides the Board with crucial insight into the practical application of our women’s healthcare productsa direct connection to senior management and the needsbenefit of medical practitioners. His experience as a leader of ACOG and continued involvement in the medical community providesmanagement’s perspective on current medical practices and procedures which aid the Board in evaluating new technologies, products and markets as our business continues to expand. Additionally, through his long-term service on our Board, Dr. Zinberg has gained a good working knowledge and understanding of our business and operations whichimmediate strategic goals. He provides efficiencyleadership, extensive knowledge of our Company, and continuity.insight on the day to day operation of the business. The Corporate Governance and Nominating Committee considers these factors important to their decision to recommend Dr. ZinbergMr. White forre-election to the Board.

 

 

The Board of Directors unanimously recommends that you vote FOR each of the nominees for director presented above.

 

 

Nominees for director will be elected by a majority of the votes cast in person or by proxy at the Annual Meeting. The number of votes cast FOR a nominee must exceed the number of votes cast AGAINST. Abstentions and brokernon-votes will not be counted as votes cast either for or against the nominee and therefore will not affect the outcome of the director elections.

 

62
58 | Page   


PROPOSAL 2 — RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

The Audit Committee has appointed the firm of KPMG LLP to act as our independent registered public accounting firm and to audit our consolidated financial statements for the fiscal year ending October 31, 2016.2019. This appointment will continue at the pleasure of the Audit Committee and is presented to the stockholders for ratification as a matter of good governance. In the event that this appointment is not ratified by our stockholders, the Audit Committee will consider that fact when it selects our independent auditor for the following fiscal year.

KPMG LLP has served as our independent registered public accounting firm since our incorporation in 1980, and one or more representatives of KPMG LLP will be present at the Annual Meeting. These representatives will be provided an opportunity to make a statement at the Annual Meeting, if they desire to do so, and will be available to respond to appropriate questions from stockholders.

 

 

The Board of Directors unanimously recommends that you vote FOR the ratification of KPMG LLP as our independent registered public accounting firm.

 

 

The proposal to ratify the selection of KPMG LLP as our independent registered public accounting firm for the 20162019 fiscal year requires an affirmative vote of the majority of the shares represented in person or by proxy at the Annual Meeting and entitled to vote on the proposal. Abstentions will have the same practical effect as votes against this proposal. Brokernon-votes will have no effect in determining the outcome of this proposal.

 

63
59 | Page   


PROPOSAL 3 APPROVAL OF THE AMENDMENT AND RESTATEMENT OF THE 2007 LONG-TERM INCENTIVE2019 EMPLOYEE STOCK PURCHASE PLAN

 

GeneralOverview

The 2007 Long-Term IncentiveCompany is seeking to have stockholders approve The Cooper Companies, Inc. 2019 Employee Stock Purchase Plan or the 2007 Plan,(the “ESPP”), described below. The ESPP was originally approvedadopted by our Board on December 11, 2018 and would become effective following stockholders on March 20, 2007 and was subsequently amended and restatedapproval at the 2019 Annual Meeting.

The ESPP would initially authorize the issuance of 1,000,000 shares of common stock, which represents approximately 2% of our outstanding shares of common stock as of January 22, 2019. The maximum aggregate number of shares of our common stock issuable under the ESPP per three month Offering Period will be 50,000.

Purpose

The purposes of the ESPP are (i) to assist eligible employees in March 2009 and March 2011. Under the 2007 Plan, as amended and restated, equity awards may beacquiring a stock ownership interest in the form of stock options, restricted stock, deferred stock and/or restricted stock units, long-term performance awards,Company pursuant to a plan intended, for those eligible employees subject to U.S. federal income tax, to qualify as an “employee stock purchase rightsplan” within the meaning of Section 423(b) of the Internal Revenue Code, and stock appreciation rights. Approximately 375 individuals currently participate(ii) to help eligible employees provide for their future security and to encourage them to remain in the 2007 Plan.employment of the Company and its designated subsidiaries. The ESPP gives our employees an opportunity to purchase shares of our common stock at a discounted price. We believe that our stockholders will benefit from an increased interest from our designated employees in our success.

As most recently approved,We believe that the 2007 Plan provides for up to 5,230,000 shares to be granted as equity awards through December 31, 2017, subject to adjustment for future stock splits, stock dividendsESPP is a powerful incentive and similar events.

As of December 31, 2015, 202,345 shares remain available for issuance under the 2007 Plan as follows:

Shares Authorized Under the 2007 Plan:

5,230,000

Shares Issued:

Stock Options granted

3,449,224

Restricted Stock Units granted

2,035,131

Performance Share Awards granted:

Completed performance cycleretention tool that will benefit both our employees and released:

368,112

Completed performance cycle and release deferred:

29,850

Not yet completed performance cycle (presented at
maximum shares payable):

229,907

Subtotal - Shares Issued:            

6,112,224
Shares returned to 2007 Plan:

Shares withheld to pay taxes on release of full value awards:

622,632

Cancelled or forfeit awards:

461,937

Subtotal - Shares Returned:            

1,084,569

Available for future grants:            

202,345

As of December 31, 2015, there were 1,477,319 stock options and 961,799 unvested full value awards outstanding under all of our currentstockholders. Specifically, we believe the ESPP will enable us to: (i) provide eligible employees with a convenient means of acquiring an equity interest in us through payroll deductions, (ii) enhance such employees’ sense of participation in our affairs, and expired plans, including(iii) provide an incentive for continued employment. The ESPP will also align the 2007 Plan. The outstanding options under the 2007 Plan and the other current and expired equity plans have an average exercise priceinterests of $93.91 and an average remaining termemployees with those of 7 years.our stockholders through increased stock ownership.

As discussed in detail below, the Board believes that it is important to our profitability and stockholder value to be able to continue to offer equity incentives to our employees and to have flexibility in the types of awards available. Based on our current grant practices, we consider it necessary to increase the number of shares authorized under the 2007 Plan and to extend the expiry dateSummary of the 2007 Plan to ensure that our ability to make competitive equity award grants is not affected.ESPP

Therefore the Board recommends the approval of an amendment and restatement of the 2007 Plan to increase the number of shares available for grant by 1,700,000 to a total of 6,930,000 shares and to extend the expiry date of the 2007 Plan to December 31, 2026.

64


The full text of the proposed 2007 Plan, as amended and restated, is attached as Exhibit A. The following general description ofThis section summarizes certain principal features of the 2007 PlanESPP. The summary is qualified in its entirety by reference to the 2007 Plan.complete text of the ESPP. Stockholders are urged to read the actual text of the ESPP in its entirety which is set forth in Exhibit A to this proxy statement.

PurposeShares Available; Administration

Long-termA total of 1,000,000 shares of common stock are initially reserved for issuance under the ESPP. We intend to register such shares on a Registration Statement on FormS-8.

The Organization and Compensation Committee (the “Committee”) (or its delegate) is designated as the Administrator of the ESPP (the “Administrator”) and has the authority to interpret the terms of the ESPP and determine eligibility of participants. No purchase rights granted under the ESPP, and no shares of our common stock, will be issued under the ESPP until the ESPP has been approved by our stockholders.

Eligibility

Under the ESPP, employees are eligible to participate in the ESPP if they are customarily employed by us or a designated subsidiary at least twenty (20) hours per week and five months or more in any calendar year. As of December 31, 2018, we had approximately 10,500 employees who would have been eligible to participate in the ESPP had the ESPP been in effect and the subsidiaries for whom such employees worked been designated as designated subsidiaries under the ESPP. We currently anticipate designating all subsidiaries of the Company, globally, as designated subsidiaries under the ESPP subject to phased expansion.

60 | Page   


An employee may not be granted rights to purchase shares of our common stock under our ESPP if such employee, immediately after the grant, would own (directly or through attribution) stock possessing 5% or more of the total combined voting power or value of all classes of our common or other class of stock.

Offering Periods, Payroll Deductions and Purchase Dates

The Company will offer shares of common stock under the ESPP during one or more offering periods. The length of the offering periods under the ESPP will be determined by the Administrator and may be up to 27 months long. Initially, the Company intends to have offering periods of three (3) months in length.

Employee payroll deductions will be used to purchase shares on each purchase date during an offering period. The ESPP permits participants to purchase shares of our common stock through payroll deductions of between 1% and 15% of their eligible compensation (subject to any lower limit specified by the Administrator), which includes a participant’s gross base compensation for services to us, and/or sales commissions, but does not include incentive compensation, bonuses, expense reimbursements, fringe benefits or other special payments. The Administrator, in its sole discretion, may, on a uniform and nondiscriminatory basis for each offering period, establish a different definition of compensation. Also, the form of equity awards, isAdministrator has the discretion to adopt a key component of our compensation program for executives and employees. The grant of equity awards with time- and/or performance-based vesting criteria encourages the long-term retention of skilled executives and employees and aligns the interests of award recipients with our stockholders.

Our use of equity awards as a component of executive compensation is detailed in theCompensation Discussion and Analysis starting on page 21 and in our executive compensation disclosures starting at page 37. We have adopted grant practices designed to offer competitive awards with retention value for participants while controlling the cost of awards and usage of shares under the 2007 Plan.

In order to continue to provide a balanced mixdifferent definition of compensation with appropriate emphasisrespect to participants on long-term performance asnon-U.S. payrolls.

The purchase dates will be the final trading day in each offering period. Offering periods under the ESPP will commence when determined by the Administrator. The Administrator may, in its discretion, modify the terms of future offering periods.

Limits

In connection with each offering period, the Administrator, in its sole discretion, may, on a companyuniform and retention of key personnel, we feel it is necessary to maintainnondiscriminatory basis, specify:

(i) a sufficient poolmaximum number of shares available under our long-term incentive plan. We are seekingof common stock that may be purchased by any individual participant on any purchase date during such offering period, which, in the absence of a contrary specification by the Administrator, will be 500 shares of common stock for offering periods of three (3) months; and

(ii) a maximum aggregate number of shares of common stock that may be purchased by all participants on any purchase date during an offering period, which, in the absence of a contrary specification by the Administrator, will be 50,000 shares of common stock for offering periods of three (3) months.

In no event will any employee be permitted to increaseaccrue the available sharesright to purchase stock under the 2007 PlanESPP at a rate in excess of $25,000 worth of shares during any calendar year during which such a purchase right is outstanding (based on the fair market value per share of common stock as of the first day of the offering period).

By its terms, the ESPP provides the Administrator some flexibility with respect to certain aspects of the operation of the ESPP, such as (a) the limit on the number of shares of common stock that may be purchased by a single participant during the offering period and (b) the limit on the aggregate number of shares of common stock that may be purchased by all participants on single purchase date or a single offering period. This flexibility allows the Administrator to be able to adapt and adjust to our future compensation objectives.

Purchase Price; Stock Purchases

On the first trading day of each offering period, each participant will automatically be granted an option to purchase shares of our common stock. The option will expire at the end of the applicable offering period and will be exercised at that time to the extent of the payroll deductions accumulated during the offering period. The purchase price of the shares will be designated by the Administrator prior to the start of an offering period and will not be less than 85% of the fair market value of our common stock on the last trading day of the offering period.

61 | Page   


Participant Withdrawal or Termination

Participants may voluntarily end their participation in the ESPP at any time by providing the Company with written notice at least 30 calendar days prior to the end of the applicable offering period, or such shorter period as determined by the Administrator, and will be paid their accrued payroll deductions that have not yet been used to purchase shares of common stock. A participant’s withdrawal from an offering period will not affect his or her ability to participate in subsequent offering periods or other Company plans. Participation ends automatically upon a participant’s termination of employment. A participant may not transfer rights granted under the ESPP other than by will, the laws of descent and distribution or as otherwise provided under the ESPP.

Changes in Capital Stock; Change in Control

In the event of certain changes in the capital stock of the Company or a change in control, the Administrator may, in order to ensure our continued abilityprevent dilution or enlargement of the benefits intended to be made available under the ESPP, make equitable adjustments by providing for (a) either the replacement of outstanding rights with other rights or property or termination of outstanding rights in exchange for cash, (b) the assumption or substitution of outstanding rights by the successor or survivor corporation or parent or subsidiary thereof, if any, (c) the adjustment in the number and type of shares of common stock subject to outstanding rights, (d) the use of participants’ accumulated payroll deductions to purchase common stock on a new purchase date prior to the next scheduled purchase date and termination of any rights under ongoing offering periods, or (e) the termination of all outstanding rights.

Non-U.S. Employees andSub-Plans

The ESPP is generally intended to provide competitive equity awardseligible employees of the Company and its designated subsidiaries with the flexibilityopportunity to design our award programsparticipate in keeping with reasonable compensation practices.

Summary of 2007 Long-Term Incentive Plan

Administration. The 2007 Planthe ESPP in a manner that is administered by the Board or, if the Board delegates its power and authorityintended to administer the plan to a committeequalify under Section 423 of the Board,Internal Revenue Code. However, the ESPP also authorizes the establishment of rules, procedures, agreements, appendices, orsub-plans to the ESPP to facilitate participation in the ESPP by eligible employees of certain subsidiaries in particular locations outside the United States in a manner that does not comply with Section 423.

The Administrator may adopt such committee. Any such committee shall consist solely of tworules, procedures, agreements, appendices, or more directors appointed bysub-plans relating to the operation and holding office at the pleasureadministration of the Board, eachESPP to accommodate local laws, customs, and procedures for jurisdictions outside of whom is a non-employee director, as defined in Rule 16b-3 under the Exchange Act. As used in this proposal,United States, the term “Committee” will referterms of which may take precedence over provisions of the ESPP, other than with respect to the above described committee or to the Board, as the case may be.

The Committee has full power to select, from among participants eligible for awards, the individuals to whom awards will be granted, to make any combinationnumber of awards to any participants and to determine the specific terms of each grant,securities subject to the provisionsESPP.

Amendment of the 2007 Plan.ESPP

Eligibility. Participants eligible to receive awards underThe Administrator may amend, suspend or terminate the 2007 Plan include the officers, consultants and other employeesESPP at any time. However, stockholder approval of the company, including our subsidiaries and affiliates, whom the Committee determines are responsible for or contributesany amendment to the management, growth and/ESPP must be obtained for any amendment which increases the aggregate number, or profitability of our business. Members ofchanges the Committee and any person who serves only as a director are not eligible to receive awards under the 2007 Plan.

Shares subject to the 2007 Plan. If approved, the amended and restated 2007 Plan would authorize the Committee to grant up to an additional 1,700,000 shares in the form of stock options, restricted stock, deferred stock and/or restricted stock units, long-term performance awards, stock purchase rights, or stock appreciation rights to eligible participants through December 31, 2026 for a total of 6,930,000 shares of Common Stock, subject to adjustment for future stock splits, stock dividends and similar events. There is no limitation under the 2007 Plan regarding the numbertype, of shares that may be used for full-value awards.

As of December 31, 2015, a total of 6,112,224 shares have been issuedsold pursuant to awardsrights under the Plan,ESPP, changes in the corporations or classes of which 2,118,686corporations whose employees are eligible to participate in the ESPP, or changes in the ESPP in any manner that would cause the ESPP to no longer be an employee stock purchase plan within the meaning of Section 423(b) of the Internal Revenue Code.

U.S. Federal Income Tax Consequences

The following is a general summary under current law of the material U.S. federal income tax consequences to an employee who participates in the ESPP. This summary deals with the general U.S. federal income tax principles that apply and is provided only for general information. Some kinds of taxes, such as state, local and foreign income taxes and federal employment taxes, are not discussed. Tax laws are complex and subject to outstanding awards which have not yet vested or

65


been exercised. The maximum number of shares anchange and may vary depending on individual participant may be granted as equity awards undercircumstances and from locality to locality. This summary also assumes that the 2007 Plan during any fiscal year is 250,000 shares. Shares subject to awards under the 2007 Plan which expire unexercised, are forfeited, are withheld to cover tax obligations, or are otherwise not paid out in stock, become available again for distribution in connectionESPP complies with future awards under the 2007 Plan. As of December 31, 2015, a total of 1,084,569 shares have been returned to the plan for distribution for future awards under these provisions.

Stock Options. The 2007 Plan permits the grant of stock options that either qualify as incentive stock options, or ISOs, under Section 422(b)423 of the Internal Revenue Code or that do not so qualify, or NQSOs. To qualify as ISOs, options must meet additional Federal tax requirements. Under current law these requirements include limitsand is based on the value of ISOs that become exercisable annually with respect to any participant, and a shorter exercise period and a higher minimum exercise pricetax laws in the case of certain large stockholders.

The 2007 Plan also permits the grant of stock options approved under the Revenue rules of the United Kingdom, and are subject to special terms and conditions. These options, called UK Approved Stock Options, qualify for special taxation rules in the United Kingdom.

The option exercise price for each share covered by an option shall be determined by the Committee, but shall be at least 100% of the Fair Market Value of a share of Common Stockeffect as of the date of grant.this proxy statement. Changes to these laws could alter the tax consequences described

62 | Page   


below. The termsummary does not discuss all aspects of each optionfederal income taxation that may be relevant in light of a participant’s personal circumstances. This summarized tax information is not tax advice and a participant should rely on the advice of his or her legal and tax advisors.

The right of U.S. participants to make purchases under the ESPP are intended to qualify under the provisions of Section 423 of the Internal Revenue Code. Under the applicable Internal Revenue Code provisions, no income will be fixedtaxable to a participant until the sale or other disposition of the shares purchased under the ESPP. Upon such sale or disposition, the participant will generally be subject to tax in an amount that depends upon the length of time such shares are held by the Committee but may not exceed tenparticipant prior to disposing of them. If the shares are sold or disposed of more than two years from the first day of the offering period during which the shares were purchased and one year from the date of grant. The Committee will determine at what time or times each option may be exercised. Options may be made exercisable in installments, and the exercisability of options may be accelerated by the Committee under certain circumstances.

The option exercise price of stock options granted under the 2007 Plan must be paid in full by cash, check, wire transfer or other immediately payable instrument acceptable to the Committeepurchase, or if the Committee so determines, by delivery of Common Stock, valued at Fair Market Value onparticipant dies while holding the exercise date, or through a broker-assisted cashless exercise, provided that payment is made prior to the delivery of any stock by the company.

As used herein, the term “Fair Market Value” means, as of any given date, unless otherwise determined by the Committee in good faith, the closing price of the Common Stock on the NYSE or, if no such sale of Common Stock occurs on the NYSE on that date, the Fair Market Value of the Common Stock as determined by the Committee in good faith.

Under the 2007 Plan, in the event of termination of a participant’s employment or consultancy by reason of normal retirement at or after age 65, approved early retirement, long-term disability or death, an option may thereafter be exercised, to the extent it was then exercisable, for a period of three years, or such shorter period as the Committee shall determine at grant, subject to the stated term of the option. If a participant’s employment or consultancy is terminated for one of these reasons andshares, the participant thereafter dies while the option is still exercisable, the option will, in general, be exercisable for twelve months,(or his or such shorter period as the Committee shall determine at grant, following death, subject to the stated term of the option. The Committee may, at or after the grant date, provide for acceleration of the exercisability of options upon termination of employment or consultancy by reason of normal retirement, approved early retirement, disability or death.

If a participant’s employment or consultancy terminates for any reason other than normal retirement at or after age 65, approved early retirement, disability or death, his options will

66


terminate, except that if a participant’s employment is involuntarily terminated without Cause as defined in the 2007 Plan, his options may be exercised, to the extent then exercisable, for three months, unless otherwise determined by the Committee, following termination, subject to the stated term of the option.

The 2007 Plan also permits the Committee at any time to offer to buy out for a payment in cash any option previously granted, based on such terms and conditions as the Committee shall establish and communicate to the participant at the time that such offer is made; provided, that the Committee shall not offer to buy out an option with an exercise price that is greater than the Fair Market Value at the time of the offer, without first obtaining stockholder approval. In addition, if permitted by the award agreement, the Committee may require that any shares issued with respect to the exercise of an option take the form of restricted stock, valued on the date of exercise without taking into account the forfeiture restrictions.

Except as may be determined by the Committee or set forth in the applicable grant agreement, stock options are transferable only by will or by the laws of descent or distribution, and all options are exercisable, during the participant’s lifetime, only by the participant or his guardian or legal representative. However, a Non-Qualified Stock Option may be transferred to, exercised by, and paid to certain trusts or foundations under the control of the participant for estate or tax planning purposes.

Stock Appreciation Rights. The Committee may also grant non-transferable stock appreciation rights, or SARs, which entitle the holder, upon exercise, to receive an amount in cash and/or shares equal in value to the excess, if any, of the Fair Market Value of a number of shares specified in the award at the date of exercise of the SARs over the Fair Market Value of such number of shares at the date of grant of the SARs.

Restricted Stock. The Committee may award shares of restricted common stock (“restricted stock” or “restricted stock award”), subject to certain conditions set forth in the 2007 Plan and such other conditions and restrictions as the Committee may determine, including the attainment of performance goals and the payment of a purchase price equal to or greater than par value. Prior to the lapse of restrictions on shares of restricted stock, the participant will have all rights of a stockholder with respect to the shares, including voting and dividend rights, subject to the conditions and restrictions generally applicable to restricted stock or specifically set forth in the participant’s restricted stock award agreement. The Committee may, in its discretion, permit or require the payment of any cash dividends to be deferred and, in its discretion, to be reinvested in additional shares of restricted stock or otherwise. Stock dividends, if any, will be treated as additional shares of restricted stock. A recipient of restricted stock must enter into a restricted stock award agreement with us, in such form as the Committee determines, setting forth the restrictions to which the shares are subject and the date or dates on which the restrictions will lapse. The Committee may permit such restrictions to lapse in installments within the restricted period or may accelerate the removal of restrictions or waive such restrictions at any time. The Plan provides that restricted stock, as well as other full value awards such as restricted deferred stock and long-term performance awards will vest over a period of not less than three years, except in the event of death, disability or change in control.

Shares of restricted stock are non-transferable, and if a participant who holds restricted stock terminates employment or his consultancy for any reason, including death, prior to the lapse or waiver of the restrictions, we, subject to the terms of the restricted stock award agreement, will have the right to require the forfeiture of the shares of restricted stock in exchange for any amount that the participant paid for them.

67


Deferred Stock. The Committee may make deferred stock awards under the 2007 Plan. These are non-transferable awards entitling the recipient to receive shares of Common Stock without any payment in cash or property in one or more installments at a future date or dates, as determined by the Committee. Receipt of deferred stock may be conditioned on such matters as the Committee shall determine, including continued employment or providing future consulting services or attainment of performance goals. The Plan provides that deferred stock generally will vest over a period of not less than three years, except in the event of death, disability or change in control. Notwithstanding these provisions, the 2007 Plan, as amended, also provides that the Committee may grant equity awards with a vesting period of less than three years provided that the total shares subject to such awards may not exceed 5% of the total shares authorized under the 2007 Plan.

A recipient of a deferred stock award must enter into an agreement setting forth the applicable provisions for deferral of the shares of Common Stock covered by such award, as determined by the Committee. If a recipient of a deferred stock award terminates employment or his consultancy for any reason, including death, during the deferral period, we, subject to the terms of the deferred stock award agreement, will have the right to require the forfeiture of the shares of deferred stock in exchange for any amount that the participant paid for them.

Any deferral restrictions under a deferred stock award may be accelerated or waived by the Committee in the event of the recipient’s retirement, death or disability or in the case of a Change in Control. The Committee may permit participants to further defer receipt of a deferred stock award or an installment of an award, if certain election requirements are met, for a specified period or until a specified event. Recipients of deferred stock awards may be entitled to receive dividend equivalents, subject to the terms of the award agreement. The Committee may, in its discretion, permit or require the payment of dividends to be deferred and reinvested in additional shares of deferred stock or otherwise. A recipient of a deferred stock award has no rights as a stockholder with respect to any shares covered by his deferred stock award until the shares are issued and delivered to the recipient electronically or by issue of a stock certificate.

Stock Purchase Rights. The Committee may grant participants stock purchase rights to purchase stock, including restricted or deferred Common Stock, at a price equal to 50% or 100% of its Fair Market Value, 100% of its book value or 100% of its par value for limited periods of up to 90 days. The Committee may impose deferral, forfeiture, or other terms and conditions upon stock purchase rights.

In connection with stock purchase rights granted under the 2007 Plan, the Committee may, if not prohibited by law, authorize loans from us to the participant for up to 90% of the purchase price. Loans, including extensions, may be for up to ten years and may be with or without recourse against the participant in the event of default. The Committee may require the participant to pledge the purchased stock or other property as security for the loan. Each loan shall be subject to such terms and conditions and shall bear such rate of interest as the Committee shall determine. Loans may be made at any time, subject to such limitations as the Committee shall prescribe. Notwithstanding this provision, the Committee does not issue loans to our executive officers for any purpose.

Long-Term Performance Awards. The Committee may also grant long-term performance awards under the 2007 Plan. Such awards shall be based on corporate, business unit and/or individual performance over designated periods, called Performance Periods. Performance objectives may vary from participant to participant, group to group, and period to period, and Performance Periods may overlap. At the beginning of the Performance Period, the Committee will determine the number of shares of Common Stock, including deferred or restricted Common Stock, subject to the long-term

68


performance award. During the Performance Period, the Committee may adjust the performance goals and measurements to take into account accounting and tax rules, and to makes changes that the Committee deems necessary or appropriate to reflect the inclusion or exclusion of unusual items, events or circumstances in order to avoid windfalls or hardships. The Plan provides that long-term performance awards will vest over a period of not less than three years, unless the long-term performance award is intended to qualify as performance based compensation under Section 162(m) of the Code, as discussed below, in which case the performance period over which the award vests may not be less than one year. However, long-term performance awards may vest upon death, disability or change in control.

Unless otherwise determined by the Committee, long-term performance awards will generally be paid out on a prorated basis in the event of termination due to retirement at or after age 65 or approved early retirement, death or disability and will be forfeited in the event of other types of termination. Long-term performance awards may be paid early, currently or on a deferred basis with interest or earnings equivalents, as determined by the Committee, and will be payable in cash or stock, including restricted or deferred Common Stock, either in a lump sum or in annual installments, as determined by the Committee.

Performance Based Compensation.If the Committee determines that any of the awards of restricted stock, deferred stock or long-term performance awards should qualify as performance based compensation under Section 162(m) of the Code, then the criteria upon which such awards will become payable will relate to one or more of the following: (i) net earnings or losses (either before or after one or more of the following: (A) interest, (B) taxes, (C) depreciation, (D) amortization and (E) non-cash equity-based compensation expense); (ii) gross or net sales or revenue or sales or revenue growth; (iii) net income (either before or after taxes); (iv) adjusted net income; (v) operating earnings [or profit] (either before or after taxes); (vi) cash flow (including, but not limited to, operating cash flow and free cash flow); (vii) return on assets; (viii) return on capital (or invested capital) and cost of capital; (ix) return on stockholders’ equity; (x) total stockholder return; (xi) return on sales; (xii) gross or net profit or operating margin; (xiii) costs, reductions in costs and cost control measures; (xiv) expenses; (xv) working capital; (xvi) earnings or loss per share; (xvii) adjusted earnings or loss per share; (xviii) price per share or dividends per share (or appreciation in and/or maintenance of such price or dividends); (xix) regulatory achievements or compliance (including, without limitation, regulatory body approval for commercialization of a product); (xx) implementation or completion of critical projects; (xxi) market share; (xxii) economic value added. Any of these criteria may be measured either in absolute terms or as compared to any incremental increase or as compared to results of a peer group.

Adjustment for Stock Dividends, Mergers, etc. The Committee is required to make appropriate substitution or equitable adjustments in connection with outstanding awards under the 2007 Plan in the event of any merger, reorganization, consolidation, recapitalization, stock dividend, stock split or similar event. In addition, in the event of any merger or other corporate transaction or event which results in shares of Common Stock being purchased for cash, or being exchanged for or converted into cash or the right to receive cash, the Committee, in its sole discretion, and on such terms and conditions as it deems appropriate, may provide that any outstanding award under the 2007 Plan shall be converted into the right to receive an amount of cash equal to the amount of cash, if any, that would have been received, in the event of such merger or corporate transaction or event, if such award had been fully exercisable or payable, or vested and had been exercised or paid immediately prior to such merger or other corporate transaction or event to the extent of the cash value thereof,

69


and, upon such conversion, such award, including any such award which under the terms of such merger or other corporate transaction or event, would have no cash value, shall be cancelled.

Amendment and Termination. The Board may amend, alter or discontinue the 2007 Plan at any time, but such amendment, alteration or discontinuation shall not adversely affect any outstanding award without the consent of each affected participant. In addition, the Board may not, without the prior approval of the stockholders, make any amendment which would: (i) increase the number of shares reserved for grants under the 2007 Plan, (ii) change the class of employees eligible to receive awards, (iii) extend the maximum term for awards, or (iv) otherwise materially alter the terms of the 2007 Plan. The Committee may amend the terms of any award or option theretofore granted, retroactively or prospectively, but no such amendment shall impair the rights of the holder of any award without the holder’s consent. The Committee may accelerate any award or option or waive any conditions or restrictions pertaining to such award or option at any time. However, the Committee is specifically prohibited from repricing options and stock appreciation rights.

FEDERAL INCOME TAX ASPECTS OF 2007 LONG-TERM INCENTIVE PLAN

THE TAX CONSEQUENCES OF THE 2007 PLAN UNDER CURRENT FEDERAL LAW ARE SUMMARIZED IN THE FOLLOWING DISCUSSION WHICH DEALS WITH THE GENERAL TAX PRINCIPLES APPLICABLE TO THE 2007 PLAN AND IS INTENDED FOR GENERAL INFORMATION ONLY. ALTERNATIVE MINIMUM TAX AND STATE, LOCAL AND FOREIGN INCOME TAXES ARE NOT DISCUSSED, AND MAY VARY DEPENDING ON INDIVIDUAL CIRCUMSTANCES AND FROM LOCALITY TO LOCALITY.

Non-Qualified Stock Options.For Federal income tax purposes, NQSOs will not be taxable upon grant, nor will we be entitled to any deduction. Generally, on exercise of NQSOs the participanther estate) will recognize ordinary income and we will be entitled to a deduction in an amount equal tomeasured as the difference betweenlesser of (1) the option exercise price and the fair market valueexcess of the Common Stock on the date of exercise. Basis for the stock for purposes of determining gain or loss on subsequent disposition of such shares generally will be the fair market value of the Common Stock on the date of exercise. Any subsequent gain or loss will be generally taxable as capital gain or loss.

Incentive Stock Options.An incentive stock option is not taxable upon grant or upon exercise. However, the amount by which the fair market value of the shares at the time of exercise exceedssuch sale or disposition over the optionpurchase price will beor (2) an “item of adjustment” for the participant for purposesamount equal to 15% of the alternative minimum tax. Gain realized on the sale of an incentive stock option is taxable at capital gains rates, and no tax deduction is available to us, unless the participant disposesfair market value of the shares within (i) two years after the date of grantas of the option, or (ii) within one yearfirst day of the date the shares were acquired upon exercise of the option.offering period. Any additional gain will be treated as long-term capital gain. If the shares of Common Stockare held for the holding periods described above but are sold for a price that is less than the purchase price, there is no ordinary income and the designated employee has a long-term capital loss for the difference between the sale price and the purchase price. If the shares are sold or otherwise disposed of before the endexpiration of the one- and two-yearholding periods specifieddescribed above, the difference betweenparticipant will recognize ordinary income generally measured as the option exercise price andexcess of the fair market value of the shares on the date of the option’s exerciseshares are purchased over the purchase price. Any additional gain or loss on such sale or disposition will be taxed at ordinary income rates, and we will belong-term or short-term capital gain or loss, depending on how long the shares were held following the date they were purchased by the participant prior to disposing of them.

The Company is not entitled to a deduction for amounts taxed as ordinary income or capital gain to a participant except to the extent the participant must recognizeof ordinary income. If suchincome recognized upon a sale or disposition takes place inof shares prior to the year of exercise, the income the participant recognizes upon sale or dispositionexpiration of the shares will not be considered income for alternative minimum tax purposes. Otherwise, if the participant sells or otherwise disposesholding periods described above.

Non-U.S. Income Tax Consequences

The Company may also grant options underSub-Plans of the shares beforeESPP to employees outside the endU.S. The specific terms of suchSub-Plans are not yet known; accordingly, it is not possible to discuss with certainty the relevant tax consequences of these plans. These plans will besub-plans of the one-ESPP that are generally not intended to qualify under the provisions of Sections 421 and two-year periods specified above, the maximum amount that will be included as alternative minimum tax income is the gain, if any, recognized on the disposition423 of the shares.

An incentive stock option exercised more than three months after terminationCode. Therefore, it is likely that at the time of employment, other than by reason of death or disability, will be taxed as a non-qualified stock option, and the

70


participant will have been deemed to have received income on the exercise taxable atof an option under such a plan, a non-U.S. employee subject to income tax would recognize ordinary income rates. We will be entitled to a tax deduction equal to the ordinary income, if any, realized.

Stock Appreciation Rights.No taxable income is realized upon the receiptexcess of a stock appreciation right, or SAR; but upon exercise of the SAR, the fair market value of the shares received, as determinedstock on the date of exercise and the purchase price, to the extent that the employing entity is consolidated with the Company for U.S. tax purposes, then the Company would be able to claim a tax deduction equal to this difference. To the extent that the employee is subject to U.S. tax withholding, then the Company would be required to withhold employment taxes and income tax at the time of the SAR, or the amount of cash received in lieu of shares, must be treated as compensation taxable as ordinary income in the year of exercise. We will be entitled to a deduction for compensation paid in the same amount which the recipient realized as ordinary income.purchase.

Restricted Stock.Accounting TreatmentFor Federal income tax purposes, the recipient generally will not have taxable income on the grant of the restricted stock, nor will we then be entitled to any deduction, unless the recipient makes a valid election under Section 83(b) of the Internal Revenue Code with company consent. However, when restrictions on shares of restricted stock lapse such that the shares are no longer subject to a substantial risk of forfeiture or are freely transferable, the recipient generally

The Company will recognize ordinary income and we will be entitledcompensation expense in connection with options outstanding under the ESPP in accordance with accounting authority with respect to stock-based compensation. So long as the Company continues issuing shares under the ESPP with a corresponding deduction, for an amount equalpurchase price at a discount to the difference between the fair market value of the shares at the date such restrictions lapse over any purchase price for the restricted stock.

Deferred Stock.The recipient generallyits stock, it will not have taxable income upon the grant of deferred stock and we will not then be entitled to a deduction. However, when deferred stock vests and is distributed, the recipient will realize ordinary income and werecognize compensation expense which will be entitleddependent on the level of participation in the ESPP.

New Plan Benefits

Because the ESPP is a new plan no amounts have been allocated to a deductionany specific employee and it is not possible to predict what employees would have elected to purchase under the plan if it had been in an amount equaleffect in prior years. The number of shares that may be purchased under the ESPP will depend on each employee’s voluntary election to the difference betweenparticipate and on the fair market value of our common stock at various future dates, the shares at the date of issuance over the purchase price, if any, for the deferred stock.actual

Stock Purchase Rights.Stock purchase rights will generally be taxed in the same manner as NQSOs.

63 | Page   

Long-Term Performance Awards.Long-term performance awards once vested will, in most instances, be taxed as ordinary income, unless distributions are in the form of shares of Common Stock subject to restrictions or deferral limitations, in which case rules similar to those applicable to restricted and deferred stock will apply.


Stock Payment.If payment of an award is made in stock in lieu of a cash payment that would otherwise have been made, the recipient generally will be taxed as if the cash payment has been received, and we will have a deduction in the same amount. Subsequent appreciation or depreciation of the stock will be generally be taxable as capital gain or loss.

Section 162(m) of the Code.In general, under Section 162(m) of the Internal Revenue Code, income tax deductions of publicly-held corporations may be limited to the extent total compensation, including base salary, annual bonus, stock option exercises and non-qualified benefits, for certain executive officers exceeds $1 million, less the amount of any “excess parachute payments” as defined in Section 280G of the Internal Revenue Code, in any taxable year of the corporation. However, under Section 162(m), the deduction limit does not apply to certain “qualified performance-based compensation.”

Awards will satisfy the “qualified performance-based compensation” exception if: (i) the awards are made by a qualifying compensation committee, (ii) the Plan sets the maximum number of shares that canmay be granted topurchased by any person within a specified period, and (iii)individual cannot be determined in advance. However, the compensation is based solely on an increase in the stock price after the grant date. The 2007 Plan has been designed to permit the Compensation Committee to grant awards which will qualify as “qualified performance-based compensation.”

71


Other Tax Consequences.We recommend that any recipientmaximum dollar value of an award consult with a personal tax advisor with respect to the applicable Federal, foreign, state and/or local tax aspects of award grants, exercises and any subsequent dispositions of Common Stock acquired under the 2007 Plan.

Other Information. The closing price of a share of our common stock on the Record Date was $121.01.

Additional information regarding the 2007 Plan and other equity award plans as of October 31, 2015 can be found in the New Plan Benefits Table and Equity Plan Compensation Table below.

New Plan Benefits Table

Grants made under the 2007 Plan are at the discretion of the Committee and grants under the 2006 Directors’ Plan may also be discretionary as well as formulaic. Therefore, the exact amount of grantsshares that may be made cannot be determined at this time. Accordingly, the following table provides information about grants madepurchased in any one calendar year by any individual is $25,000.Non-executive directors are not eligible to participate in the last fiscal yearESPP. No shares of common stock have been issued under the 2007 Plan.ESPP as it is not yet effective.

Equity Compensation Plan Information Table

 

Name and Position (1)  

Number of Units:

 

 
  

Stock
Options (2)

 

   

Full Value
Awards (3)

 

 

Robert S. Weiss

 

   

 

65,195

 

  

 

   

 

5,398

 

  

 

President & Chief Executive Officer

 

     

Daniel G. McBride

 

   

 

11,807

 

  

 

   

 

6,037

 

  

 

Executive Vice President & Chief Operating Officer; President of CooperVision, Inc.

 

     

Albert G. White, III

 

   

 

7,537

 

  

 

   

 

4,005

 

  

 

Executive Vice President & Chief Strategy Officer

 

     

Carol R. Kaufman

 

   

 

8,929

 

  

 

   

 

4,864

 

  

 

Executive Vice President, Secretary, Chief Administrative Officer & Chief Governance Officer

 

     

Greg W. Matz

 

   

 

7,537

 

  

 

   

 

4,005

 

  

 

Senior Vice President, Chief Financial Officer & Chief Risk Officer

 

     

All current executive officers

 

   

 

114,368

 

  

 

   

 

32,671

 

  

 

All current non-employee directors

 

   

 

-0-

 

  

 

   

 

-0-

 

  

 

All other employees including current non-executive officers

 

   

 

9,036

 

  

 

   

 

185,433

 

  

 

  Plan category

 

  

No. of
Securities to
be Issued
upon
Exercise of
Outstanding  
Options,
Warrants
and Rights
(1)

 

  

Weighted-
average
Exercise
Price of
Outstanding  
Options,
Warrants
and Rights

 

  

No. of Securities  
Remaining
Available for
Future Issuance
under Equity
Compensation
Plans (excluding  
securities
reflected in
column (A))

 

    

(A)

 

  

(B)

 

  

(C)

 

 

  Equity compensation plans approved by stockholders (2)

  1,692,007  $160.31  1,572,390

 

  Equity compensation plans not approved by stockholders

  -  $-  -

 

  Total

 

  1,692,007

 

  $160.31

 

  1,572,390

 

 

(1)All grants to employees are pursuant to the 2007 Plan. Our Non-Employee Directors do not receive awards under the 2007 Plan. All Non-Employee Director Awards are pursuant to the 2006 Directors’ Plan which is not presented for action.
(2)These awards include stock options granted to our executive officers and non-executive employees on December 9, 2014 which have an exercise price of $162.28. All stock options are granted at 100% of fair market value on the date of grant and have a 10-year term.
(3)Full value awards include deferred stock awards to our executive officers and non-executive employees in the form of restricted stock units and performance share awards. Performance share awards granted in the last full fiscal year are subject to achievement of specified increases in our earnings per share and do not yet have a defined payout. Awards are included here at their target level of achievement opportunity.

72


Equity Plan Compensation Table

Plan category

 

  

No. of Securities to
be Issued upon
Exercise of
Outstanding
Options, Warrants
and Rights (1)

(A)

  

Weighted-average
Exercise Price of
Outstanding
Options, Warrants
and Rights

(B)

  

No. of Securities
Remaining Available for 
Future Issuance under
Equity Compensation
Plans

(excluding securities
reflected in column (A))

(C)

Equity compensation plans approved by stockholders (2)

 

  

 

1,866,494

  

 

$79.85

  

 

943,522

Equity compensation plans not approved by stockholders

 

  

 

-

  

 

$ -

  

 

-

Total

  1,866,494  $79.85  943,522
(1)

The amount of total securities to be issued under Company equity plans upon exercise of outstanding options, warrants, and rights shown in Column A includes 516,206487,314 Restricted Stock Units granted pursuant to the Company’s equity plans. These awards allow for the distribution of shares to the grant recipient upon the completion of time-based holdingvesting periods. The total also includes 29,850 shares to be issued pursuant to Performance Share Awards which previously vested and receipt of shares was deferred for a specified period of time and 229,907117,695 shares representing the maximum number of shareshares that may be issued subject to Performance Share Awards without a defined payout.outstanding as of the end of the fiscal year. Restricted Stock Units and Performance Share Awards do not have an associated exercise price. Accordingly, these awards are not reflected in the weighted-average exercise price disclosed in Column B.

(2)

Includes information with respect to the SecondThird Amended and Restated 2007 Long-Term Incentive Plan for Employees of the Cooper Companies, Inc. (“2007 Plan”), which was approved by stockholders on March 16, 2011,17, 2016, and provides for the issuance of up to 5,230,0006,930,000 shares of Common Stock, and the Second Amended and Restated 2006 Long-TermLong Term Incentive Plan forNon-Employee Directors of Thethe Cooper Companies, Inc. (the “Directors’ Plan”), which was approved by stockholders on March 16, 2011 and provides for the issuance of up to 950,000 shares of Common Stock.

As of October 31, 2015,2017, up to 757,7471,441,896 shares of Common Stock may be issued pursuant to the 2007 Plan and 185,775130,494 shares of Common Stock may be issued pursuant to the 2006 Directors’ Plan.

 

 

The Board of Directors unanimously recommends that you vote FOR the approval of the amendment and restatement of the 2007 Long-Term Incentive2019 Employee Stock Purchase Plan.

 

 

Under New YorkThe proposal to approve the 2019 Employee Stock Exchange (“NYSE”) rules, the approval of the amendment and restatement of the 2007Purchase Plan requires thean affirmative vote of the majority of the votes cast on the proposalshares represented in person or by proxy provided thatat the total votes cast on the proposal represent more than 50% of outstanding sharesAnnual Meeting and entitled to vote on the proposal. Votes “For” and “Against” and abstentions count as votes cast, while broker non-votes do not count as votes cast but count as outstanding shares. Thus, the total sum of votes “For,” plus votes “Against,” plus abstentions, which is referred to as the “NYSE Votes Cast,” must be greater than 50% of the total outstanding shares. Further, the number of votes “For” the proposal must be greater than 50% of the NYSE Votes Cast. Thus, abstentionsAbstentions will have the same practical effect as a votevotes against this proposal. Brokernon-votes will have no effect in determining the proposal. Brokers do not have discretionary authority to vote shares onoutcome of this proposal without direction from the beneficial owner. Thus, broker non-votes could impair our ability to satisfy the requirement that the NYSE Votes Cast represent over 50% of the outstanding shares.

proposal.

 

73
64 | Page   


PROPOSAL 4 — ADVISORY VOTE ON EXECUTIVE COMPENSATION

 

We are requesting stockholder approval, on an advisory basis, of the compensation of our Named Executive Officers as presented in theCompensation Discussion and Analysis beginning on page 2120 and the compensation tables and associated narrative disclosure included in the discussion ofExecutive Compensation executive compensation beginning on page 37.

Our executive compensation program has been designed to retain and incentivize a talented, motivated, and focused executive team by providing compensation that is competitive compensation within our market. We believe that our executive compensation program provides an appropriate balance between salary and “at-risk”“at-risk” forms of incentive compensation, as well as a mix of incentives that encourage executive focus on both short-term and long-term goals as a company without encouraging inappropriate risks to achieve performance.

We were pleased to receive a favorable vote for our compensation practices at both our 20152017 and 2018 Annual Meeting,Meetings, with 95%over 90% of the votes cast by our stockholders on ourSay-on-Pay proposal proposals voted in favor of the compensation of the named executive officers.Named Executive Officers each year. We consider these voting results to affirm stockholder support for our executive compensation practices and we continue to take steps to maintain alignment between executive pay and Company performance.

Highlights of our executive compensation program include:

A mixture of base salary and incentive compensation that provides formakes a significant portion of executive compensation to be “at-risk” and dependent on our performance as a company;

Checks and balances within our compensation packages to balance focus on both short-term and long-term goals, encouraging our executives to focus on the health of the company both during the immediate fiscal year and for the future;

Compensation on termination of employment, other than resulting from a change in control, is limited for most executives to the standard severance policies used for all employees; and

Clawback provisions in our short-term incentive compensation program.

As an advisory vote, this proposal is not binding upon us as a Company. However, our Compensation Committee, which is responsible for the design and administration of our executive compensation practices,program, values the opinions of our stockholders as expressed through your vote on this proposal. The Compensation Committee will consider the outcome of this vote in making future compensation decisions for our Named Executive Officers.

Accordingly, we will present the following resolution for vote at the 20162019 Annual Meeting of Stockholders:

“RESOLVED, that the stockholders of The Cooper Companies, Inc. (the “Company”) approve, on an advisory basis, the compensation of the Company’s Named Executive Officers as described in the Compensation Discussion and Analysis and disclosed in the Summary Compensation Table and related compensation tables and narrative disclosure as set forth in our Proxy Statement.”

 

 

The Board of Directors unanimously recommends that you vote FOR the approval, on an advisory basis, of our executive compensation program as presented in this Proxy Statement.

 

 

The proposal to approve our executive compensation program, on an advisory basis, requires an affirmative vote of the majority of the shares represented in person or by proxy at the Annual Meeting and entitled to vote on the proposal. Abstentions will have the same practical effect as votes against this proposal. Brokernon-votes will have no effect in determining the outcome of this proposal.

 

74
65 | Page   


OTHER MATTERS

 

The Board knows of no other matters to be presented at the Annual Meeting, but if any such matters properly come before the Annual Meeting, it is intended that the persons holding the accompanying proxy will vote in accordance with their best judgment.

RECOMMENDATIONS

 

The Board unanimously recommends that the stockholders vote:

 

FOR the election of each of the nominees for director named in this Proxy Statement;

FOR ratification of the appointmentratification of KPMG LLP as our independent registered public accounting firm for the fiscal year ending October 31, 2016;2019;

FORthe amendment and restatementapproval of the 2007 Long-Term Incentive2019 Employee Stock Purchase Plan; and

FOR the approval, on an advisory basis, of the compensation of our Named Executive Officers as presented in this Proxy Statement.

When a properly executed proxy in the form enclosed with this Proxy Statement is returned, the shares will be voted as indicated or, if no directions are indicated, the shares will be voted in accordance with the recommendations of the Board.

By Order of the Board of Directors

LOGO

A. Thomas Bender

Chairman of the Board of Directors

75


Exhibit A

Exhibit A - Amended and Restated 2007 Long-Term Incentive Plan

As Approved by Stockholders: [l ]

By Order of the Board of Directors
LOGO
A. Thomas Bender

Chairman of the Board of Directors

 

Section 1. Purpose; Definitions.

A-1

Section 2. Administration.

A-3

Section 3. Stock Subject To Plan.

A-5

Section 4. Eligibility.

A-6

Section 5. Stock Options.

A-6

Section 6. Stock Appreciation Rights.

A-966 | Page   

Section 7. Restricted Stock.

A-10

Section 8. Deferred Stock.

A-11

Section 9. Stock Purchase Rights.

A-13

Section 10. Long-Term Performance Awards.

A-13

Section 11. Amendments And Termination.

A-15

Section 12. Unfunded Status Of Plan and 409A.

A-16

Section 13. General Provisions.

A-16

Section 14. Effective Date Of Plan.

A-18

Section 15. Term Of Plan.

A-18

Section 16. Certain Stock Options For United Kingdom Employees.

A-18

Schedule A. Tax Approved Options For United Kingdom Employees

A-19


The Cooper Companies, Inc.

Third Amended and Restated 2007 Long-Term Incentive PlanEXHIBIT A – 2019 EMPLOYEE STOCK PURCHASE PLAN

 

Section 1.    Purpose; Definitions.Purposes of the Plan

The purposepurposes of this The Cooper Companies, Inc. 2007 Long-Term Incentive2019 Employee Stock Purchase Plan (the ‘Plan’) is to enable the Company to attract, retain and reward key employees and consultants to the Company and its Subsidiaries and Affiliates, and strengthen the mutuality of interests between such key employees and consultants and the Company’s stockholders, by offering such key employees and consultants performance-based incentive equity interests in the Company.

For purposes of the Plan, the following terms shall(as it may be defined as set forth below:

(a)“Affiliate” means any entity other than the Company and its Subsidiaries that is designated by the Board as an entity for which the Company has a legitimate business interest in allowing such entity to be a participating employer under the Plan, provided that the Company directlyamended or indirectly owns at least 20% of the combined voting power of all classes of stock of such entity or at least 20% of the ownership interests in such entity.

(b)“Board” means the Board of Directors of the Company.

(c)“Book Value” means, as of any given date, on a per share basis (i) the Stockholders’ Equity in the Company as of the end of the immediately preceding fiscal year as reflected in the Company’s consolidated balance sheet, subject to such adjustments as the Committee shall specify at or after grant, divided by (ii) the number of then outstanding shares of Stock as of such year-end date (as adjusted by the Committee for subsequent events).

(d)“Code” means the Internal Revenue Code of 1986, as amendedrestated from time to time, and any successor thereto.

(e)“Committee” shall mean the Board or, if the Board delegates its power and authority“Plan”) are to administer this Plan to a committeeassist Eligible Employees of the Board described in this Section 2 of the Plan, such committee.

(f)“Company” means The Cooper Companies, Inc., a Delaware corporation organized under(the “Company”), and its Designated Subsidiaries in acquiring a stock ownership interest in the laws of the State of Delaware, or any successor corporation.

(g)“Deferred Stock” or“Deferred Stock Award” means an award madeCompany pursuant to Section 8 below of the righta plan that is intended, for Eligible Employees subject to receive Stock at the end of a specified deferral period.

(h)“Disability” means disability as determined under procedures established by the Committee for purposes of this Plan.

(i)“Early Retirement” means retirement from consulting or active employment with the Company and any Subsidiary or Affiliate after satisfying the requirements for early retirement under the provisions of the applicable pension plan of such entity, and receiving the consent of the Company priorU.S. federal income tax, to such retirement under the terms of this Plan.

Adopted:

Approved by Stockholders:

A-1


Third Amended and Restated 2007 Long-Term Incentive Plan

(j)“Exchange Act” means the Securities Exchange Act of 1934, as amended.

(k)“Fair Market Value” means, as of any given date, unless otherwise determined by the Committee in good faith, (i) the closing price of the Stock on the New York Stock Exchange as reported onhttp://finance.yahoo.com, (ii) if no such sale of Stock occurs on the New York Stock Exchange on such date, the closing price of the Stock on the trading day immediately prior to such date, or (iii) if the Stock is not publicly traded, then the fair market value of the Stock as determined by the Committee in good faith.

(l)“Full Value Award” means any Grant other than an Option, Stock Appreciation Right or other Grant for which the Participant pays the intrinsic value existing as of the date of grant (whether directly or by forgoing a right to receive a payment from the Company).

(m)“Grant” means an instrument or agreement evidencing an option, SAR, Restricted Stock, Deferred Stock, Stock Purchase Right or Long-term Performance Award, granted hereunder, which may, but need not be, acknowledged by the recipient thereof.

(n)“Incentive Stock Option” or“ISO” means any Stock Option intended to be and designatedqualify as an ‘Incentive Stock Option’“employee stock purchase plan” within the meaning of Section 422423(b) of the Code (a “Qualified ESPP”), and to help Eligible Employees provide for their future security and to encourage them to remain in the employment of the Company and its Designated Subsidiaries. The provisions of the Plan shall, accordingly, be construed so as to extend and limit participation in a manner consistent with the requirements of that section of the Code.

(o)“Long-term Performance Award”2.    Definitions and Construction means an award under Section 10 below that is valued

Wherever the following terms are used in whole or in part based on the achievement of Company, Subsidiary, Affiliate, or individual performance factors or criteria as the Committee may deem appropriate.

(p)“Non-Employee Director” shallPlan, they will have the meaning set forth in Rule 16b-3 as promulgated bymeanings specified below, unless the Securities and Exchange Commission under the Exchange Act, or any successor definition adopted by the Commission.

(q)“Non-Qualified Stock Option” or“NQSO” means any Stock Option that is not an Incentive Stock Option.

(r)“Normal Retirement” means retirement from consulting or active employment with the Company and any Subsidiary or Affiliate on or after age 65.

(s)“Performance Criteria” means any one or more of the following: (i) net earnings or losses (either before or after one or more of the following: (A) interest, (B) taxes, (C) depreciation, (D) amortization and (E) non-cash equity-based compensation expense); (ii) gross or net sales or revenue or sales or revenue growth; (iii) net income (either before or after taxes); (iv) adjusted net income; (v) operating earnings [or profit] (either before or after taxes); (vi) cash flow (including, but not limited to, operating cash flow and free cash flow); (vii) return on assets; (viii) return on capital (or invested capital) and cost of capital; (ix) return on stockholders’ equity; (x) total stockholder return; (xi) return on sales; (xii) gross or net profit or operating margin; (xiii) costs, reductions in costs and cost control measures; (xiv) expenses; (xv) working capital; (xvi) earnings or loss per share; (xvii) adjusted earnings or loss per share; (xviii) price per share or dividends per share (or appreciation in and/or maintenance of such price or dividends); (xix) regulatory achievements or compliance (including, without limitation, regulatory body approval for commercialization of a product); (xx) implementation or completion of critical projects; (xxi) market share; (xxii) economic value added. Any of these criteria may be measured either in absolute terms or as compared to any incremental increase or as compared to results of a peer group.context clearly indicates otherwise.

 

(a)

“Administrator” means the Organization and Compensation Committee of the Board or any of its delegates, including committees, administering the Plan, in accordance with Section 11 of the Plan.

(b)

“Affiliate” means any corporation, partnership, joint venture or other entity in which the Company holds an equity, profit or voting interest of more than fifty percent (50%).

(c)

“Applicable Law” means the requirements relating to the administration of equity incentive plans under U.S. federal and state securities, tax and other applicable laws, rules and regulations, the applicable rules of any stock exchange or quotation system on which the Common Stock is listed or quoted and the applicable laws and rules of any foreign country or other jurisdiction where rights under this Plan are granted.

(d)

“Board” means the Board of Directors of the Company.

(e)

“Change in Control” means the occurrence of any of the following events:

(i)

The acquisition by any individual, entity or group (within the meaning of section 13(d)(3) or 14(d)(2) of the Exchange Act) (a “Person”) of beneficial ownership (within the meaning of Rule13d-3 promulgated under the Exchange Act) of fifty percent (50%) or more of the combined voting power of the then outstanding securities entitled to vote generally in the election of Board members (“Voting Stock”) of the Company;

(ii)

Consummation of a reorganization, merger or consolidation, a sale or other disposition of all or substantially all of the assets of the Company, or other transaction (each, a “Business Combination”), unless, in each case, immediately following such Business Combination, (A) all or substantially all of the individuals and entities who were the beneficial owners of Voting Stock of the Company immediately prior to such Business Combination beneficially own, directly or indirectly, more than fifty percent (50%) of the combined voting power of the then outstanding shares of Voting Stock of the entity resulting from such Business Combination (including, without limitation, an entity which as a result of such transaction owns the Company or all or substantially all of the Company’s assets either directly or through one or more subsidiaries) in substantially the same proportions relative to each other as their ownership, immediately prior to such Business Combination, of the Voting Stock of the Company and (B) no Person beneficially owns, directly or indirectly, fifty percent (50%) or more of the combined voting power of the then outstanding shares of Voting Stock of the entity resulting from such Business Combination; or

(iii)

The Company’s stockholders approve a plan of complete liquidation or dissolution of the Company.

(f)

“Code” means the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.

A-1 | Page   


(g)

“Common Stock” means the common stock of the Company and such other securities of the Company that may be substituted therefore pursuant to Section 8.

(h)

“Company” means The Cooper Companies, Inc., a Delaware corporation, or any successor.

(i)

“Compensation” of an Eligible Employee means the gross base compensation and/or sales commissions received by such Eligible Employee as compensation for services to the Company or any Designated Subsidiary, but excluding overtime payments, incentive compensation, bonuses, expense reimbursements, fringe benefits and other special payments. The Administrator, in its sole discretion, may, on a uniform and nondiscriminatory basis for each Offering, establish a different definition of Compensation. Further, the Administrator shall have the discretion to determine the application of this definition to Participants on payrolls outside of the United States.

(j)

“Designated Subsidiary” means any Subsidiary designated by the Administrator as participating in the Plan in accordance with Section 11(c)(ii).

(k)

“Effective Date” means the date the Plan is adopted by the Board; provided, however, that no Employee will have any rights under the Plan before the first Offering Period, which will be determined by the Administrator in its sole discretion.

(l)

“Eligible Employee” means an Employee (i) who does not, immediately after any rights under this Plan are granted, own (directly or through attribution) stock possessing five percent (5%) or more of the total combined voting power or value of all classes of Common Stock and other stock of the Company, a Parent or a Subsidiary (as determined under Section 423(b)(3) of the Code) and (ii) whose customary employment is for at least twenty (20) hours per week and five (5) months or more in any calendar year. For purposes of the foregoing sentence, the rules of Section 424(d) of the Code with regard to the attribution of stock ownership will apply in determining the stock ownership of an individual, and stock that an Employee may purchase under outstanding options will be treated as stock owned by the Employee; provided, however, that the Administrator may determine in its discretion that an Employee will not be eligible to participate in an Offering if: (x) such Employee is a highly compensated employee within the meaning of Section 423(b)(4)(D) of the Code; and/or (y) such Employee has not met a service requirement designated by the Administrator pursuant to Section 423(b)(4)(A) of the Code (which service requirement may not exceed two (2) years); and/or (z) such Employee is a citizen or resident of a foreign jurisdiction and the grant of a right to purchase Common Stock under the Plan to such Employee would be prohibited under the laws of such foreign jurisdiction or the grant of a right to purchase Common Stock under the Plan to such Employee in compliance with the laws of such foreign jurisdiction would cause the Plan to violate the requirements of Section 423 of the Code, as determined by the Administrator in its sole discretion; provided, further, that any exclusion in clauses (x), (y), or (z) will be applied in an identical manner to all Participants of each Offering in accordance with Treasury RegulationAdopted:Section 1.423-2(e). In the case of individuals who perform services for the Company or a Designated Subsidiary in jurisdictions in which local law prohibits the Company from discriminating in its granting of benefits on the basis of number of hours worked, the determination of who is an Eligible Employee will be made without regard to the number of hours worked.

(m)

“Employee” means any officer or other employee (as defined in accordance with Section 3401(c) of the Code) of the Company or any Designated Subsidiary. “Employee” does not include any director of the Company or a Designated Subsidiary who does not render services to the Company or a Designated Subsidiary as an employee within the meaning of Section 3401(c) of the Code. For purposes of the Plan, the employment relationship will be treated as continuing intact while the individual is on sick leave or other leave of absence approved by the Company or Designated Subsidiary and meeting the requirements of Treasury RegulationSection 1.421-1(h)(2). Where the period of leave exceeds three (3) months and the individual’s right to reemployment is not guaranteed either by statute or by contract, the employment relationship will be deemed to have terminated on the first day immediately following such three (3) month period, unless provided otherwise under Applicable Law. For purposes of clarity, the term “Employee” will not include the following, regardless of any subsequent reclassification as an employee by

A-2 | Page   


 the Company or a Designated Subsidiary, any governmental agency, or any court: (i) any independent contractor; (ii) any consultant; (iii) any individual performing services for the Company or a Designated Subsidiary under a purchase order, a supplier agreement or any other agreement that the Company or a Designated Subsidiary enters into for services; (iv) any individual classified by the Company or a Designated Subsidiary as contract labor (such as contractors, contract employees, job shoppers), regardless of length of service; and (vi) any leased employee. The Administrator will have exclusive discretion to determine whether an individual is an Employee for purposes of the Plan.

(n)

“Enrollment Date” means the first Trading Day of each Offering Period.

(o)

“Exchange Act” means the Securities Exchange Act of 1934, as amended from time to time.

(p)

“Fair Market Value” means the value of a Share on a particular date determined by such methods or procedures as may be established by the Administrator. Unless otherwise determined by the Administrator, the Fair Market Value of Common Stock as of any date is the closing price for the Common Stock as reported on the New York Stock Exchange (or on any other national securities exchange on which the Common Stock is then listed) for that date or, if no closing price is reported for that date, the closing price on the immediately preceding date for which a closing price was reported.

(q)

“Offering” has the meaning given to such term in Section 4(a).

(r)

“Offering Document” has the meaning given to such term in Section 4(a).

(s)

“Offering Period” has the meaning given to such term in Section 4(a).

(t)

“Parent” means any corporation, other than the Company, in an unbroken chain of corporations ending with the Company if, at the time of the determination, each of the corporations other than the Company owns stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such chain.

(u)

“Participant” means any Eligible Employee who has executed a subscription agreement and been granted rights to purchase Common Stock pursuant to the Plan.

(v)

“Plan” means this The Cooper Companies, Inc. 2019 Employee Stock Purchase Plan, as it may be amended from time to time.

(w)

“Purchase Date” means the last Trading Day of each Offering Period.

(x)

“Purchase Price” means the purchase price designated by the Administrator in the applicable Offering Document (which purchase price will not be less than eighty-five percent (85%) of the Fair Market Value of a Share on the Purchase Date); provided, however, that, in the event no purchase price is designated by the Administrator in the applicable Offering Document, the purchase price for the Offering Periods covered by such Offering Document will be eighty-five percent (85%) of the Fair Market Value of a Share on the Purchase Date; provided, further, that the Purchase Price may be adjusted by the Administrator without shareholder approval to any purchase price that complies with Section 423 of the Code, including pursuant to Section 8(a), and will not be less than the par value of a Share.

(y)

“Qualified ESPP” has the meaning given to such term in Section 1.

(z)

“Securities Act” means the Securities Act of 1933, as amended.

(aa) “Share” means a share of Common Stock.

(bb)

“Subsidiary” means any corporation, other than the Company, in an unbroken chain of corporations beginning with the Company if, at the time of the determination, each of the corporations other than the last corporation in an unbroken chain owns stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such chain; provided, however, that a limited liability company or partnership may be treated as a Subsidiary to the extent either (i) such entity is treated as a disregarded entity under Treasury RegulationA-2Section 301.7701-3(a) by reason

A-3 | Page   


 of the Company or any other Subsidiary that is a corporation being the sole owner of such entity, or (ii) such entity elects to be classified as a corporation under Treasury RegulationSection 301.7701-3(a) and such entity would otherwise qualify as a Subsidiary.


(cc)

“Trading Day” means a day on which national stock exchanges in the United States are open for trading.

Third Amended and Restated 2007 Long-Term Incentive3.    Shares Subject to the Plan

 

(a)

Number of Shares. Subject to Section 8, the aggregate number of Shares that may be issued pursuant to rights granted under the Plan is One Million (1,000,000) Shares. If any right granted under the Plan terminates for any reason without having been exercised, the Common Stock not purchased under such right will again become available for issuance under the Plan.

(t)

(b)

Stock Distributed. Any Common Stock distributed pursuant to the Plan may consist, in whole or in part, of authorized and unissued Common Stock, treasury stock, or Common Stock purchased on the open market.

“Plan”4.    Offering Periods; Offering Documents means this 2007 Long-Term Incentive

(a)

Offering Periods. The Administrator may from time to time grant or provide for the grant of rights to purchase Common Stock under the Plan to Eligible Employees (an “Offering”) during one (1) or more periods (each, an “Offering Period”) selected by the Administrator. The terms and conditions applicable to each Offering Period will be set forth in an “Offering Document” adopted by the Administrator, which Offering Document will be in such form and will contain such terms and conditions as the Administrator will deem appropriate and will be incorporated by reference into and made part of the Plan and will be attached hereto as part of the Plan. The provisions of separate Offering Periods under the Plan need not be identical.

(b)

Offering Documents. Each Offering Document with respect to an Offering Period will specify (through incorporation of the provisions of this Plan by reference or otherwise):

(i)

The length of the Offering Period, which period will not exceed twenty-seven (27) months;

(ii)

The maximum number of Shares that may be purchased by any Eligible Employee during such Offering Period, to be determined by the Administrator as set forth in Section 5(e); and

(iii)

Such other provisions as the Administrator determines are appropriate, subject to the Plan.

5.    Eligibility and Participation

(a)

Eligibility. Any Eligible Employee who is employed by the Company or a Designated Subsidiary on a given Enrollment Date for an Offering Period is eligible to participate in the Plan during such Offering Period, subject to the requirements of this Section 5 and the limitations imposed by Section 423(b) of the Code.

(b)

Enrollment in Plan:

(i)

Except as otherwise set forth in an Offering Document or determined by the Administrator, an Eligible Employee may become a Participant in the Plan for an Offering Period by delivering a subscription agreement to the Company by such time prior to the Enrollment Date for such Offering Period (or such other date specified in the Offering Document) designated by the Administrator and in such form as the Company provides.

(ii)

Each subscription agreement will designate a whole percentage of such Eligible Employee’s Compensation to be withheld by the Company or the Designated Subsidiary employing such Eligible Employee on each payday during the Offering Period as payroll deductions under the Plan. The percentage of Compensation designated by an Eligible Employee as payroll deductions may not be less than one percent (1%) and may not be more than fifteen percent (15%), or such lower limit as may be set by the Administrator for the Offering Period. The payroll deductions made for each Participant will be credited to an account for such Participant under the Plan and will be deposited with the general funds of the Company, unless required otherwise under Applicable Law.

A-4 | Page   


(iii)

A Participant may increase (but not decrease) the percentage of Compensation designated in his or her subscription agreement, subject to the limits of this Section 5(b), prior to the Enrollment Date for such Offering Period (or such other date specified in the Offering Document) designated by the Administrator and in such form as the Company provides, or may suspend his or her payroll deductions. A Participant may not decrease the percentage of Compensation designated in his or her subscription agreement; such Participant may only suspend deductions or withdraw from such Offering Period in accordance with Section 7(a). Any increase or suspension of payroll deductions will become effective as soon as reasonably practicable after the Company’s receipt of the Participant’s new subscription agreement and, to the extent possible, within the Offering Period with respect to which it is requested by the Participant. In the event a Participant suspends his or her payroll deductions, the balance of the amount credited to the account of such Participant will be applied to the purchase of Shares on the next following Purchase Date. The balance of the amount credited to the account of any Participant that has not been applied to the purchase of Shares by reason of Section 423(b)(8) of the Code, Section 5(e) or the other limitations set forth in this Plan will be paid to such Participant in one lump sum in cash as soon as reasonably practicable.

(iv)

Except as otherwise set forth in an Offering Document or determined by the Administrator, a Participant may participate in the Plan only by means of payroll deduction and may not make contributions by lump sum payment for any Offering Period, unless required otherwise under Applicable Law.

(c)

Payroll Deductions. Except as otherwise provided in the applicable Offering Document, payroll deductions for a Participant will commence on the first payroll following the Enrollment Date and will end on the last payroll in the Offering Period to which the Participant’s authorization is applicable, unless sooner terminated by the Participant as provided in Section 7 or suspended by the Participant or the Administrator as provided in Section 5(b) and Section 5(e), respectively.

(d)

Effect of Enrollment. A Participant’s completion of a subscription agreement will enroll such Participant in the Plan for each subsequent Offering Period on the terms contained therein until the Participant either submits a new subscription agreement, withdraws from participation under the Plan as provided in Section 7 or otherwise becomes ineligible to participate in the Plan.

(e)

Limitation on Purchase of Common Stock. In connection with each Offering Period, the Administrator, in its sole discretion, may, on a uniform and nondiscriminatory basis, specify:

(i)

A maximum number of Shares that may be purchased by any Participant on any Purchase Date during such Offering Period, which, in the absence of a lower specification by the Administrator, will be five hundred (500) Shares (subject to adjustment under Section 8) for Offering Periods of three (3) months; and

(ii)

A maximum aggregate number of Shares that may be purchased by all Participants on any Purchase Date during an Offering Period, which, in the absence of a lower specification by the Administrator, will be Fifty Thousand (50,000) Shares (subject to adjustment under Section 8) for Offering Periods of three (3) months.

If the aggregate number of Shares issuable upon exercise of purchase rights during the Offering Period would exceed any such maximum aggregate number, then, in the absence of any Administrator action otherwise, the maximum aggregate number of Shares will be allocated on a pro rata basis according to each Participant’s accumulated payroll deduction (rounded down to the nearest whole Share). An Eligible Employee may be granted rights under the Plan as hereinafter amended from timeonly if such rights, together with any other rights granted to time.

(u)“Restricted Stock” means an award of shares of Stock that is subject to restrictionssuch Eligible Employee under Section 7 below.

(v)“Retirement” means Normal or Early Retirement.

(w)“Stock” means the Common Stock, $-0-.10 par value per share,“employee stock purchase plans” of the Company.

(x)“Stock Appreciation Right”Company, any Parent or“SAR” means any Subsidiary, as specified by Section 423(b)(8) of the right pursuantCode, do not permit such employee’s rights to an award granted under Section 6 below to receive frompurchase stock of the Company an amount of cash or shares of Stock withany Parent or Subsidiary to accrue at a Fair Market Value equal to the excess, if any,rate that exceeds twenty five thousand dollars (US$25,000) of the Fair Market Value of a number of shares of Stock specified in such award at the time of exercise of the right over a base price as set by the Committee at the time of grant (which base price shall not be less than the Fair Market Value on the date the right was granted).

(y)“Stock Option” or“Option” means any option to purchase shares of Stock (including Restricted Stock and Deferred Stock, if the Committee so determines) granted pursuant to Section 5 below.

(z)“Stock Purchase Right” means the right to purchase Stock pursuant to Section 9.

(aa)“Subsidiary” means any corporation (other than the Company) in an unbroken chain of corporations beginning with the Company if each of the corporations (other than the last corporation in the unbroken chain) owns stock possessing 50%, or more of the total combined voting power of all classes of stock in one of the other corporations in the chain.

In addition, the term “Cause” shall have the meaning set forth in Section 5(i) below.

Section 2. Administration.

The Plan shall be administered by the Board or, if the Board delegates its power and authority to administer this Plan to a committee of the Board, such committee. Any such committee shall consist solely of two or more directors appointed by and holding office at the pleasure of the Board, at least two of whom is a “Non-Employee Director” of the Company as defined in Rule 16b-3 of the Exchange Act and an “outside director” for purposes of Section 162(m) of the Code. If the Board delegates its power and authority to administer this Plan to a committee, the members of such committee shall serve at the pleasure of the Board, such committee members may resign at any time by delivering written notice to the Board and vacancies in the committee may be filled by the Board.

The Committee shall have full authority to grant, pursuant to the terms of the Plan, to officers, consultants and other key employees eligible under Section 4: (i) Stock Options, (ii) Stock Appreciation Rights, (iii) Restricted Stock, (iv) Deferred Stock, (v) Stock Purchase Rights, and/or (vi) Long-term Performance Awards.

In particular, the Committee shall have the authority:

(i) to select the officers, consultants and other key employees of the Company and its Subsidiaries and Affiliates to whom Stock Options, Stock Appreciation Rights, Restricted Stock, Deferred Stock, Stock Purchase Rights, and/or Long-term Performance Awards may from time to time be granted hereunder;

Adopted:A-3


Third Amended and Restated 2007 Long-Term Incentive Plan

(ii) to determine whether and to what extent Incentive Stock Options, Non-Qualified Stock Options, Stock Appreciation Rights, Restricted Stock, Deferred Stock, Stock Purchase Rights, and/or Long-term Performance Awards, or any combination thereof, are to be granted hereunder to one or more eligible employees;

(iii) to determine the number of shares, if applicable, to be covered by each such award granted hereunder;

(iv) to determine the terms and conditions, not inconsistent with the terms of the Plan, of any award granted hereunder (including, but not limited to, the share price and any restriction or limitation, or any vesting acceleration or waiver of forfeiture restrictions as a result of death, Disability, Retirement or Change in Control, regarding any award and/or the shares of Stock relating thereto, based in each case on such factors as the Committee shall determine, in its sole discretion);

(v) to determine whether and under what circumstances an award may be settled in cash instead of Stock;

(vi) to determine whether, to what extent and under what circumstances awards under the Plan and/or other cash awards made by the Company are to be made, and operate, on a tandem basis vis à vis other awards under the Plan and/or cash awards made outside of the Plan, or on an additive basis;

(vii) to determine whether, to what extent and under what circumstances Stock and other amounts, payable with respect to an award under this Plan shall be deferred either automatically or at the election of the participant (including providing for and determining the amount (if any) of any deemed earnings on any deferred amount during any deferral period); and

(viii) to determine the terms and restrictions applicable to Stock Purchase Rights and the Stock purchased by exercising such Rights.

(ix) to interpret the Plan and remedy any inconsistencies and ambiguities herein and between any agreement evidencing an award thereunder.

The Committee shall have the authority to adopt, alter and repeal such rules, guidelines and practices governing the Plan as it shall, from time to time, deem advisable; to interpret the terms and provisions of the Plan and any award issued under the Plan (and any agreements relating thereto); and to otherwise supervise the administration of the Plan.

All decisions made by the Committee pursuant to the provisions of the Plan shall be made in the Committee’s sole discretion and shall be final and binding on all persons, including the Company and Plan participants.

Adopted:A-4


Third Amended and Restated 2007 Long-Term Incentive Plan

Section 3. Stock Subject To Plan.

(a) The total number of shares of Stock reserved and available for distribution pursuant to stock options or other awards relating to Stock made under the Plan shall be 6,930,000 shares. Such shares may consist, in whole or in part, of authorized and unissued shares or treasury shares. The maximum number of shares with respect to which an employee may be granted awards under this Plan during any fiscal year is 250,000. The maximum number of shares that may be subject to the grant of Incentive Stock Options shall be 6,930,000 shares.

(b) Subject to Section 6(b)(iv) below, if any shares of Stock subject to a Stock Option or Stock Appreciation Right is forfeited or lapse without being exercised, or if any shares of Stock that are subject to any Restricted Stock or Deferred Stock Award, Stock Purchase Right, or Long-term Performance Award granted hereunder are forfeited or any such award otherwise terminates without a payment being made to the participant in the form of Stock, such shares shall again be available for distribution in connection with future awards under the Plan. Any Shares repurchased by the Company under Sections 7(c)(iii), or 8(b)(iii) at the same price paid by the participant so that such shares are returned to the Company shall again be available for future awards under the Plan.

(c) In the event of any merger, reorganization, consolidation, recapitalization, Stock dividend, Stock split, combination or exchange of shares, merger, consolidation or other distribution (other than normal cash dividends) of Company assets to stockholders, or other change in corporate structure affecting the Stock, an equitable and appropriate substitution or adjustment shall be made in the aggregate number of shares reserved for issuance under the Plan, in the number and option or base price of shares subject to outstanding Options and SARs granted under the Plan, in the number and purchase price of shares subject to outstanding Stock Purchase Rights under the Plan, and in the number of shares subject to other outstanding awards granted under the Plan, provided that the number of shares subject to any Grant shall always be a whole number. The right to have such substitutions and adjustments made is nondiscretionary, but how such substitutions and adjustments are made shall be determined in the discretion of the Committee. In addition, in the event of any merger or other corporate transaction or event which results in shares of Stock being purchased for cash, or being exchanged for or converted into cash or the right to receive cash, the Committee, in its sole discretion, and on such terms and conditions as it deems appropriate, may provide that any Stock Option, Stock Appreciation Right, Restricted Stock or Deferred Stock Award, Stock Purchase Right, or Long-term Performance Award shall be converted into the right to receive an amount of cash equal to the amount of cash, if any, that would have been received, in the event of such merger or corporate transaction or event, if such Stock Option, Stock Appreciation Right, Restricted Stock or Deferred Stock Award, Stock Purchase Right, or Long-term Performance Award had been fully exercisable or payable, or vested and had been exercised or paid immediately prior to such merger or other corporate transaction or event to the extent of the cash value thereof, and, upon such conversion, such Stock Option, Stock Appreciation Right, Restricted Stock or Deferred Stock Award, Stock Purchase Right, or Long-term Performance Award (including any such Stock Option, Stock Appreciation Right, Restricted Stock or Deferred Stock Award, Stock Purchase Right, or Long-term Performance Award which, under the terms of such merger or other corporate transaction or event, would have no cash value) shall be cancelled.

Adopted:A-5


Third Amended and Restated 2007 Long-Term Incentive Plan

Section 4. Eligibility.

Officers, consultants and such employees of the Company and its Subsidiaries and Affiliates (but excluding members of the Committee and any person who serves only as a director) whom the Committee determines is responsible for or contributes to the management, growth and/or profitability of the business of the Company and/or its Subsidiaries and Affiliates are eligible to be granted awards under the Plan.

Section 5. Stock Options.

Stock Options may be granted alone, in addition to or in tandem with other awards granted under the Plan and/or cash awards made outside of the Plan. Any Stock Option granted under the Plan shall be in such form as the Committee may from time to time approve.

Stock Options granted under the Plan may be of two types: (i) Incentive Stock Options and (ii) Non-Qualified Stock Options.

The Committee shall have the authority to grant to any optionee Incentive Stock Options, Non-Qualified Stock Options, or both types of Stock Options (in each case with or without Stock Appreciation Rights); provided, however that Incentive Stock Options shall only be granted to an individual who, at the time of grant, is an employee of the Company or a Subsidiary.

Options granted under the Plan shall be subject to the following terms and conditions and shall contain such additional terms and conditions, not inconsistent with the terms of the Plan, as the Committee shall deem desirable:

(a)Option Price. The option price per share of Stock purchasable under a Stock Option shall be determined by the Committee at the time of grant but shall not be less than the Fair Market Value on the date of grant.

(b)Option Term. The term of each Stock Option shall be fixed by the Committee, but no Stock Option shall be exercisable more than ten years after the date the Option is granted. No Incentive Stock Option shall be granted more than ten years after the date this Plan is approved by the stockholders of the Company under Section 14.

(c)Exercisability. Stock Options shall be exercisable at such time or times and subject to such terms and conditions as shall be determined by the Committee in its sole discretion at or after grant.

(d)Method of Exercise. Subject to whatever exercise provisions apply under Section 5(c), Stock Options may be exercised in whole or in part at any time during the option period, by giving written notice of exercise to the Company specifying the number of shares to be purchased. Such notice shall be accompanied by payment in full of the purchase price, either by check, note or such other instrument as the Committee may accept. Except as otherwise prohibited by law, as determined by the Committee, in its sole discretion, at or after grant, payment in full or in part may also be made (i) in the form of Stock subject to an award (based, in each case, on the Fair Market Value of the Stock on the date the option is exercised, as determined by the Committee); provided, however, that, in the case of an Incentive Stock Option, the right to make a payment in the form of already owned shares may be authorized only at the time the option is granted; or (ii) through the delivery of a

Adopted:A-6


Third Amended and Restated 2007 Long-Term Incentive Plan

notice that the optionee has placed a market sell order with a broker with respect to shares of Stock then issuable upon exercise of the Option, and that the broker has been directed to pay a sufficient portion of the net proceeds of the sale to the Company in satisfaction of the Option exercise price, provided that payment of such proceeds is made to the Company prior to the delivery of any shares of Stock by the Company. No shares of Stock shall be issued until full payment therefor has been made. An optionee shall generally have the rights to dividends or other rights of a stockholder with respect to shares subject to the Option when the optionee has given written notice of exercise, has paid in full for such shares, and, if requested, has given the representation described in Section 13(a).

(e)Transferability of Options. No Stock Option shall be transferable by the optionee otherwise than by will or by the laws of descent and distribution, and all Stock Options shall be exercisable, during the optionee’s lifetime, only by the optionee or by his guardian or legal representative. Notwithstanding the foregoing, a Non-Qualified Stock Option may be transferred to, exercised by and paid to a trust in which the optionee has a fifty percent or more interest or a foundation which the optionee controls the management of the assets, provided that (i) the optionee receives no consideration for such transfer, and (ii) the transferee receives the Non-Qualified Stock Option subject to the same restrictions imposed upon the transferor and pursuant to such conditions and procedures as the Committee may establish. Any permitted transfer shall be subject to the condition that the Committee receives evidence satisfactory to it that the trust is and shall remain under the control of the optionee and that the transfer is being made for estate and/or tax planning purposes and on a basis consistent with the Company’s lawful issue of securities.

(f)Termination by Death. Subject to Section 5(j), if an optionee’s employment by or consultancy with the Company and any Subsidiary or Affiliate terminates by reason of death, any Stock Option held by such optionee may thereafter be exercised, to the extent such option was exercisable at the time of death or on such accelerated basis as the Committee may determine at or after grant (or as may be determined in accordance with procedures established by the Committee), by the legal representative of the estate or by the legatee of the optionee under the will of the optionee, for a period of three years (or such other period as the Committee may specify at grant) from the date of such death or until the expiration of the stated term of such Stock Option, whichever period is the shorter.

(g)Termination by Reason of Disability. Subject to Section 5(j), if an optionee’s employment by or consultancy with the Company and any Subsidiary or Affiliate terminates by reason of Disability, any Stock Option held by such optionee may thereafter be exercised by the optionee, to the extent it was exercisable at the time of termination or on such accelerated basis as the Committee may determine at or after grant (or as may be determined in accordance with procedures established by the Committee), for a period of three years (or such other period as the Committee may specify at grant) from the date of such termination of employment or consultancy or until the expiration of the stated term of such Stock Option, whichever period is the shorter; provided, however, that, if the optionee dies within such three-year period (or such other period as the Committee shall specify at grant), any unexercised Stock Option held by such optionee shall thereafter be exercisable to the extent to which it was exercisable at the time of death for a period of twelve months from the date of such death or until the expiration of the stated term of such Stock Option, whichever period is the shorter. In the event of termination of employment by reason of Disability, if an Incentive Stock Option is exercised after the expiration of the exercise periods that apply for purposes of Section 422 of the Code, such Stock Option will thereafter be treated as a Non-Qualified Stock Option.

Adopted:A-7


Third Amended and Restated 2007 Long-Term Incentive Plan

(h)Termination by Reason of Retirement. Subject to Section 5(j), if an optionee’s employment by or consultancy with the Company and any Subsidiary or Affiliate terminates by reason of Normal or Early Retirement, any Stock Option held by such optionee may thereafter be exercised by the optionee, to the extent it was exercisable at the time of such Retirement or on such accelerated basis as the Committee may determine at or after grant (or as may be, determined in accordance with procedures established by the Committee), for a period of three years (or such other period as the Committee may specify at grant) from the date of such termination of employment or consultancy or the expiration of the stated term of such Stock Option, whichever period is the shorter; provided, however, that, if the optionee dies within such three-year period (or such other period as the Committee may specify at grant), any unexercised Stock Option held by such optionee shall thereafter be exercisable, to the extent to which it was exercisable at the time of death, for a period of twelve months from the date of such death or until the expiration of the stated term of such Stock Option, whichever period is the shorter. In the event of termination of employment by reason of Retirement, if an Incentive Stock Option is exercised after the expiration of the exercise periods that apply for purposes of Section 422 of the Code, the option will thereafter be treated as a Non-Qualified Stock Option.

(i)Other Termination. Unless otherwise determined by the Committee (or pursuant to procedures established by the Committee) at or after grant, if an optionee’s employment by or consultancy with the Company and any Subsidiary or Affiliate terminates for any reason other than death, Disability or Normal or Early Retirement, the Stock Option shall thereupon terminate, except that such Stock Option may be exercised for the lesser of three months or the balance of such Stock Option’s term if the optionee is involuntarily terminated by the Company and any Subsidiary or Affiliate without Cause. For purposes of this Plan, “Cause” means the conviction of, or plea of nolo contendere to a felony by the participant, or a participant’s willful misconduct or dishonesty, any of which is directly and materially harmful to the business or reputation of the Company or any Subsidiary or Affiliate.

(j)Incentive Stock Options. Anything in the Plan to the contrary notwithstanding, no term of this Plan relating to Incentive Stock Options shall be interpreted, amended or altered, nor shall any discretion or authority granted under the Plan be so exercised, so as to disqualify the Plan under Section 422 of the Code, or, without the consent of the optionee(s) affected, to disqualify any Incentive Stock Option under such Section 422.

To the extent required for ‘incentive stock option’ status under Section 422(b)(7) of the Code (taking into account applicable Internal Revenue Service regulations and pronouncements), the Plan shall be deemed to provide that the aggregate Fair Market Value (determined as of the time of grant)first day of the stock with respect toOffering Period during which Incentive Stock Optionssuch rights are exercisablegranted) for the first time by the optionee during anyeach calendar year under the Plan and/orin which such rights are outstanding at any other stock option plan of the Company or any Subsidiary or parent corporation (within the meaning of Section 424 of the Code) after 1986 shall not exceed $100,000. If the aggregate Fair Market Value exceeds $100,000, then those options in excess of $100,000 will not be treated as ISOs. Those shares not treated as ISOstime. This limitation will be taxed at ordinary income rates on exercise. If Section 422 is hereafter amended to delete the requirement now in Section 422(b)(7) that the plan text expressly provide for the $100,000 limitation set forth in Section 422(b)(7), then this paragraph of Section 5(j) shall no longer be operative.

Adopted:A-8


Third Amended and Restated 2007 Long-Term Incentive Plan

(k)Buyout Provisions. The Committee may at any time offer to buy out for a payment in cash, Stock or Restricted Stock an option previously granted, based on such terms and conditions as the Committee shall establish and communicate to the optionee at the time that such offer is made; provided, however, that unless stockholder approval is obtained, the Committee shall not offer to buy out any Option having a per share exercise price greater than the per share Fair Market Value of a share of Stock at the time of such offer. In no event may the Company buyout any Stock Option with the grant of another Stock Option, with a lower exercise price without shareholder approval.

(l)Settlement Provisions. If the option agreement so provides at grant, or is amended after grant and prior to exercise to so provide (with the optionee’s consent), the Committee may require that all or part of the shares to be issued with respect to the spread value of an exercised Option take the form of Restricted Stock, which shall be valued on the date of exercise on the basis of the Fair Market Value (as determined by the Committee) of such Restricted Stock determined without regard to the forfeiture restrictions involved.

(m)10% Stockholders. No Incentive Stock Option may be granted under this Plan to any employee who, at the time the Incentive Stock Option is granted, owns, or is considered as owning, within the meaning of Section 422 of the Internal Revenue Code, shares possessing more than ten percent (10%) of the total combined voting power or value of all classes of stock of the Company, a Subsidiary or a parent corporation (within the meaning of Section 424 of the Code) unless the option price under such Option is at one hundred ten percent (110%) of the Fair Market Value of a share of Stock on the date such Option is granted and the duration of such Option is no more than five (5) years.

Section 6. Stock Appreciation Rights.

(a)Exercise. A Stock Appreciation Right may be exercised by a recipient, subject to Section 6(b),applied in accordance with the procedures established by the Committee for such purpose. Upon such exercise, the recipient shall be entitled to receive an amount determined in the manner prescribed in Section 6(b).

(b)Terms and Conditions. Stock Appreciation Rights shall be subject to such terms and conditions, not inconsistent with the provisions of the Plan, as shall be determined from time to time by the Committee, including the following:

(i) Upon the exercise of a Stock Appreciation Right, a recipient shall be entitled to receive an amount in cash and/or shares of Stock with a Fair Market Value, as the Committee in its sole discretion shall determine, equal to the excess of the Fair Market Value of a number of shares of Stock specified in the award at the date of exercise of the Stock Appreciation Right over the base price as specified in the Grant. When payment is to be made in shares, the number of shares to be paid shall be calculated on the basis of the Fair Market Value of the shares on the date of exercise.

(ii) Stock Appreciation Rights shall not be transferable by the recipient thereof otherwise than by will or by the laws of descent and distribution, and all Stock Appreciation Rights shall be exercisable, during the recipient’s lifetime, only by the recipient.

Adopted:A-9


Third Amended and Restated 2007 Long-Term Incentive Plan

Section 7. Restricted Stock.

(a)Administration. Shares of Restricted Stock may be issued either alone, in addition to or in tandem with other awards granted under the Plan and/or cash awards made outside of the Plan. The Committee shall determine the eligible persons to whom, and the time or times at which, grants of Restricted Stock will be made, the number of shares to be awarded, the price to be paid by the recipient of Restricted Stock (subject to Section 7(b)), the time or times within which such awards may be subject to forfeiture, and all other terms and conditions of the awards.

The Committee may condition the grant of Restricted Stock upon the attainment of specified performance goals (including goals based on the Performance Criteria) or such other factors as the Committee may determine, in its sole discretion.

The provisions of Restricted Stock awards need not be the same with respect to each recipient.

(b)Awards and Certificates. The prospective recipient of a Restricted Stock Award shall not have any rights with respect to such award, unless and until such recipient has executed an agreement evidencing the award and has delivered a fully executed copy thereof to the Company, and has otherwise complied with the applicable terms and conditions of such award. Each award shall be subject to the following terms and conditions:

(i) Unless the Committee determines that no purchase price is required by law, then the purchase price for shares of Restricted Stock shall be equal to or greater than their par value.

(ii) Awards of Restricted Stock must be accepted within a period of 60 days (or such shorter period as the Committee may specify at grant) after the award date, by executing a Restricted Stock Award agreement and paying whatever price is required under Section 7(b)(i).

(iii) Each participant receiving a Restricted Stock Award shall be issued shares of Stock, either in book form or electronically, evidencing the grant of the Restricted Stock, registered in the name of such participant, noting the terms, conditions and restrictions applicable to such award. The Committee in its sole discretion may issue stock certificates to evidence the Restricted Stock Award. If a stock certificate is issued, it shall bear an appropriate legend referring to the terms, conditions, and restrictions applicable to such award.

(iv) The Committee shall require that any stock certificates evidencing such shares issued be held in custody by the Company until the restrictions, if any, thereon shall have lapsed, and that, as a condition of any Restricted Stock Award, the participant shall have delivered a stock power, endorsed in blank, relating to the Stock covered by such award.

(c)Restrictions and Conditions. The shares of Restricted Stock awarded pursuant to this Section 7 shall be subject to the following restrictions and conditions:

(i) Subject to the provisions of this Plan and the award agreement, during a period set by the Committee commencing with the date of such award (the ‘Restriction Period’), the participant shall not be permitted to sell, transfer, pledge or assign shares of Restricted Stock awarded under the Plan. Within these limits, the Committee, in its sole discretion, may provide for the lapse of such restrictions in installments in whole or in part, based on service, performance and/or such other factors or criteria as the Committee may determine, in its sole discretion.

Adopted:A-10


Third Amended and Restated 2007 Long-Term Incentive Plan

(ii) Except as provided in this paragraph (ii) and Section 7(c)(i), the participant shall have, with respect to the shares of Restricted Stock, all of the rights of a stockholder of the Company, including the right to vote the shares, and the right to receive any cash dividends. The Committee, in its sole discretion, as determined at the time of award, may permit or require the payment of cash dividends to be deferred and, if the Committee so determines, reinvested, subject to Section 13(e), in additional Restricted Stock to the extent shares are available under Section 3, or otherwise reinvested. Pursuant to Section 3 above, Stock dividends issued with respect to Restricted Stock shall be treated as additional shares of Restricted Stock that are subject to the same restrictions and other terms and conditions that apply to the shares with respect to which such dividends are issued. In addition, with respect to a share of Restricted Stock with performance-based vesting, dividends which are paid prior to vesting shall only be paid out to the participant to the extent that the performance-based vesting conditions are subsequently satisfied and the share of Restricted Stock vests.

(iii) Subject to the applicable provisions of the award agreement and this Section 7, upon termination of a participant’s employment or consultancy with the Company and any Subsidiary or Affiliate for any reason during the Restriction Period, all shares still subject to restriction will vest, or be forfeited, in accordance with the terms and conditions established by the Committee at or after grant. If any Restricted Stock is forfeited, the Company shall pay to the participant (or the estate of a deceased participant) an amount equal to the price, if any, that the participant paid with respect to such Restricted Stock.

(iv) If and when the Restriction Period expires without a prior forfeiture of the Restricted Stock subject to such Restriction Period, an appropriate number of unrestricted shares shall be delivered to the participant promptly in book, electronic or other form, or by issuance of share certificates as determined in the sole discretion of the Committee.

Section 8. Deferred Stock.

(a)Administration. Deferred Stock may be awarded either alone, in addition to or in tandem with other awards granted under the Plan and/or cash awards made outside of the Plan. The Committee shall determine the eligible persons to whom and the time or times at which Deferred Stock shall be awarded, the number of shares of Deferred Stock to be awarded to any person, the duration of the period (the ‘Deferral Period’) during which, and the conditions under which, receipt of the Stock will be deferred, and the other terms and conditions of the award in addition to those set forth in Section 8(b).

The Committee may condition the grant of Deferred Stock upon the attainment of specified performance goals (including goals based on the Performance Criteria) or such other factors or criteria as the Committee shall determine, in its sole discretion.

The provisions of Deferred Stock Awards need not be the same with respect to each recipient.

(b)Terms and Conditions. The shares of Deferred Stock awarded pursuant to this Section 8 shall be subject to the following terms and conditions:

(i) Subject to the provisions of this Plan and the award agreement referred to in Section 8(b)(vi) below, Deferred Stock Awards may not be sold, assigned, transferred, pledged or

Adopted:A-11


Third Amended and Restated 2007 Long-Term Incentive Plan

otherwise encumbered during the Deferral Period. At the expiration of the Deferral Period (or the Elective Deferral Period referred to in Section 8(b)(v), where applicable), the Company shall deliver to the recipient shares of Stock equal to the shares covered by the Deferred Stock Award. Such shares may be delivered in book, electronic or other form, or by issuance of share certificates as determined in the sole discretion of the Committee.

(ii) Unless otherwise determined by the Committee at grant, amounts equal to any dividends declared during the Deferral Period with respect to the number of shares covered by a Deferred Stock Award will be paid to the participant currently, or deferred and deemed to be reinvested in additional Deferred Stock, or otherwise reinvested, all as determined at or after the time of the award by the Committee, in its sole discretion. In addition, with respect to Deferred Stock Award with performance-based vesting, dividends which are paid prior to vesting shall only be paid out to the participant to the extent that the performance-based vesting conditions are subsequently satisfied and the Deferred Stock Award vests.

(iii) Subject to the provisions of the award agreement and this Section 8, upon termination of a participant’s employment or consultancy with the Company and any Subsidiary or Affiliate for any reason during the Deferral Period for a given award, the Deferred Stock in question will vest, or be forfeited, in accordance with the terms and conditions established by the Committee at or after grant. If any Deferred Stock is forfeited, the Company shall pay to the participant (or the estate of a deceased participant) an amount equal to the price, if any, the participant paid with respect to such Deferred Stock.

(iv) Based on service, performance and/or such other factors or criteria as the Committee may determine, the Committee may, at or after grant, accelerate the vesting of all or any part of any Deferred Stock Award and/or waive the deferral limitations for all or any part of such award.

(v) A participant may elect to further defer receipt of an award (or an installment of an award) for a specified period or until a specified event (the ‘Elective Deferral Period’), subject in each case to the Committee’s approval and to such terms as are determined by the Committee, all in its sole discretion. Subject to any exceptions adopted by the Committee, such election must generally be made 12 months prior to completion of the Deferral Period for such Deferred Stock Award (or such installment) and shall not take effect for at least 12 months. The Elective Deferral Period must be at least five years or, if elected by the participant, until termination of employment or a change in control of the Company (as determined under Section 409A of the Code) if earlier. Any such election shall comply with the requirements of Section 409A of the Code.

(vi) Each award shall be confirmed by, and subject to the terms of, a Deferred Stock agreement executed by the Company and the participant.

(vii) A recipient of a Deferred Stock Award shall have no rights as a stockholder with respect to any shares covered by his Deferred Stock Award until the issuance of a stock certificate for such shares.

Adopted:A-12


Third Amended and Restated 2007 Long-Term Incentive Plan

Section 9. Stock Purchase Rights.

(a)Awards and Administration. Subject to Section 3 above, the Committee may grant eligible participants Stock Purchase Rights which shall enable such participants to purchase Stock (including Deferred Stock and Restricted Stock):

(i) at its Fair Market Value on the date of grant;

(ii) at 50% of such Fair Market Value on such date;

(iii) at an amount equal to Book Value on such date; or

(iv) at an amount equal to the par value of such Stock on such date.

However, no share of Stock shall be sold at less than its par value. The Committee shall also impose such deferral, forfeiture and/or other terms and conditions as it shall determine, in its sole discretion, on such Stock Purchase Rights or the exercise thereof.

The terms of Stock Purchase Rights Awards need not be the same with respect to each participant. Each Stock Purchase Right Award shall be confirmed by, and be subject to the terms of, a Stock Purchase Rights agreement.

(b)Exercisability. Stock Purchase Rights shall generally be exercisable for such period after grant as is determined by the Committee, but not to exceed 90 days.

(c)Loans. Unless otherwise prohibited by law, if the Committee so determines, the Company shall make or arrange for a loan to a participant with respect to the exercise of Stock Purchase Rights. The Committee shall have full authority to decide whether such a loan should be made and to determine the amount, term and other provisions of any such loan, including the interest rate to be charged, whether the loan is to be with or without recourse against the borrower, the security, if any, therefor, the terms on which the loan is to be repaid and the conditions, if any, under which it may be forgiven. However, no loan hereunder shall have a term (including extensions) exceeding ten years in duration or be in an amount exceeding 90% of the total purchase price paid by the borrower.

Section 10. Long-Term Performance Awards.

(a)Administration. Long-term Performance Awards may be granted either alone or in addition to other awards granted under the Plan. The Committee shall determine the nature, length and starting date of the performance period (the ‘Performance Period’) for each Long-term Performance Award and shall determine the performance objectives to be used in the valuation of Long-term Performance Awards and determining the extent to which such Long-term Performance Awards have been earned. Performance objectives may vary, from participant to participant and between groups of participants and shall be based upon such Company, Subsidiary, Affiliate or individual performance factors or criteria as the Committee may deem appropriate, including, but not limited to the Performance Criteria. Performance Periods may overlap and participants may participate simultaneously with respect to Long-term Performance Awards that are subject to different Performance Periods and different performance factors and criteria. Long-term Performance Awards shall be confirmed by, and be subject to the terms of, a Long-term Performance Award agreement. The terms of such awards need not be the same with respect to each participant.

Adopted:A-13


Third Amended and Restated 2007 Long-Term Incentive Plan

At the beginning of each Performance Period, the Committee shall determine for each Long-term Performance Award subject to such Performance Period, the number of shares of Stock (including Deferred or Restricted Stock) to be awarded to the participant at the end of the Performance Period if and to the extent that the relevant measures of performance for such Long-term Performance Award are met. Such number of shares of Stock may be fixed or may vary in accordance with such performance or other criteria as may be determined by the Committee.

(b)Adjustment of Awards. The Committee may adjust the performance goals and measurements applicable to the Long-term Performance Awards to take into account changes in law and accounting and tax rules and to make such adjustments as the Committee deems necessary or appropriate to reflect the inclusion or exclusion of the impact of extraordinary, unusual or infrequent items, events or circumstances in order to avoid windfalls or hardships. Such adjustments may include, but are not limited to, one or more of the following: (i) items related to a change in applicable accounting standards; (ii) items relating to financing activities; (iii) expenses for restructuring or productivity initiatives; (iv) other non-operating items; (v) items related to acquisitions; (vi) items attributable to the business operations of any entity acquired by the Company during the performance period; (vii) items related to the sale or disposition of a business or segment of a business; (viii) items related to discontinued operations that do not qualify as a segment of a business under applicable accounting standards; (ix) items attributable to any stock dividend, stock split, combination or exchange of stock occurring during the performance period; (x) any other items of significant income or expense which are determined to be appropriate adjustments; (xi) items relating to unusual or extraordinary corporate transactions, events or developments, (xii) items related to amortization of acquired intangible assets; (xiii) items that are outside the scope of the Company’s core, on-going business activities; (xiv) items related to acquired in-process research and development; (xv) items relating to changes in tax laws; (xvi) items relating to major licensing or partnership arrangements; (xvii) items relating to asset impairment charges; (xviii) items relating to gains or losses for litigation, arbitration and contractual settlements; (xix) items attributable to expenses incurred in connection with a reduction in force or early retirement initiative; (xx) items relating to foreign exchange or currency transactions and/or fluctuations; or (xxi) items relating to any other unusual or nonrecurring events or changes in applicable law, applicable accounting standards or business conditions.

(c)Termination. Unless otherwise provided in the applicable Long-term Performance Award agreement, if a participant terminates employment or his consultancy during a Performance Period because of death, Disability or Retirement, such participant shall be entitled to a payment with respect to each outstanding Long-term Performance Award at the end of the applicable Performance Period:

(i) based, to the extent relevant under the terms of the award, upon the participant’s performance for the portion of such Performance Period ending on the date of termination and the performance of the Company or any applicable business unit for the entire Performance Period, and

(ii) prorated for the portion of the Performance Period during which the Participant was employed by the Company, a subsidiary or affiliate,

all as determined by the Committee. The Committee may provide for an earlier payment in settlement of such award in such amount and under such terms and conditions as the Committee deems appropriate and not inconsistent with Section 409A423(b)(8) of the Code.

 

A-5 | Page   


(f)

Suspension of Payroll Deductions. Notwithstanding the foregoing, to the extent necessary to comply with Section 423(b)(8) of the Code and Section 5(e) or the other limitations set forth in this Plan, a Participant’s payroll deductions may be suspended by the Administrator at any time during an Offering Period. The balance of the amount credited to the account of each Participant that has not been applied to the purchase of Shares by reason of Section 423(b)(8) of the Code, Section 5(e) or the other limitations set forth in this Plan will be paid to such Participant in one lump sum in cash as soon as reasonably practicable after the Purchase Date.

(g)

Foreign Employees. Subject to Section 12, the terms of which shall control, in order to facilitate participation in the Plan, the Administrator may provide for such special terms applicable to Participants who are citizens or residents of a foreign jurisdiction, or who are employed by a Designated Subsidiary outside of the United States, as the Administrator may consider necessary or appropriate to accommodate differences in local law, tax policy or custom. For an Offering, such special terms may not be more favorable than the terms of rights granted under the Plan to Eligible Employees who are residents of the United States. Moreover, the Administrator may approve such supplements to, or amendments, restatements or alternative versions of, this Plan as it may consider necessary or appropriate for such purposes without thereby affecting the terms of this Plan as in effect for any other purpose. No such special terms, supplements, amendments or restatements will include any provisions that are inconsistent with the terms of this Plan as then in effect unless this Plan could have been amended to eliminate such inconsistency without further approval by the stockholders of the Company.

(h)

Leave of Absence. If a Participant ceases active service by reason of a leave of absence, then the Participant shall have the election, exercisable up until no later than thirty (30) calendar days prior to the end of the Offering Period (or by such later date prior to the end of the Offering Period as the Administrator determines in its sole discretion) in which such leave of absence commences (or, if earlier, the date immediately preceding the date on which the Participant ceases to be an Eligible Employee), to (i) withdraw all the funds in the Participant’s account at the commencement of such leave or (ii) have such funds held for the purchase of Shares at the end of such Offering Period. If no such election is made, then such funds shall automatically be held for the purchase of Shares at the end of such Offering Period. In no event, however, shall any further payroll deductions be added to the Participant’s account following the commencement of such leave of absence, unless otherwise required by Applicable Law. Should the Participant return to active service (x) within three (3) months following the commencement of his or her leave of absence or (y) prior to the expiration of any longer period for which such Participant’s right to reemployment with the Company is guaranteed by statute or contract, then his or her payroll deductions under the Plan shall automatically resume upon his or her return at the rate in effect at the time the leave began, and if a new Offering Period begins during the period of the leave, then the Participant will automatically be enrolled in that purchase period at the rate of payroll deduction in effect for him or her at the time the leave commenced, but payroll deductions for that Offering Period shall not actually begin until the Participant returns to active service, unless otherwise required by Applicable Law. However, an individual who returns to active employment following a leave of absence that exceeds in duration the applicable (x) or (y) time period will be treated as a new Employee for purposes of subsequent participation in the Plan and must accordinglyre-enroll in the Plan (by making a timely filing of the prescribed enrollment forms) on or before the start date of any subsequent Offering Period in which he or she wishes to participate.

6.        Grant and Exercise of Rights

(a)

Grant of Rights. On the Enrollment Date of each Offering Period, each Eligible Employee participating in such Offering Period will be granted a right to purchase the maximum number of Shares specified under Section 4(b), subject to the limits in Section 5(e), and will have the right to buy, on each Purchase Date during such Offering Period (at the applicable Purchase Price), such number of whole and fractional Shares as is determined by dividing (A) such Participant’s payroll deductions accumulated prior to such Purchase Date and retained in the Participant’s account as of the Purchase Date, by (B) the applicable Purchase

A-6 | Page   


Price. The right will expire on the earlier of: (x) the last Purchase Date of the Offering Period, (y) the last day of the Offering Period and (z) the date on which the Participant withdraws in accordance with Section 7(a) or Section 7(c).

(b)

On each Purchase Date, each Participant’s accumulated payroll deductions and any other additional payments specifically provided for in the applicable Offering Document will be applied to the purchase of whole and fractional Shares, up to the maximum number of Shares permitted pursuant to the terms of the Plan and the applicable Offering Document, at the Purchase Price. Shares issued pursuant to the Plan may be evidenced in such manner as the Administrator may determine and may be issued in certificated form or issued pursuant to book-entry procedures.

(c)

Pro Rata Allocation of Shares. If the Administrator determines that, on a given Purchase Date, the number of Shares with respect to which rights are to be exercised may exceed (i) the number of Shares that were available for issuance under the Plan on the Enrollment Date of the applicable Offering Period, or (ii) the number of Shares available for issuance under the Plan on such Purchase Date, the Administrator may in its sole discretion provide that the Company will make a pro rata allocation of the Shares available for purchase on such Enrollment Date or Purchase Date, as applicable, among all Participants for whom rights to purchase Common Stock are to be exercised pursuant to this Section 6 on such Purchase Date, and will either (i) continue all Offering Periods then in effect, or (ii) terminate any or all Offering Periods then in effect pursuant to Section 9. The Administrator may make pro rata allocation of the Shares available on the Enrollment Date of any applicable Offering Period pursuant to the preceding sentence, notwithstanding any authorization of additional Shares for issuance under the Plan by the Company’s stockholders subsequent to such Enrollment Date. The balance of the amount credited to the account of each Participant that has not been applied to the purchase of Shares will be paid to such Participant in one lump sum in cash as soon as reasonably practicable after the Purchase Date.

(d)

Withholding. The Participant must make adequate provision for any federal, state, or other tax withholding obligations that arise in connection with the Participant’s participation in the Plan. The Company and the Designated Subsidiaries are authorized to withhold any applicable taxes from the Participant’s compensation, from the Shares purchased under the Plan, from the proceeds of the sale of Shares purchased under the Plan or by such other means as permissible under Applicable Law.

(e)

Conditions to Issuance of Common Stock. The Company is not required to issue or deliver any certificate or certificates for, or make any book entries evidencing, Shares purchased upon the exercise of rights under the Plan prior to fulfillment of all of the following conditions:

(i)

The admission of such Shares to listing on all stock exchanges, if any, on which the Common Stock is then listed;

(ii)

The completion of any registration or other qualification of such Shares under any state or federal law or under the rulings or regulations of the Securities and Exchange Commission or any other governmental regulatory body, that the Administrator will, in its absolute discretion, deem necessary or advisable;

(iii)

The obtaining of any approval or other clearance from any state or federal governmental agency that the Administrator, in its absolute discretion, determines to be necessary or advisable;

(iv)

The payment to the Company or a Designated Subsidiary of all amounts that the Company or the Designated Subsidiary is required to withhold under federal, state or local law as a result of the Participant’s participation in the Plan; and

(v)

The lapse of such reasonable period of time following the exercise of the rights as the Administrator may from time to time establish for reasons of administrative convenience.

(f)

ESPP Broker. If the Administrator designates or approves a stock brokerage or other financial services firm (the “ESPP Broker”) to hold shares purchased under the Plan for the accounts of Participants, the following procedures will apply. Promptly following each Purchase Date, the number of shares of Common Stock

A-7 | Page   


purchased by each Participant will be deposited into an account established in the Participant’s name with the ESPP Broker. Each Participant will be the beneficial owner of the Common Stock purchased under the Plan and will have all rights of beneficial ownership in such Common Stock. A Participant will be free to undertake a disposition of the shares of Common Stock in his or her account at any time, but, in the absence of such a disposition, the shares of Common Stock purchased under the Plan must remain in the Participant’s account at the ESPP Broker. Dividends paid in the form of shares of Common Stock with respect to Common Stock in a Participant’s account shall be credited to such account.

7.        Withdrawal; Cessation of Eligibility

(a)

Withdrawal. A Participant may withdraw all but not less than all of the payroll deductions credited to his or her account and not yet used to exercise his or her rights under the Plan at any time by giving written notice to the Company in a form acceptable to the Company no later than thirty (30) calendar days prior to the end of the Offering Period, or by such later date prior to the end of the Offering Period as the Administrator determines in its sole discretion. All of the Participant’s payroll deductions credited to his or her account during an Offering Period will be paid to such Participant as soon as reasonably practicable after receipt of notice of withdrawal and such Participant’s rights for the Offering Period will be automatically terminated, and no further payroll deductions for the purchase of Shares will be made for such Offering Period. If a Participant withdraws from an Offering Period, payroll deductions will not resume at the beginning of the next Offering Period unless the Participant timely delivers to the Company a new subscription agreement.

(b)

Future Participation. A Participant’s withdrawal from an Offering Period will not have any effect upon his or her eligibility to participate in any similar plan that may hereafter be adopted by the Company or a Designated Subsidiary or in subsequent Offering Periods that commence after the termination of the Offering Period from which the Participant withdraws.

(c)

Cessation of Eligibility. Upon a Participant’s ceasing to be an Eligible Employee for any reason, he or she will be deemed to have elected to withdraw from the Plan pursuant to this Section 7 and the payroll deductions credited to such Participant’s account during the Offering Period will be paid to such Participant or, in the case of his or her death, to the person or persons entitled thereto under Section 13(d), as soon as reasonably practicable, and such Participant’s rights for the Offering Period will automatically terminate.

8.        Adjustments Upon Changes in Stock

(a)

Changes in Capitalization. Subject to Section 8(c), in the event that the Administrator determines that any dividend or other distribution (whether in the form of cash, Common Stock, other securities, or other property), Change in Control, reorganization, merger, amalgamation, consolidation, combination, repurchase, recapitalization, liquidation, dissolution, or sale, transfer, exchange or other disposition of all or substantially all of the assets of the Company, or sale or exchange of Common Stock or other securities of the Company, issuance of warrants or other rights to purchase Common Stock or other securities of the Company, or other similar corporate transaction or event, as determined by the Administrator, affects the Common Stock such that an adjustment is determined by the Administrator to be appropriate in order to prevent dilution or enlargement of the benefits or potential benefits intended by the Company to be made available under the Plan or with respect to any outstanding purchase rights under the Plan, the Administrator will make equitable adjustments, if any, to reflect such change with respect to (i) the aggregate number and type of Shares (or other securities or property) that may be issued under the Plan (including, but not limited to, adjustments of the limitations in Sections 3(a) and 4(e), and the limitations established in each Offering Document pursuant to Section 4(b) on the maximum number of Shares that may be purchased); (b) the class(es) and number of Shares and price per Share subject to outstanding rights; and (c) the Purchase Price with respect to any outstanding rights.

A-8 | Page   


(b)

Subject to Section 8(c), in the event of any transaction or event described in Section 8(a) or any unusual or nonrecurring transactions or events affecting the Company, any Affiliate, or the financial statements of the Company or any Affiliate (including without limitation any Change in Control), or of changes in Applicable Law or accounting principles, the Administrator, in its discretion, and on such terms and conditions as it deems appropriate, is hereby authorized to take any one or more of the following actions whenever the Administrator determines that such action is appropriate in order to prevent the dilution or enlargement of the benefits or potential benefits intended to be made available under the Plan or with respect to any right under the Plan, to facilitate such transactions or events or to give effect to such changes in laws, regulations or principles:

(i)

To provide for either (A) termination of any outstanding right in exchange for an amount of cash, if any, equal to the amount that would have been obtained upon the exercise of such right had such right been currently exercisable or (B) the replacement of such outstanding right with other rights or property selected by the Administrator in its sole discretion;

(ii)

To provide that the outstanding rights under the Plan will be assumed by the successor or survivor corporation, or a parent or subsidiary thereof, or will be substituted for by similar rights covering the stock of the successor or survivor corporation, or a parent or subsidiary thereof, with appropriate adjustments as to the number and kind of shares and prices;

(iii)

To make adjustments in the number and type of Shares (or other securities or property) subject to outstanding rights under the Plan and/or in the terms and conditions of outstanding rights and rights that may be granted in the future;

(iv)

To provide that Participants’ accumulated payroll deductions may be used to purchase Common Stock prior to the next occurring Purchase Date on such date as the Administrator determines in its sole discretion and the Participants’ rights under the ongoing Offering Period(s) will be terminated; and

(v)

To provide that all outstanding rights will terminate without being exercised.

(c)

No Adjustment Under Certain Circumstances. No adjustment or action described in this Section 8 or in any other provision of the Plan is authorized to the extent that such adjustment or action would cause the Plan to fail to satisfy the requirements of Section 423 of the Code with respect to any offerings under the Plan.

(d)

No Other Rights. Except as expressly provided in the Plan, no Participant will have any rights by reason of any subdivision or consolidation of shares of stock of any class, the payment of any dividend, any increase or decrease in the number of shares of stock of any class or any dissolution, liquidation, merger, or consolidation of the Company or any other corporation. Except as expressly provided in the Plan or pursuant to action of the Administrator under the Plan, no issuance by the Company of shares of stock of any class, or securities convertible into shares of stock of any class, will affect, and no adjustment by reason thereof will be made with respect to, the number of Shares subject to outstanding rights under the Plan or the Purchase Price with respect to any outstanding rights.

9.        Amendment, Modification and Termination

(a)

Amendment, Modification and Termination. The Administrator may amend, suspend or terminate the Plan at any time and from time to time; provided, however, that approval of the Company’s stockholders will be required to amend the Plan to: (i) increase the aggregate number, or change the type, of shares that may be sold pursuant to rights under the Plan under Section 3(a) (other than an adjustment as provided by Section 8); (ii) change the corporations or classes of corporations whose employees may be granted rights under the Plan; or (iii) change the Plan in any manner that would cause the Plan to no longer be an “employee stock purchase plan” within the meaning of Section 423(b) of the Code.

(b)

Certain Changes to Plan. Without stockholder consent and without regard to whether any Participant rights may be considered to have been adversely affected, to the extent permitted by Section 423 of the Code, the Administrator is entitled to change the Offering Periods, limit the frequency and/or number of changes in the amount withheld from Compensation during an Offering Period, establish the exchange ratio applicable to amounts withheld in a currency other than U.S. dollars, permit payroll withholding in

A-9 | Page   


excess of the amount designated by a Participant in order to adjust for delays or mistakes in the Company’s processing of payroll withholding elections, establish reasonable waiting and adjustment periods and/or accounting and crediting procedures to ensure that amounts applied toward the purchase of Common Stock for each Participant properly correspond with amounts withheld from the Participant’s Compensation, and establish such other limitations or procedures as the Administrator determines in its sole discretion to be advisable that are consistent with the Plan.

(c)

Actions In the Event of Unfavorable Financial Accounting Consequences. In the event the Administrator determines that the ongoing operation of the Plan may result in unfavorable financial accounting consequences, the Administrator may, in its discretion and, to the extent necessary or desirable and permitted under Applicable Law, modify or amend the Plan to reduce or eliminate such accounting consequence including, but not limited to:

(i)

Altering the Purchase Price for any Offering Period including an Offering Period underway at the time of the change in Purchase Price;

(ii)

Shortening any Offering Period so that the Offering Period ends on a new Purchase Date, including an Offering Period underway at the time of the Administrator action; and

(iii)

Allocating Shares among Participants, provided that such allocation is consistent with Section 13(f).

Such modifications or amendments will not require stockholder approval or the consent of any Participant.

(d)

Payments Upon Termination of Plan. Upon termination of the Plan, the balance in each Participant’s Plan account will be refunded as soon as practicable after such termination, without any interest thereon, unless required otherwise by Applicable Law.

10. Term of Plan

The Plan is effective as of the Effective Date. The effectiveness of the Plan is subject to approval of the Plan by the stockholders of the Company within twelve months following the date the Plan is first approved by the Board. No right may be granted under the Plan prior to such stockholder approval. No rights may be granted under the Plan during any period of suspension of the Plan or after termination of the Plan.

11.    Administration

(a)

Administrator. Unless otherwise determined by the Board, the Administrator of the Plan will be the Organization and Compensation Committee of the Board (or another committee or subcommittee of the Board to which the Organization and Compensation Committee of the Board delegates administration of the Plan) (such committee, the “Committee”). Additionally, the Administrator may delegate theAdopted:day-to-day administration of the Plan to a committee or group of management and other Employees, provided that such committee or group shall act in accordance with the terms of the Plan and within the scope of the Administrator’s delegation. Notwithstanding the forgoing, the Board may at any time vest in the Board any authority or duties for administration of the Plan.

(b)

Action by the Administrator. Unless otherwise established by the Board or in any charter of the Administrator, a majority of the members comprising the Administrator will constitute a quorum. The acts of a majority of the members present at any meeting at which a quorum is present and, subject to Applicable Law and the Bylaws of the Company, acts approved in writing by a majority of the Administrator in lieu of a meeting, will be deemed the acts of the Administrator. Each member of the Administrator is entitled to, in good faith, rely or act upon any report or other information furnished to that member by any officer or other Employee, the Company’s independent certified public accountants, or any executive compensation consultant or other professional retained by the Company to assist in the administration of the Plan.

A-10 | Page   


(c)

Authority of Administrator. The Administrator will have the power, subject to, and within the limitations of, the express provisions of the Plan:

(i)

To determine when and how rights to purchase Common Stock will be granted and the provisions of each offering of such rights (which need not be identical).

(ii)

To designate, from time to time (A) which Subsidiaries will be Designated Subsidiaries participating in the Plan, (B) which Subsidiaries will not be Designated Subsidiaries participating in the Plan, (C) which branches, representative offices or other disregarded entities of the Company or of any Designated Subsidiary may be excluded from participation in the Plan, in each case to the extent consistent with Section 423 of the Code, and (D) which Designated Subsidiaries will participate in each separate Offering (to the extent that the Company makes separate Offerings). Such designation may be made without the approval of the stockholders of the Company. To construe and interpret the Plan and rights granted under it, and to establish, amend and revoke rules and regulations for its administration. The Administrator, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan, in a manner and to the extent it will deem necessary or expedient to make the Plan fully effective.

  A-14

To amend, suspend or terminate the Plan as provided in Section 9.

 (iii)

Generally, to exercise such powers and to perform such acts as the Administrator deems necessary or expedient to promote the best interests of the Company and its Subsidiaries and to carry out the intent that the Plan be treated as a Qualified ESPP.


Third Amended and Restated 2007 Long-Term Incentive Plan

Except as otherwise provided in the applicable Long-term Performance Award agreement, if a participant terminates employment or his consultancy during a Performance Period for any other reason, then such participant shall not be entitled to any payment
(d)

Decisions Binding. The Administrator’s interpretation of the Plan, any rights granted pursuant to the Plan, any subscription agreement and all decisions and determinations by the Administrator with respect to the Plan are final, binding, and conclusive on all parties.

12.Non-U.S. Offerings

Notwithstanding any provision to the Long-term Performance Award subjectcontrary in this Plan, the Administrator may adopt such rules, procedures, agreements, appendices, orsub-plans (collectively,“Sub-Plans”) relating to such Performance Period,the operation and administration of the Plan to accommodate local laws, customs and procedures for jurisdictions outside of the United States, the terms of whichSub-Plans may take precedence over other provisions of this Plan, with the exception of Section 3 and Section 9 hereof, but unless the Committee shall otherwise determine.

(d)Form of Payment. The earned portion of a Long-term Performance Award may be paid currently or on a deferred basis with such interest or earnings equivalent as may be determinedsuperseded by the Committee. Payment shall be made interms of suchSub-Plan, the formprovisions of whole sharesthis Plan will govern the operation of Stock, including Restricted Stock or Deferred Stock, as the Committee shall determine.suchSub-Plan. To the extent a Long-term Performance Award is payable in Stock andinconsistent with the full amount thereforrequirements of Section 423 of the Code, any suchSub-Plan will be considered part of an Offering that is not paid in Stock, then the shares of Stock representing the portion of the value of the Long-term Performance Awardintended to, and purchase rights granted thereunder will not paid in Stock shall again become available for award under the Plan.

Section 11. Amendments And Termination.

The Board may amend, alter, or discontinue the Plan, but no amendment, alteration, or discontinuation shall be made which would impair the rights of an optionee or participant under a Stock Option, Stock Appreciation Right, Restricted Stock or Deferred Stock Award, Stock Purchase Right, or Long-term Performance Award theretofore granted, without the optionee’s or participant’s consent, or which, without the approval of the Company’s stockholders, would:

(a) except as expressly provided in Section 3(c) of this Plan, increase the total number of shares reserved for the purpose of the Plan;

(b) change the employees or class of individuals eligible to participate in the Plan;

(c) extend the maximum option period under Section 5(b) of the Plan; or

(d) otherwise materially alterrequired by the terms of the Plan to, the extent required by law or any stock exchange on which the shares of Stock are traded.

The Committee may amend the terms of any award theretofore granted, prospectively or retroactively, but, subject tocomply with Section 3 above, no such amendment shall impair the rights of any holder without the holder’s consent. Notwithstanding any provision in this Plan to the contrary, except as provided in Section 3(c) no Stock Option or Stock Appreciation Right may be amended to reduce the price per share of the shares subject to such Stock Option or the exercise price of such Stock Appreciation Right, as applicable, below the option price or exercise price as of the date the Stock Option or Stock Appreciation Right is granted. In addition, except as provided in Section 3(c) no Stock Option or Stock Appreciation Right may be granted in exchange for or in connection with the cancellation or surrender of a Stock Option, Stock Appreciation Right or other Grant if the new Stock Option, Stock Appreciation Right or other Grant has an option or exercise price (including no exercise price) which is less than the option or exercise price of the Stock Option or Stock Appreciation Right being exchanged, cancelled or surrendered.

Subject to the above provisions, the Board shall have broad authority to amend the Plan to take into account changes in applicable securities and tax laws and accounting rules, as well as other developments.

Adopted:A-15


Third Amended and Restated 2007 Long-Term Incentive Plan

Section 12. Unfunded Status Of Plan and 409A.

(a)Unfunded Plan. The Plan is intended to constitute an ‘unfunded’ plan for incentive and deferred compensation. With respect to any payments not yet made to a participant or optionee by the Company, nothing contained herein shall give any such participant or optionee any rights that are greater than those of a general creditor of the Company. In its sole discretion, the Committee may authorize the creation of trusts or other arrangements to meet the obligations created under the Plan to deliver Stock or payments in lieu of or with respect to awards hereunder, provided, however, that, unless the Committee otherwise determines with the consent of the affected participant, the existence of such trusts or other arrangements is consistent with the ‘unfunded’ status of the Plan.

(b)Section 409A. To the extent that the Committee determines that any award granted under the Plan is subject to Section 409A of the Code, the agreement evidencing such award shall incorporate the terms and conditions required by Section 409A423 of the Code. To the extent applicable, the Plan and such agreements shall be interpreted in accordance with Section 409A of the Code and Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the date this Plan is effective. In that regard, to the extent any award under the Plan or any other compensatory plan or arrangement of the Company or any of its Subsidiaries or Affiliates is subject to Section 409A, and such award or other amount is payable on account of a participant’s termination of service (or any similarly defined term), then (A) such award or amount shall only be paid to the extent such termination of service qualifies as a “separation from service” as defined in Section 409A, and (B) if such award or amount is payable to a “specified employee” as defined in Section 409A then to the extent required in order to avoid a prohibited distribution under Section 409A, such award or other compensatory payment shall not be payable prior to the earlier of (i) the expiration of the six-month period measured from the date of the participant’s termination of service, or (ii) the date of the participant’s death. Notwithstanding any provision of the Plan to the contrary, in the event that following the effective date of the Plan the Committee determines that any award may be subject to Section 409A of the Code and related Department of Treasury guidance, the Committee may adopt such amendments to the Plan and the applicable agreement or adopt other policies and procedures (including amendments, policies and procedures with retroactive effect), or take any other actions, that the Committee determines are necessary or appropriate to (a) exempt the award from Section 409A of the Code and/or preserve the intended tax treatment of the benefits provided with respect to the award, or (b) comply with the requirements of Section 409A of the Code and related Department of Treasury guidance.

Section 13. General Provisions.

(a) The Committee may require each person purchasing shares pursuant to a Stock Option or other award under the Plan to represent to and agree with the Company in writing that the optionee or participant is acquiring the shares for investment and without a view to distribution thereof. The certificates for such shares may include any legend which the Committee deems appropriate to reflect any restrictions on transfer.

The Committee may condition the exercise of an Option or the issuance and delivery of Stock upon the listing, registration or qualification of the Stock upon a securities exchange or under applicable securities laws.

Adopted:A-16


Third Amended and Restated 2007 Long-Term Incentive Plan

All certificates for shares of Stock or other securities delivered under the Plan shall be subject to such stock-transfer orders and other restrictions as the Committee may deem advisable under the rules, regulations, and other requirements of the Securities and Exchange Commission, any stock exchange upon which the Stock is then listed, and any applicable Federal or state securities law, and the Committee may cause a legend or legends to be put on any such certificates to make appropriate reference to such restrictions.

(b) Nothing contained in this Plan shall prevent the Board from adopting other or additional compensation arrangements, subject to stockholder approval if such approval is required; and such arrangements may be either generally applicable or applicable only in specific cases.

(c) The making of an award under this Plan shall not confer upon any employee of the Company or any Subsidiary or Affiliate any right to continued employment with the Company or a Subsidiary or Affiliate, as the case may be, nor shall it interfere in any way with the right of the Company or a Subsidiary or Affiliate to terminate the employment of any of its employees at any time.

(d) All awards (including any proceeds, gains or other economic benefit actually or constructively received by a participant upon any receipt or exercise of any award or upon the receipt or resale of any shares underlying the award) shall be subject to the provisions of any claw-back policy implemented by the Company, including, without limitation, any claw-back policy adopted to comply with the requirements of applicable law, including, without limitation, the Dodd-Frank Wall Street Reform and Consumer Protection Act and any rules or regulations promulgated thereunder, whether or not such claw-back policy was in place at the time of grant of an award, to the extent set forth in such claw-back policy and/or in the applicable Grant agreement.

(e) No later than the date as of which an amount first becomes includable in the gross income of the participant for Federal income tax purposes with respect to any award under the Plan, the participant shall pay to the Company, or make arrangements satisfactory to the Committee regarding the payment of, any Federal, state, or local taxes of any kind required by law to be withheld with respect to such amount. Unless otherwise determined by the Committee, withholding obligations may be settled with Stock, including Stock that is part of the award that gives rise to the withholding requirement. The obligations of the Company under the Plan shall be conditional on such payment or arrangements and the Company and its Subsidiaries or Affiliates shall, to the extent permitted by law, have the right to deduct any such taxes from any payment of any kind otherwise due to the participant.

(f) The actual or deemed reinvestment of dividends or dividend equivalents in additional Restricted Stock (or in Deferred Stock or other types of Plan awards) at the time of any dividend payment shall only be permissible if sufficient shares of Stock are available under Section 3 for such reinvestment (taking into account then outstanding Stock Options, Stock Purchase Rights and other Plan awards).

(g) The Plan and all awards made and actions taken thereunder shall be governed by and construed in accordance with the laws of the State of Delaware.

(h) Notwithstanding any other provision of this Plan to the contrary, Full Value Awards shall become vested over a period of not less than three years (or, in the case of vesting based upon the

Adopted:A-17


Third Amended and Restated 2007 Long-Term Incentive Plan

attainment of Performance Criteria or other performance-based objectives, over a period of not less than one year) following the date the Grant is made; and all other awards granted under the Plan shall vest no earlier than the first anniversary of the date the award is granted;provided,however, that, notwithstanding the foregoing, awards that result in the issuance of an aggregate of up to 5% of the shares of Stock available pursuant to the Plan may be granted to any one or more participants without respect to such minimum vesting provisions. Nothing in this Section 13(h) shall preclude the Committee from taking action, in its sole discretion, to accelerate the vesting of any award in connection with or following a participant’s death, disability, termination of service or the consummation of a change in control.

Section 14. Effective Date Of Plan.

The Plan was originally adopted effective as of January 1, 2007 and approved by the shareholders of the Company on March 20, 2007. The Plan has been amended and restated and subsequently approved by the shareholders on March 18, 2009 and March 16, 2011. The provisions of the Plan as reflected in this amendment and restatement was approved by the Board of Directors of the Company on December 10, 2015 and is subject to approval of the holders of a majority of the shares of the Company’s Common Stock present, or represented, and entitled to vote at the annual meeting of stockholders to be held in 2016. In the event that the Company’s stockholders do not approve the Plan at the 2016 stockholders meeting, then the terms of this amended and restated Plan will not become effective, and the terms of the Plan as in existence on December 10, 2015 will continue in full force and effect.

Section 15. Term Of Plan.

No Stock Option, Stock Appreciation Right, Restricted Stock Award, Deferred Stock Award, Stock Purchase Right, Other Stock-Based Award, or Long-term Performance Award shall be granted pursuant to the Plan on or after December 31, 2026, but awards granted prior to such date may extend beyond that date.

Section 16. Certain Stock Options For United Kingdom Employees.

Stock Options granted under Section 5 which are Non-Qualified Stock Options may be granted subject to the terms and conditions of Schedule A hereto. Such Non-Qualified Stock Options shall be subject to the terms and conditions of the Plan, including Section 5.

Adopted:A-18


Exhibit A

2007 Long-Term Incentive Plan

SCHEDULE A

TAX APPROVED OPTIONS FOR UNITED KINGDOM EMPLOYEES

(Providing for the grant of Stock Options which it is intended shall satisfy the requirements of Her Majesty’s Revenue and Customs pursuant to Schedule 4 to the UK Income Tax (Earnings and Pensions) Act 2003 (“ITEPA”), such options to be referred to in this Schedule as “Approved Options”).

Approved Options may be granted pursuant to this Schedule A in accordance with such provisions as would be applicable if the provisions of the Cooper Companies, Inc. 2007 Long-Term Incentive Plan (the “Plan”) relating to Stock Options were here set out in full (provided that Sections 6, 7, 8, 9 and 10 shall not apply to this Schedule A), subject to the following further modifications:

Section A1. Eligibility.

Approved Options may only be granted under this Schedule A to individuals who are employees of the Company and its subsidiaries (and for this purpose a subsidiary shall mean any company of which the Company has control as defined in section 840 of the UK Income and Corporation Taxes Act 1988 (“Control”)) and who are not ineligible to participate in accordance with the provisions of paragraph 9 of Schedule 4 to ITEPA and, if a director, is required to work in that capacity for the Company and/or any such subsidiary for at least 25 hours per week, excluding meal breaks. For the avoidance of doubt, no Approved Options shall be granted to a consultant and references to “consultant/consultancy” in the Plan shall have no relevance under this Schedule A.

Section A2. Stock Subject To The Plan.

(a) Approved Options granted under this Schedule A may only be made and may only be exercised in respect of Stock which satisfies the requirements of paragraphs 16-20 of Schedule 4 to ITEPA.

(b) Only in the event of any reorganization, consolidation, Stock split or other variation of the Company’s Stock, may an adjustment be made under Section 3 of the Plan to the amount of Stock which is the subject of Approved Options granted under this Schedule A and the option price payable in respect thereof and then only with the prior approval of HM Revenue and Customs.

Section A3. Stock Options.

(a) Approved Options may only be granted pursuant to this Schedule A at an option price which is not less than 100% of Fair Market Value as of the date of grant provided that if no sale of Stock occurs on the New York Stock Exchange on such date the option price shall not be less than the Fair Market Value of the Stock as determined in accordance with Part VIII of the UK Taxation of Chargeable Gains Act 1992 and agreed on or before that date for the purposes of this Schedule A with HM Revenue and Customs Shares and Assets Valuation.

(b) No Approved Options may be granted to an employee or director which will result in the aggregate option price for all the Stock comprised in outstanding Approved Options granted to him under this Schedule A together with the aggregate option price of all Stock comprised in outstanding

A-19


Exhibit A

2007 Long-Term Incentive Plan

options granted to him under any other stock option scheme established by the Company or any associated company (as defined in paragraph 35 of Schedule 4 to ITEPA) approved under Schedule 4 to ITEPA exceeding 30,000 UK pounds sterling (converting, for this purpose the option price into pounds sterling using the exchange rate applicable on the date of grant of such option) or such other amount as is for the time being specified as being the appropriate limit for the purposes of paragraph 6(1) of Schedule 4 to ITEPA. For the avoidance of doubt, the limit set out in Section 5(j) of the Plan applying to Incentive Stock Options shall not apply to Approved Options granted under this Schedule A.

(c) Section 5(c) shall be substituted as follows: “The Board may impose a schedule for vesting of the Stock comprised in the Approved Option and set out in the Option Agreement (the “Vesting Schedule”) containing only objective conditions on any Approved Option which they grant preventing its exercise except to the extent that the Vesting Schedule has been complied with. If, after the Board have imposed such a condition, events happen which cause them to consider that it is no longer appropriate, they may vary the Vesting Schedule provided always that any such amendment may only be one which the Board reasonably consider will result in a fairer measure of the performance of the job of the optionee, will ensure that this Plan operates more effectively in the achievement of its purpose of providing share benefits for employees who contribute to the prosperity of the Company and will be no more difficult to satisfy than would have been the case if there had been no such amendment.”

(d) In the third paragraph of Section 3, the words “but acting fairly and reasonably” shall be added after “in its sole discretion” and the words “may be exercised in full immediately before the consummation of the merger or other corporate transactions and if not so exercised shall be cancelled at the time of the consummation of the merger or other corporate transaction” shall be substituted for the words “shall be converted into the right to receive an amount of cash” to the end of the paragraph.

(e) Section 5(e) shall be substituted as follows: “No Approved Option shall be transferable other than to the personal representatives of an optionee. No Approved Option shall be assigned or used as a charge and any purported transfer, assignment or charge shall cause the Approved Option immediately to lapse”.

(f) In the event of the optionee’s death an Approved Option granted pursuant to this Schedule A must be exercised within twelve months of the optionee’s death whereupon, to the extent it has not been exercised, such Approved Option shall lapse.

(g) No Approved Option granted under this Schedule A may be exercised at any time if the holder of such option is precluded from participating under this Schedule A by paragraph 9 of Schedule 4 to ITEPA.

(h) The retirement age for the purposes of paragraph 35A of Schedule 4 to ITEPA is 55.

(i) Sections 5(j),(k), (l) and for the avoidance of doubt Section 5(m) of the Plan shall not apply to Approved Options granted under this Schedule A. For the avoidance of doubt, Approved Options granted under this Schedule A shall automatically be exercisable by virtue of being involuntary termination without cause when the optionee’s employment ceases by reason of redundancy within the meaning of the Employment Rights Act 1996.

A-20


Exhibit A

2007 Long-Term Incentive Plan

(j) Within 30 days of the receipt of a written notice (in the form prescribed by the Company) duly signed by the optionee together with their option certificate and the full purchase price of the Stock being acquired pursuant to the exercise of their option the Company shall procure that the optionee acquires the Stock in respect of which the Approved Option has been validly exercised by (i) allotting Stock to the optionee; or (ii) procuring the transfer of Stock to the optionee and shall issue a definitive certificate or other evidence of title (whether paper or electronic) for the Stock acquired pursuant to the exercise of the option. Alternatively, the optionee may exercise his options pursuant to Section 5(d) of the Plan, although Section 5(d)(i) shall not apply to Approved Options, (and Section 5(d)(ii) shall only apply with the consent of the optionee).

(k) Stock issued pursuant to this Schedule A shall rank pari passu with the issued Stock and the Company shall at all times keep available sufficient Stock to satisfy the exercise of, to the full extent possible, all Approved Options granted pursuant to this Schedule A which have neither lapsed nor become fully exercisable.

(l) If an acquiring company:

(i) obtains Control of the Company as a result of making (a) a general offer to acquire the whole of the issued ordinary share capital of the Company which is made on a condition such that if it is satisfied the person making the offer will have Control of the Company, or (b) a general offer to acquire all the shares in the Company which are of the same class as the Stock which may be acquired by the exercise of the Approved Options granted under this Plan;

(ii) obtains Control of the Company in pursuance of a compromise or arrangement sanctioned by a court under provisions closely comparable to section 425 of the UK Companies Act 1985; or

(iii) becomes bound or entitled to acquire shares in the Company under provisions closely comparable to Part 28 of the UK Companies Act 2006

any optionee may at any time within the appropriate period (which expression shall be construed in accordance with paragraph 26(3) of Schedule 4 to ITEPA), by prior agreement with the acquiring company and HM Revenue & Customs, release any Approved Option granted under this Plan which has not lapsed (the “Old Option”) in consideration of the grant to him of an option (the “New Option”) which (for the purposes of that paragraph) is equivalent to the Old Option but relates to shares in a different company (whether the acquiring company itself or some other company falling within paragraph 16(b) or (c) of Schedule 4 to ITEPA).

The New Option shall not be regarded for the purposes of Section A3(k) above as equivalent to the Old Option unless the conditions set out in paragraph 27(4) of Schedule 4 are satisfied, but so that the provisions of this Plan shall for this purpose be construed as if:

(i) the New Option were an option granted under this Plan at the same time as the Old Option;

(ii) the expression the “Company” was defined as “the company whose shares may be acquired by the exercise of Options granted under this Plan”.

A-21


Exhibit A

2007 Long-Term Incentive Plan

(m) Section 13(a) of the Plan shall not apply to Approved Options granted under this Schedule A other than to comply with US federal or state securities law. Section 13(d) only applies to the extent that the optionee has not already provided an amount of money to cover the tax payable.

(n) Section 13(d) of the Plan shall apply as if the references to United States taxation applied to UK taxation and National Insurance contributions, provided that the references to settling a liability in Stock shall only apply if the optionee has agreed to such method of deduction. This facility is restricted to Stock acquired by the exercise of options granted under this Schedule A.

(o) Participation in this Plan by an optionee is a matter entirely separate from any pension right or entitlement he may have and from his terms or conditions of employment with any participating company and participation in this Plan shall in no respects whatever affect in any way an optionee’s pension rights or entitlement or terms or conditions of employment with any participating company. In particular (but withoutWithout limiting the generality of the foregoing, words) any optionee who leaves employment with any participating company shall not be entitledthe Administrator is authorized to any compensationadoptSub-Plans for any loss of any right or benefit or prospective right or benefit under this Plan which he might otherwise have enjoyed whether such compensation is claimed by way of damages for wrongful dismissal or breach of contract by way of compensation for loss of office or otherwise howsoever.

(p) Any discretion exercisable under eitherparticularnon-U.S. jurisdictions that modify the Plan or this Schedule A by the Company, any Subsidiary or Affiliate or any body thereof shall be applied fairly and reasonably.

Section A4. Amendments And Termination.

No amendments to this Schedule A (including any provisionterms of the Plan which is incorporated within this Schedule A) pursuant to Section 11 which fall withinmeet applicable local requirements, customs or procedures regarding, without limitation, (i) eligibility to participate, (ii) the definition of Compensation, (iii) the dates and duration of offering periods and purchase periods, (iv) any minimum or maximum amount of payroll deductions a key feature withinParticipant may make in an offering period or other specified period under the meaningapplicableSub-Plan, (v) the method of paragraph 30(4) of Schedule 4contribution to ITEPA shall have effect until the approval of HM Revenue and Customs has been obtained in respect thereof. This Section A4 shall not however restrict the general power of the Board to amend the Plan, whereincluding by means of check, wire transfer, electronic fund transfer or such other contribution method other than payroll deductions, (vi) the amendment will not applyestablishment of bank, building society or trust accounts to this Schedule A.

No assurance or warranty is given by the Company that the tax favourable treatment of Approved Options will apply on exercise of the option or that any corporate restructuring or mergerhold payroll deductions or other corporate activity will permitcontributions to the Plan, (vii) the payment of interest, (viii) conversion of local currency, (ix) obligations to pay payroll tax, favourable treatment to apply.(x) withholding procedures and (xi) handling of share issuances.

13.    Miscellaneous

 

(a)

Restriction upon Assignment. A right granted under the Plan will not be transferable other than by will or the applicable laws of descent and distribution, and is exercisable during the Participant’s lifetime only by the Participant. Except as provided in Section 13(d) hereof, a right under the Plan may not be exercised to any extent except by the Participant. The Company will not recognize and will be under no duty to recognize any assignment or alienation of the Participant’s interest in the Plan, the Participant’s rights under the Plan or any rights thereunder.

A-11 | Page   


(b)

Rights as a stockholder. With respect to Shares subject to a right granted under the Plan, a Participant will not be deemed to be a stockholder of the Company, and the Participant will not have any of the rights or privileges of a stockholder, until such Shares have been issued to the Participant or his or her nominee following exercise of the Participant’s rights under the Plan. No adjustments will be made for dividends (ordinary or extraordinary, whether in cash securities, or other property) or distribution or other rights for which the record date occurs prior to the date of such issuance, except as otherwise expressly provided herein or as determined by the Administrator.

(c)

Interest. No interest will accrue on the payroll deductions or contributions of a Participant under the Plan, unless otherwise required by Applicable Law.

(d)

Designation of Beneficiary.

 A-22(i)

A Participant may, if permitted by the Administrator, file a written designation of a beneficiary who is to receive any Shares and/or cash, if any, from the Participant’s account under the Plan in the event of such Participant’s death subsequent to a Purchase Date on which the Participant’s rights are exercised but prior to delivery to such Participant of such Shares and cash. In addition, if permitted by the Administrator, a Participant may file a written designation of a beneficiary who is to receive any cash from the Participant’s account under the Plan in the event of such Participant’s death prior to exercise of the Participant’s rights under the Plan. If the Participant is married and resides in a community property state, a designation of a person other than the Participant’s spouse as his or her beneficiary will not be effective without the prior written consent of the Participant’s spouse.

 (ii)

Such designation of beneficiary may be changed by the Participant at any time by written notice to the Company. In the event of the death of a Participant and in the absence of a beneficiary validly designated under the Plan who is living at the time of such Participant’s death, the Company will deliver such Shares and/or cash to the executor or administrator of the estate of the Participant, or if no such executor or administrator is appointed (to the knowledge of the Company), the Company, in its discretion, may deliver such Shares and/or cash to the spouse or to any one or more dependents or relatives of the Participant, or if no spouse, dependent or relative is known to the Company, then to such other person as the Company may designate.


(e)

Notices. All notices or other communications by a Participant to the Company under or in connection with the Plan will be deemed to have been duly given when received in the form specified by the Company at the location, or by the person, designated by the Company for the receipt thereof.

 

(f)

Equal Rights and Privileges. Subject to Section 5(g), all Eligible Employees in each Offering will have equal rights and privileges under this Plan so that the Offering qualifies as an offering under a Qualified ESPP. Subject to Section 5(g), any provision of this Plan that is inconsistent with Section 423 of the Code will, without further act or amendment by the Company, the Board or the Administrator, be reformed to comply with the equal rights and privileges requirement of Section 423 of the Code.

(g)

Use of Funds. All payroll deductions received or held by the Company under the Plan may be used by the Company for any corporate purpose, and the Company will not be obligated to segregate such payroll deductions, unless required otherwise by Applicable Law.

(h)

Reports. Statements of account will be given to Participants at least annually, which statements will set forth the amounts of payroll deductions, the Purchase Price, the number of Shares purchased and the remaining cash balance, if any.

(i)

No Employment Rights. Nothing in the Plan will be construed to give any person (including any Eligible Employee or Participant) the right to remain in the employ of the Company or any Parent or Subsidiary or affect the right of the Company or any Parent or Subsidiary to terminate the employment of any person (including any Eligible Employee or Participant) at any time, with or without cause.

(j)

Notice of Disposition of Shares. Each Participant participating in the Plan will give prompt notice to the Company of any disposition or other transfer of any Shares purchased upon exercise of a right under the

A-12 | Page   


Plan. Such notice will specify the date of such disposition or other transfer and the amount realized, in cash, other property, assumption of indebtedness or other consideration, by the Participant in such disposition or other transfer.

(k)

Governing Law. The Plan and any agreements hereunder will be administered, interpreted and enforced under the internal laws of the State of Delaware without regard to conflicts of laws thereof or of any other jurisdiction

(l)

Electronic Forms. To the extent permitted by Applicable Law and in the discretion of the Administrator, an Eligible Employee may submit any form or notice as set forth herein by means of an electronic form approved by the Administrator. Before the commencement of an Offering Period, the Administrator will prescribe the time limits within which any such electronic form will be submitted to the Administrator with respect to such Offering Period in order to be a valid election.

A-13 | Page   


 

LOGO

 

NOTICE OF

ANNUAL MEETING

OF STOCKHOLDERS

AND

PROXY STATEMENT

 

Meeting Date

 

March 14, 201618, 2019

 

LOGO

LOGO


ANNUAL MEETING OF STOCKHOLDERS OF

THE COOPER COMPANIES, INC.

March 14, 201618, 2019

GO GREEN

 

PROXY VOTING INSTRUCTIONS

INTERNET - Access “www.voteproxy.com” and follow the on-screen instructions or scan the QR code with your smartphone. Have your proxy card available when you access the web page.

TELEPHONE - Call toll-free1-800-PROXIES(1-800-776-9437) in the United States or1-718-921-8500from foreign countries from any touch-tone telephone and follow the instructions. Have your proxy card available when you call.

Vote online/phone until 11:59 PM EST the day before the meeting.

MAIL - Sign, date and mail your proxy card in the envelope provided as soon as possible.

IN PERSON - You may vote your shares in person by attending the Annual Meeting.

GO GREEN-e-Consent makes it easy to go paperless. Withe-Consent, you can quickly access your proxy material, statements and other eligible documents online, while reducing costs, clutter and paper waste. Enroll today via www.amstock.comwww.astfinancial.com to enjoy online access.

LOGO

 

 

COMPANY NUMBER

ACCOUNT NUMBER

 

NOTICE OF INTERNET AVAILABILITY OF PROXY MATERIALMATERIAL::

The Notice of Meeting, Proxy Statement, Annual Report on Form 10-K

and Proxy Card are available at investor.coopercos.com/financials.cfm

 

Please sign, date and mail

your proxy card in the

envelope provided as soon

as possible.

 

i$ Please detach along perforated line and mail in the envelope providedIF you are not voting via the Internet or telephone.  provided. $i

 

¢   00033333333030300000    800033333333330330000    6     031416031819

 

THE BOARD OF DIRECTORS RECOMMENDS THAT YOU VOTE “FOR” ITEMS 1 THRU 4.

PLEASE SIGN, DATE AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE. PLEASE MARK YOUR VOTE IN BLUE OR

BLACK INK AS SHOWN HERE  

THE BOARD OF DIRECTORS RECOMMENDS THAT YOU VOTE “FOR” ITEMS 1 THRU 4.

PLEASE SIGN, DATE AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE. PLEASE MARK YOUR VOTE IN BLUE OR BLACK INK AS SHOWN HERE  x

In their discretion, the proxies are authorized to vote for the election of such substitute nominee(s) for directors as such proxies may select in the event that any nominee(s) named herein become unable to serve, and on such other matters as may properly come before the meeting or any adjournments or postponements thereof.

 

THIS PROXY WILL REVOKE ALL PRIOR PROXIES SIGNED BY YOU.

    1. ELECTION OF SEVENNINE DIRECTORS. FOR AGAINST ABSTAIN
    

    A. Thomas Bender

 ¨ ¨ ¨
    

    Colleen E. Jay

 Michael H. Kalkstein

 

¨

 

¨

 

¨

    

    Michael H. Kalkstein

 Jody S. Lindell

 

¨

 

¨

 

¨

 

    Gary S. Petersmeyer

¨

¨

¨

    Allan E. Rubenstein, M.D.

¨

¨

¨

    Robert S. Weiss

¨

¨

¨

    Stanley Zinberg, M.D.

¨

¨

¨

       

2.

 

    William A. Kozy

    Jody S. Lindell

    Gary S. Petersmeyer

    Allan E. Rubenstein, M.D.

    Robert S. Weiss

    Albert G. White III

2.

Ratification of the appointment of KPMG LLP as the independent registered public accounting firm for The Cooper Companies, Inc. for the fiscal year ending October 31, 2016;2019;

 

¨

 

¨

 

¨

   3. 

Approve the 2019 Employee Stock Purchase Plan;

 
   

3.4.

 

An advisory vote on the compensation of our named executive officers as presented in the Proxy Statement; and

Approval of the amendment and restatement of the 2007 Long Term Incentive Plan to add 1,700,000 shares to the total reserved for grant and extend the term of the Plan;

 

¨

 

¨

 

¨

       

4.

5.
 

Hold an advisory vote on the compensation of our named

executive officers as presented in the Proxy Statement; and

¨

¨

¨

5.

The transaction ofTransact any other business that my properly come up before the meeting or any continuations, adjournment or postponements thereof.

To change the address on your account, please check the box at right and indicate your new address in the address space above. Please note that changes to the registered name(s) on the account may not be submitted via this method.

  ¨     

 

Signature of Stockholder

    Date:      Signature of Stockholder    Date:    

¢ Note: 

Please sign exactly as your name or names appear on this Proxy. When shares are held jointly, each holder should sign.   When signing as executor, administrator, attorney, trustee or guardian, please give full title as such. If the signer is a corporation, please sign full corporate name by duly authorized officer, giving full title as such. If signer is a partnership, please sign in partnership name by authorized person.

 ¢


 

 

0

LOGO                     ¢

PROXY

THE COOPER COMPANIES, INC.

PROXY FOR ANNUAL MEETING OF STOCKHOLDERS, MARCH 14, 201618, 2019

SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS

The undersigned stockholder of The Cooper Companies, Inc., a Delaware corporation, hereby appoints RANDAL L. GOLDEN, CAROL R. KAUFMAN, GREGORY W. MATZ and ROBERT S. WEISS, and each of them, proxies, with full power of substitution, to vote all of the shares of common stock of The Cooper Companies, Inc. which the undersigned is entitled to vote at the Annual Meeting of Stockholders of The Cooper Companies, Inc. to be held at 6140 Stoneridge Mall Road, Suite 145,The undersigned stockholder of The Cooper Companies, Inc., a Delaware corporation, hereby appoints BRIAN G. ANDREWS, RANDAL L. GOLDEN, DANIEL G. MCBRIDE AND ALBERT G. WHITE III, and each of them, proxies, with full power of substitution, to vote all of the shares of common stock of The Cooper Companies, Inc. which the undersigned is entitled to vote at the Annual Meeting of Stockholders of The Cooper Companies, Inc. to be held at the offices of The Cooper Companies, Inc., 6140 Stoneridge Mall Road, Suite 590, Pleasanton, CA 94588 at 8:00 a.m., (P.D.T.), and at any continuations, adjournments or postponements thereof, as set forth on the reverse, and in their discretion upon any other business that may properly come before the meeting.

THIS PROXY WILL BE VOTED IN THE MANNER DIRECTED HEREIN BY THE UNDERSIGNED STOCKHOLDER. IF NO DIRECTION IS MADE, THIS PROXY WILL BE VOTED “FOR” ITEMS 1 THRU 4, AND WILL GRANT DISCRETIONARY AUTHORITY PURSUANT TO ITEM 5.

(Continued and to be signed on the reverse side.)

 

¢  1.1  14475  ¢